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Abstract
Cardiovascular disease (CVD) accounts for over 50% of morbidity and mortality in 
patients with end stage renal failure (ESRF), including those suitable for renal 
transplantation. Furthermore, CVD is the most common cause for loss of a functioning 
renal allograft. The strongest predictors of cardiovascular (CV) outcome in this 
population have been identified as left ventricular (LV) abnormalities, namely left 
ventricular hypertrophy (LVH), left ventricular dilation (LVDil) and left ventricular 
systolic dysfunction (LVSD). However, inaccuracies inherent to the measurement of LV 
mass and volumes using echocardiography have meant that, unlike other populations 
such as those with essential hypertension, there is no reliable, consistent evidence that 
regression of LV abnormalities is possible or whether regression of LV abnormalities 
improves long term outcome.
Cardiovascular magnetic resonance (CMR) imaging is now established as the standard of 
reference for the measurement of LV mass, volumes and function, and unlike 
echocardiography is ‘loading independent’. The aim of this thesis is to evaluate the 
uraemic heart using CMR, identify the determinants of LV abnormalities and define the 
relationship between coronary artery disease (CAD) and LV abnormalities in a 
population of patients with ESRF felt suitable for renal transplantation.
Methods
A total of 154 patients with ESRF who were either already awaiting renal transplantation 
or undergoing assessment for transplantation were recruited for the study. Patients 
underwent the standard CV risk assessment used by the West of Scotland transplant
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assessment clinic and in addition underwent CMR imaging and measurement of serum 
brain natriuretic peptide (BNP). A proportion of patients (60) also underwent an 
additional CMR protocol using a gadolinium based contrast agent and 84 patients 
returned after a mean period of 8 months for a follow-up CMR scan to study the natural 
history of LV abnormalities whilst patients await renal transplantation.
Results
In contrast to previous echocardiographic studies, rather than three types of uraemic 
cardiomyopathy, namely concentric LVH, eccentric LVH and LVSD, the results of this 
study suggest only two major types of uraemic cardiomyopathy exist; concentric LVH 
and ischaemic cardiomyopathy (ICM). The predominant type of cardiomyopathy was 
concentric LVH, which was associated with hypertension and diabetes and 50% of the 
total cohort were found to have this type of cardiomyopathy. Thereafter, LVDil was 
found to be associated with LVSD in the majority of cases and patients with LVDil 
and/or LVSD were much more likely to have associated CAD than patients with either 
normal ventricles or concentric LVH. Only a very small proportion of the total cohort 
was found to have eccentric LVH (6%) when a loading independent method of 
measurement was used for the assessment of LV abnormalities.
With follow-up, 45% patients who were found to have an initially normal LV developed 
concentric LVH, whilst patients with an initially abnormal LV showed little further 
progression during the study period. Patients with LVSD or LVDil had a poorer outcome 
than those with concentric LVH or normal ventricles after 4 years of follow-up and 
patients who displayed contrast enhancement after administration of a gadolinium based
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contrast agent, indicative of myocardial necrosis/fibrosis also had a significantly poorer 
outcome compared to those with no evidence of contrast enhancement.
Age, a prior history of ischaemic heart disease (IHD) or diabetes and an elevated BNP 
level were all found to be independent predictors of all cause mortality in this population 
after 4 years of follow-up.
Conclusions
LV abnormalities are common in patients with ESRF awaiting renal transplantation. The 
two major types of cardiomyopathy in this population, identified using CMR, are 
concentric hypertrophic cardiomyopathy and ICM. Concentric hypertrophic 
cardiomyopathy, which is the most prevalent type of cardiomyopathy, is determined by 
hypertension, diabetes and volume overload and future studies targeting regression of 
LVH in this population should concentrate on treatment in these areas. LVSD and LVDil 
are under recognised in this population and both abnormalities are closely associated with 
CAD. A finding of either LVSD or LVDil should precipitate careful investigation for 
underlying CAD and strategies for the early non-invasive detection of CAD, before the 
development of ICM, in this population are required.
The mortality rate of patients awaiting renal transplantation remains high and is 
dependent on age, diabetes and EHD. In addition to established methods of CV risk 
stratification prior to renal transplantation, BNP level may prove to be a useful non- 
invasive marker of CV risk assessment in this population and further studies are 
warranted in parallel with those targeting LV abnormalities and CAD.
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Chapter 1 
Introduction
1.1 The scale of the problem of Cardiovascular Disease 
in patients with Chronic Renal Failure
Renal transplantation, along with advances in immunosuppressive drug regimens and 
improved access to renal replacement therapy (RRT) has significantly improved the 
survival of patients with progressive renal failure (1-5). These improvements in survival, 
in combination with an aging population have resulted in an expansion of dialysis 
programmes in the United Kingdom (UK). In Scotland, the number of patients 
commencing dialysis increased from 60 patients per million (PPM) in 1989 to 108 PPM 
in 1999 (6) and the total number of patients in a dialysis programme in Scotland in 2006 
was 2146 (an increase of 400 patients over 6 years) (7). This translates into a higher 
number of patients undergoing assessment for renal transplantation and being placed on 
renal transplant waiting lists. In 1996, there were 4322 patients on an active renal 
transplant waiting list in the UK and by 2005 this number had progressively increased to 
5863 patients (8). However, this increase in demand has not been matched with a similar 
increase in supply of donor kidneys. In the UK, 1578 renal transplants were carried out in 
1996, whereas only 1324 transplants were performed in 2005. This decrease in transplant 
activity reflects a drop in the number of donors, from 822 in 1996, to 721 in 2005 (8), felt 
to be due to a decrease in the number of deaths due to road traffic accidents and 
sub arachnoid haemorrhage amongst other factors.
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Renal transplantation is the most successful and cost effective treatment for renal failure. 
Not all patients on dialysis are suitable for transplantation and there is a variation in 
selection criteria, both between different renal units within the UK (9) and between 
different countries (10). In Scotland, 38% patients entering dialysis programmes are 
placed on the renal transplant waiting list (11) and studies have confirmed that renal 
transplantation significantly increases the life expectancy of patients with ESRF 
compared to those who remain on the transplant waiting list (1,3).
As the number of patients on waiting lists increases, the average length of time spent on 
the list before undergoing transplantation also increases. Until recently, it was thought 
that a longer wait for renal transplant impacted negatively on the morbidity and mortality 
benefit gained by transplantation. However, more recent evidence suggests that 
individual benefit from transplantation does not diminish with an increased length of 
waiting time, but instead is associated with a lower relative risk of death compared with 
remaining on dialysis (12). Patients left on the waiting list have a higher rate of mortality 
and with progression of time those patients remaining on the waiting list are those with 
less co-morbidity, who gain a similar benefit from transplantation as those who were 
transplanted earlier.
Thus it is realised, that to maximise the benefit of renal transplantation, rather than 
rationing access to the waiting list, when individual benefit of transplant can increase life 
expectancy by up to three times that of remaining on RRT, emphasis should be placed on 
improving outcome in patients awaiting renal transplant and in the first post transplant 
year (12).
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The success of renal transplantation and improved survival on RRT has uncovered a 
greatly increased risk of CVD in this population (13-17). It is now well recognised that 
mortality from CV causes is higher in patients from the earliest stages of chronic renal 
failure (CRF) compared to the general population (18-19) but dramatically increases in 
patients with ESRF. In patients on RRT, CVD is responsible for over one third of 
hospitalization (14) and 50% of deaths are due to CV causes (14-15,17,20).
Statistics from the United States Renal Data Service (USRDS) estimates the mortality 
from CVD in patients on RRT in America is 10% per year, which is 30 times higher than 
that of the general population (14). After stratification for age and sex, the mortality from 
CVD remains 10-20 times higher (Graph 1.1) (17) and in patients with ESRF due to 
diabetic nephropathy the mortality from CVD is up to 50 times that of the general 
population. This increased risk is relatively higher in younger age groups, such that a 25 
year old on RRT has the same CV risk as a patient of 85 years old in the general 
population (Graph 1.1).
Due to the selection bias of patients who are placed on renal transplant waiting lists, the 
mortality rate in this subset of patients is significantly lower than that of other patients on 
RRT (1,3) but death from CV causes still accounts for the majority of deaths and this 
subset of patients are 10 times more likely to die of CV causes than those in the general 
population (1). In the immediate period post renal transplant, acute myocardial infarction 
(AMI) and/or sudden arrhythmic death are major reasons for patient morbidity and 
mortality (13) and longitudinal studies of patients placed on renal transplant waiting lists 
show a sharp increase in mortality at time of transplant, to higher than that of those 
remaining on the waiting list (1,3, 12-13). Over the first 12 months post transplantation,
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the mortality rate in patients with a functioning allograft significantly falls to below that 
of remaining on RRT but patients remain at 5 times greater CV risk compared to patients 
in the general population and CV death is the most common cause of loss of a 
functioning renal allograft.
Thus CVD is the major cause of morbidity and mortality at all stages of progressive renal 
failure, accounting for over 50% of deaths and is the primary reason for loss of an 
otherwise functioning renal allograft. It is therefore clear that to further improve the 
survival of patients with renal failure both before and after renal transplantation and to 
maximise the survival benefits of the limited number of donor kidneys available in the 
UK, improvements in both the detection and treatment of underlying CV disease in 
patients with renal failure are required.
1.2 The Natural History of Cardiovascular Disease in 
patients with Chronic Renal Failure
With improvements in survival and longevity in the general population, the incidence of 
CRF is rising and is reflected in part, in the increased number of patients entering dialysis 
programmes. However, the proportion of patients commencing RRT and ultimately 
undergoing renal transplantation is much smaller than the proportion of patients with 
CRF in the general population (21). In America it is estimated that whilst 0.1% of the 
population have ESRF, 10% have CRF. Therefore, the majority of patients with CRF die 
before ever reaching ESRF and these patients are over 20 times more likely to die from 
CV causes than entering a dialysis programme (22).
There are few large prospective studies examining the incidence of CVD in patients with 
CRF not requiring dialysis, without CVD at baseline. Jungers et a l (18) followed 147
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patients with a glomerular filtration rate (GFR) of between 20-50ml/min/1.73m2 and no 
history of CVD for 10 years. The study found the incidence of CV events to be 41% in 
men and 19% in women. The incidence of AMI was 3 times higher in men than that of 
the general population in all age groups and similar differences were observed for women 
up until the age of 65 when the difference became less marked.
The degree of CV risk seems to increase as GFR declines. In the ARIC study (19), the 
incidence of de novo CV events was 4.8% per year for patients with stage 2 CRF (GFR 
60-89ml/min) but was 9.3% per year in those with stage 3-4 CRF (GFR 15-59ml/min). 
Similarly, in a cohort of 6223 patients in the Framingham study (22), 18% of men and 
20% of women with renal impairment had CVD. The incidence rate of CV events was 
23.1/1000 patient years for men and 25.6/1000 patient years for women with stage 3 CRF 
(GFR 30-59ml/min), whereas the corresponding rates for patients with stage 2 CRF were 
18.5/1000 patient years and 11.0/1000 patient years respectively.
The prevalence of CAD and ‘congestive’ heart failure (CHF) is also higher in patients 
with CRF compared to those in the general population. Levin et al. (23) found a 
prevalence of CAD of 14.9% in patients with a GFR of <60ml/min and a prevalence of 
CHF of 7.2%. Conversely, in patients presenting with acute coronary syndromes (ACS) 
up to 33% have stage 3 or greater CRF (24).
Once patients reach ESRF and require dialysis, CV risk dramatically increases compared 
to both the general population and those in the earlier stages of progressive renal failure 
and it has been estimated that men over 60 commencing RRT have a poorer 5 year 
survival than men with colon cancer and women over 60 commencing RRT have a poorer 
outcome than women with breast cancer (14). The prevalence of IHD in patients
20
commencing RRT differs according to geographical location. In the US, 41% of patients 
have IHD (25), whereas in Australia and New Zealand the prevalence is 36% (26) and in 
Canada, 28% (14). In the UK, Metcalfe et a l (27) studied 523 patients who started 
dialysis in Scotland between 1998 and 1999 and found that 29% of patients had a history 
of IHD. In another study by Barrett et a l (28) of 822 patients commencing RRT, 18% of 
patients had had a previous AMI and 21% had a history of IHD. This in part, may be 
explained by the relatively high proportion of patients entering dialysis programmes with 
diabetes. In America, around 40% of patients commencing RRT are diabetic, whereas in 
Canada the proportion is lower at 29% and in the study of Metcalfe et a l 24% of patients 
in Scotland commencing RRT were diabetic. The high proportion of patients with IHD 
and/or diabetes is also reflected in a relatively high prevalence of other forms of vascular 
disease, namely peripheral vascular disease (PVD) and cerebrovascular disease (CBD), 
which is estimated at 17% and 5% respectively in patients commencing RRT (28).
CHF is also prevalent in patients commencing RRT. Heart failure in patients with 
advanced renal failure is usually defined clinically as typical symptoms of breathlessness 
and oedema and the clinical findings of bibasal crackles on chest auscultation. Therefore, 
volume overload could also be responsible for symptoms of CHF in patients with CRF, 
rather than primary myocardial dysfunction and in practice the two are often found in 
combination. In the US, 40% of patients on RRT have a history of CHF (14) whereas in 
the Canadian study of Barrett et a l 35% of patients had a prior history of CHF (28). 
Despite this clinical definition of CHF, the presence of the typical symptoms confers 
worsened prognosis. Patients commencing RRT with symptoms of CHF are 93% more 
likely to die than those commencing RRT with no such symptoms (29). Similarly, those
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starting dialysis with a history of IHD, also usually symptom defined, have a 48% higher 
rate of mortality than patients commencing RRT with no prior history of IHD (30).
Once established on RRT, a high incidence of new onset IHD and CHF further 
contributes to the burden of CVD. In a Canadian study by Churchill et a l (31) the 
incidence of AMI was 8.2% per year and 10% per year for CHF. Longitudinal studies of 
patients on dialysis with no initial history of IHD or CHF have found that the 
development of de novo IHD and CHF is 3.6% per year (29) and 7.6% per year (30) 
respectively. With an already high prevalence of CVD in patients commencing RRT and 
the continued development of both IHD and CHF once established on RRT, it is 
unsurprising that 50% of patients on dialysis die of CV causes. In the study of Metcalfe et 
a l  after 2 years follow up of 523 patients commencing RRT in Scotland, 41.5% of 
patients had died. The most common cause of death was from CV causes, accounting for 
44% of total deaths. Thereafter, the most common reason for death was the withdrawal of 
RRT in the face of intractable co-morbidity, a proportion of which was also due to CVD. 
It should be noted that the majority of these studies were carried out in patients using 
haemodialysis as mode of RRT. Large studies solely in patients on peritoneal dialysis 
(PD) are lacking and comparison between modalities is difficult as selection bias exists 
with regard to choice of mode of RRT and patients with a prior history of CVD are more 
likely to be placed on haemodialysis programmes. However, data from the USRDS 
suggests the rate of de novo IHD and CHF and mortality of patients once established on 
PD is similar to that of patients on haemodialysis with an annual CV mortality of 9.6% 
(14) and a recent review of 9 studies examining the outcome of patients on PD compared
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to those on haemodialysis found no real difference after adjustment for factors such as 
age, diabetes and co-morbidity (32).
Around one third of patients with ESRF will be identified as suitable candidates for renal 
transplantation. Several studies have shown that patients identified as transplant 
candidates are younger, more likely to be male and have non-diabetic renal failure (1,3) 
than those on RRT not placed on waiting lists. Patients on transplant waiting lists are also 
less likely to have vascular disease and less likely to have a history of either angina or 
previous AMI (1,3). In the study of Oniscu et al. (3) patients remaining on RRT had a 
prevalence of IHD of 30.8% and 19.2% were diabetic. However, patients who were wait 
listed had a prevalence of IHD of 13.8% and only 11.2% were diabetic. Mortality is 
therefore around 50% that of patients remaining on RRT not felt suitable for transplant 
but CV mortality remains responsible for 50% deaths whilst waiting for renal transplant 
and the annual mortality rate of listed patients is 6.3%, which rises to 10% if the wait 
listed patient is diabetic (1). Recently in the UK, Sharma et a l (33) followed 125 renal 
transplant candidates for 18 months. Overall mortality during follow-up was 9.6% and 
58% of deaths were due to CV causes. On average, patients wait for a renal transplant for 
2 years after being listed although, with an increasing shortage of donor organs, that time 
is expected to rise over the next 10 years. With an average list waiting time of 5 years not 
unreasonable in the future, the estimated risk of a diabetic patient dying whilst awaiting 
transplant is 30% (34).
Peri-operatively and in the immediate post-op period, mortality actually increases to 2.5 
times that of patients remaining on the waiting list (1,3,35). The majority of this excess 
risk is due to the CV complications of AMI, arrhythmia and cardiac arrest. In a study by
Humar et al. (35) the overall incidence of peri-operative cardiac complications was 6.1% 
in a cohort of 2694 transplant candidates and in a retrospective study of AMI in 53,300 
patients awaiting transplant, Kasiske et al. (36) found that although the relative risk (RR) 
of AMI 30 days post transplant rose 2.5 times above those remaining on the waiting list 
(2.8% per year), with a longer period of follow up, those who were transplanted had a 
17% lower risk of sustaining an AMI.
Over the first 12 months post transplant morbidity and mortality gradually decreases to 
below that of patients remaining on the waiting list (Graph 1.2) and after 3 years of 
follow up the mortality rate of patients with a functioning renal allograft is 68% less than 
that of remaining on the list. CV risk remains lower whilst the patient has a functioning 
allograft but CV mortality remains the most common cause of death, responsible for 32% 
of deaths in this population. On average, the life expectancy of an allograft is around 10 
years and if the allograft fails and the patient requires RRT once more, CV risk again 
increases to 20 times that of the general population and the patients will require 
reassessment for renal transplantation if felt appropriate.
1.3 Cardiovascular Risk Factors and Chronic Renal
Failure
For the purposes of description, the risk factors for CVD in patients with renal failure are 
usually split into ‘traditional’ and ‘non-traditional’. Traditional risk factors are those that 
have been defined and validated in the general population through prospective cohort 
studies such as the Framingham cohort, namely hypertension, diabetes, hyperlipidaemia, 
smoking, family history of premature IHD, age and male sex (Table 1.1) (37). Patients
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with CRF have a higher prevalence of many of these risk factors especially those felt, in 
part, modifiable; hypertension, hyperlipidaemia and diabetes.
The prevalence of hypertension is high in patients with CRF and in those who are not yet 
dialysis dependant is 70-80% (38-39). The prevalence of hypertension increases as GFR 
declines (40) and level of systolic blood pressure (BP) is directly correlated with the level 
of GFR and proteinuria (41). Observational studies of patients with CRF Stages 1-4 (GFR 
>15ml/min) have shown that hypertension is an independent risk factor for the 
development of LVH (42) and for CV events (18,43). Indeed, in a recent retrospective 
study of 184 non-diabetic patients with CRF Stage 1-4, uncontrolled hypertension 
(>140/90mmHg) was the strongest independent risk factor for CV mortality (RR 2.93, 
p<0.001, 95% CI= 1.69-5.12) (44).
Hypertension is the norm once patients reach ESRF and over 80-90% have hypertension 
at instigation of dialysis (45-46). The relationship of BP and CVD in patients on dialysis 
is complex. Higher BP has been shown to be a risk factor for LVH, IHD and CHF (47) 
but a low BP has been associated with a higher risk of all cause mortality (48-49). It is 
generally believed that the increased risk for all cause mortality in individuals with low 
BP is due to underlying co-morbidity that is associated with lower BP. For example, 
patients with low BP may already have structural cardiac disease and therefore may be at 
higher risk for CVD events (17). This U shaped relationship of BP with outcome and the 
high prevalence of BP in this population have meant BP does not have the same strength 
of association with outcome in patients on RRT and few observational studies have 
associated hypertension with shorter survival (50) and excellent BP control with 
increased survival (51).
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The aetiology of hypertension is also different in patients with ESRF compared to those 
in the general population. Increased peripheral resistance due to arteriosclerosis results in 
a decrease in compliance of the arterial tree and a combination of systolic and diastolic 
hypertension. However, volume overload secondary to salt and water retention plays a 
major role in the hypertension associated with ESRF and increased cardiac output (CO) 
secondary to arteriovenous fistulae and anaemia may also be factors (52). Thus, the 
treatment of hypertension in patients with ESRF may involve manipulation of dialysis 
programmes as well antihypertensive drug therapy (52).
Similar to the relationship of BP with outcome in patients on RRT, the relationship 
between dyslipidaemia and outcome also displays the phenomenon of ‘reverse 
epidemiology’ in patients with ESRF. Dyslipidaemia is common in patients with renal 
failure and the pattern and severity varies with the stage of renal disease (Table 1.2  ^(53) 
but hyperlipidaemia has not consistently been associated with CV outcome in patients 
with CRF, although it is associated with CV outcome in patients after renal 
transplantation (54-55). Cross-sectional studies of patients on RRT have failed to show 
an association between high total cholesterol and CV events (56-57), whilst other studies 
have shown high LDL cholesterol to be associated with CV events in patients on 
haemodialysis (58) and others have demonstrated a T  or ‘U’ relationship between serum 
cholesterol and outcome (59-60) with low and high levels of total cholesterol associated 
with poor outcome. With regard to the association of low cholesterol with adverse CV 
outcome, it is known that chronic inflammation will decrease levels of cholesterol and 
that inflammation is associated with an increased risk of both all-cause (61) and CV 
mortality (62) in patients with CRF. The prevalence of dyslipidaemia is higher in patients
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with CRF than the general population and the situation is made more complex as patients 
established on haemodialysis have a different lipid profile compared to those on PD 
(Table 1.2V Thus, as with hypertension, hyperlipidaemia does not have a strong 
association with outcome in patients with ESRF.
In the general population, it is well recognised that diabetes is a risk factor for the 
development of CVD. Around 40% of patients with diabetes have reduced GFR (38) and 
the majority of these have diabetic kidney disease. The presence of diabetes is associated 
with CVD in patients with Stage 1-4 CRF (38) and increasing levels of proteinuria in 
diabetic kidney disease are associated with a higher risk of CVD and all cause mortality 
(63).
Diabetes is the cause of ESRF in approximately 40% of dialysis patients (14) and is an 
independent risk factor for IHD and all-cause mortality for both patients using 
haemodialysis (29,56) and PD (29) as mode of RRT. In the study of Foley et a l (64), 116 
diabetic patients commencing RRT were followed up for 41 months. Compared to 315 
non-diabetic patients, those with diabetes had a higher prevalence of IHD and CHF and a 
higher incidence of new onset IHD during the study. Both all-cause and CV mortality in 
the diabetic cohort were significantly higher (Graph 1.3) and the presence of either IHD 
or CHF at initiation of dialysis were strong predictors of death (Hazard Ratio 2.3(1.5-4.0) 
and 2.1(1.0-4.4) respectively). However, there are no studies examining the impact of 
tight glycaemic control on CV outcome in patients with CRF, although it is recognised 
that improved glycaemic control may reduce the progression of renal failure in the earlier 
stages of CRF.
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Finally, with regard to potentially modifiable traditional risk factors, smoking is 
associated with CVD and all cause mortality at all stages of CRF, including those who 
have a functioning renal allograft (18,55-57). However, there are no studies that have 
demonstrated that smoking cessation improves CV outcome in CRF but it would seem 
advisable in view of the association with adverse outcome that patients are counselled 
regarding smoking cessation and offered the same help as those in the general population 
to stop smoking.
Given that the relationship of the potentially reversible risk factors of hypertension and 
dyslipidaemia with outcome in ESRF is inconsistent and that risk scores using ‘standard’ 
CV risk factors dramatically underestimate CV events in this population, it is widely 
accepted that other ‘uraemic’ or non-traditional risk factors exist in patients with renal 
failure (Table 1.1).
Atherosclerosis is increasingly recognised as a chronic inflammatory disease of the vessel 
wall (65) and progression of atherosclerotic plaques has been shown to be associated with 
secretion of pro-inflammatory cytokines and mediators, and progressive accumulation of 
inflammatory cells (65). Patients with renal failure, especially if on haemodialysis, have 
been shown to have high levels of circulating pro-inflammatory cytokines, such as 
interleukin-6 (66) and TNF alpha (67), and this suggests uraemia per se may cause a pro- 
inflammatory status with ongoing acute phase response This hypothesis is supported by 
finding of higher circulating levels of C-reactive protein (CRP) in patients with ESRF 
compared to those without renal failure (68). However, whether or not this process is 
modifiable with agents such as statins or aspirin is unknown.
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Other uraemia related cardiac risk factors such as hyperhomocysteinemia, oxidative 
stress and abnormal calcium/phosphate metabolism have been identified and studied but 
similar to inflammation it is unknown whether modification of these factors would confer 
improvement in CV outcome or if these factors are even modifiable.
In the search for modifiable CV risk factors in patients with ESRF, seminal work by 
Parfrey et al. (69-71) in the mid-1990’s established abnormalities of LV structure and 
function, namely LVH, LVDil and LVSD as independent risk factors for CV outcome in 
patients with dialysis dependent renal failure. Indeed, these LV abnormalities have been 
found to be the strongest independent predictors of outcome in this population (17). LV 
abnormalities are also strongly associated with adverse outcome in the general population 
but the prevalence, incidence and natural history of these LV abnormalities are different 
in patients with ESRF and due to these differences they are collectively termed ‘uraemic 
cardiomyopathy’
1.4 Left Ventricular abnormalities and Chronic Renal
Failure
Abnormalities of LV structure and function, defined by echocardiography, are more 
strongly associated with outcome than standard CV risk factors in patients with ESRF 
and have been described as being prevalent for over two decades (17,69,71-74). These 
abnormalities, especially LVH, are found early in the course of CRF and worsen as GFR 
declines (42). It is estimated that the prevalence of LVH in patients with a GFR 
>50ml/min is 27%, whereas in those with a GFR of 25-50ml/min the proportion is 31% 
which increases to 40% in patients with a GFR of <25ml/min (42).
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Once patients require dialysis as many as 85% of patients have an abnormal LV as 
defined by echocardiography and in one of the largest of these studies, Foley et a l (69) 
reported the prevalence of LV abnormalities in a cohort of 433 patients entering a long 
term dialysis programme in Canada from 1982-1991. They found that 74% of the cohort 
had LVH, 35% had LVDil and 15% had LVSD. Only 16% of the cohort had a normal LV 
(Figure 1.1T Other studies have reported similar findings for the prevalence of LV 
abnormalities in patients who are dialysis dependant and up to 80% have been found to 
have LVH identified by echocardiography (75-76). The prevalence of LVH in the normal 
population and in patients with hypertension is much lower than that observed in dialysis 
patients. Data from the Framingham study suggests that the prevalence of LVH in women 
is up to 33% in older age groups and 23% in older men (77) whereas studies of 
hypertensive patients observed a prevalence of 42.2% for LVH (78).
The observed pattern of LV abnormalities in ESRF has led to the classification of three 
types of cardiomyopathy in this population; concentric LVH, eccentric LVH and LVSD 
(69). Previous groups have proposed two models for the development of the LV 
abnormalities in patients with ESRF (79-80). The first is caused by predominantly 
pressure overload with an increase in pulse pressure. Initially, this is adaptive and in 
theory potentially reversible but when sustained overload occurs especially if associated 
with non-haemodynamic factors such as inflammation or ischaemia, fibrosis can develop 
eventually culminating in diastolic dysfunction and heart failure. Pressure overload is 
associated with hypertension secondary to increased arterial calcification and 
arteriosclerosis with a resultant decrease in aortic compliance and distensibility and
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increased aortic stiffness (80-81). This produces initially concentric LVH, an increase in 
relative LV wall thickness with normal LV volumes.
The second proposed model is caused by hypertension due to volume overload and 
produces eccentric LVH with initial dilation of the ventricle followed by compensatory 
hypertrophy. Renal failure, with salt and water retention, causes volume overload which 
is further exacerbated by the creation of arteriovenous fistulae which can increase CO by 
up to 25% (82-84). Anaemia also increases CO and contributes to volume overload (85). 
In any individual patient with ESRF both mechanisms may play a role in the 
development of LV abnormalities. The end-point of both mechanisms is cardiac failure 
and systolic dysfunction. In the case of pressure overload and concentric hypertrophy, 
after a period of diastolic dysfunction, eventually LV dilation will occur followed by 
systolic dysfunction.
Patients on dialysis who are considered candidates for renal transplantation are generally 
younger and fitter than those who remain on dialysis and as they have less co-morbidity it 
could be presumed that the prevalence of LV abnormalities is lower in this group. Studies 
in our own population of transplant candidates however do not support this hypothesis. In 
a study by McGregor et a l (86), 141 non-diabetic patients on the transplant waiting list 
underwent echocardiography just prior to undergoing renal transplant. The prevalence of 
LVH was found to be 70% for men and 65% for women, 83% were identified as having 
LVDil and 28% had systolic dysfunction, defined by Fractional Shortening (FS) <25%. 
However, due to the nature of the study, patients were not necessarily examined on a post 
dialysis day which may have overestimated the proportion of patients with LV 
abnormalities. In a more recent study by Sharma et a l (87), 203 patients on the renal
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transplant waiting list in London were studied and 21% of these patients were diabetic. 
The prevalence of concentric LVH was found to be 60% in the whole cohort and the 
prevalence of eccentric LVH and LVSD was 11% and 7% respectively. Thus, whilst the 
prevalence of LVH remains high in those awaiting transplant, the prevalence of LVDil 
and LVSD may be lower than those remaining on dialysis and it is notable that in the 
institution where the study of Sharma et a l was carried out, patients with an Ejection 
Fraction (EF) of <30% are excluded from the renal transplant waiting list. However, in 
both these studies, the proportion of patients with a normal ventricle was still small at 
13% and 22% respectively.
Prognosis is adversely affected by the presence of LV abnormalities (29,75-76,87) and 
outcome worsens progressively with the echocardiographic findings of LVH, LVDil and 
LVSD. With follow up of the cohort of Foley et al. (70) it was found that median time to 
the development of clinical cardiac failure was 19 months for patients with LVSD, 38 
months in LVDil and 38 months in those with LVH. The rate of mortality is also higher 
in patients with LVSD. Median survival was found to be only 38 months if a patient was 
found to have LVSD whereas it was 48 months in those with LVH, 56 months in those 
with LVDil without systolic dysfunction and over 66 months in patients with normal 
ventricles (70). Around two thirds of patients on dialysis with LVH die from heart failure 
or sudden death and the 5 year mortality increases from 23% to 52% when comparing a 
LV mass index (LVMI) of less than or more than 125g/m2 (72).
In addition to identifying patients with a poorer prognosis, the presence of an abnormal 
ventricle serves as a marker or risk factor for the development of de novo CHF and IHD. 
For example, the presence of LVSD on echocardiography is the strongest independent
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risk factor for the development of CHF in this population (RR 2.05) (30) and the presence 
of any LV abnormality will independently increase the risk of developing IHD with a RR 
of 5.92, 5.35 and 12.2 for LVH, LVDil and LVSD respectively (71).
With follow up, observational studies have shown a gradual progression of the degree of 
LVH and LVDil observed in an individual patient (70), although regression of LVH may 
be possible with manipulation of dialysis programmes (89) and tight control of BP with 
agents such as angiotensin converting enzyme inhibitors (ACEI) (75). Regression of 
LVH and LVDil is also observed after renal transplantation (90-91) and pre-transplant 
LV abnormalities have been shown to be predictive of CV outcome after renal 
transplantation (86-87). Recently, the work of Zocalli et a l (76,92-93) has shown that the 
strongest prognostic indicators of outcome in patients with ESRF are the LV 
abnormalities of LVH and LVSD, especially if the degree of magnitude of these 
abnormalities worsens with time and in a study by Paoletti et a l (94) worsening LVH in 
patients with ESRF was the strongest predictor of sudden death after 10 years of follow 
up. These findings suggest that serial monitoring of LV abnormalities may provide 
additional prognostic information over a single measurement.
Several studies have examined potential risk factors for the development of LV 
abnormalities and have found that risk factors differ depending on type of LV 
abnormality found on echocardiography. Systolic hypertension has most consistently 
been associated with the development of concentric LVH (29,42,69,74) and anaemia has 
also become inseparably linked with LVH in nephrology literature. Factors associated 
with progression of LVH include age and diabetes (69,71). Anaemia has been more 
strongly associated with eccentric LVH than with concentric LVH (75) and other factors
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such as hypoalbuminaemia and haemodialysis as mode of dialysis therapy have also been 
found to accelerate progression of LVDil and a history of IHD may also play a role. 
LVSD implies a poor outcome in this patient population and is associated more 
consistently with a history of IHD and diabetes. Again, other factors such as BP and 
anaemia have been associated with LVSD but with much less consistency than that of 
IHD (71,92,95).
Despite a wealth of data on the epidemiology of echocardiographically defined LV 
abnormalities in ESRF and the association of potentially reversible risk factors such as 
hypertension and anaemia with these abnormalities, there is still a lack of interventional 
trials to show that targeting reversible risk factors produces regression of LV 
abnormalities thereby translating into improved outcomes. One recent study by London et 
al. (75) targeting both hypertension (pre-dialysis BP>140/90mmHg) and anaemia 
(Hb<l l.Og/dL) in 153 dialysis patients, produced regression of LV mass of 10% in 46% 
patients in the study and ‘responders’ had improved outcome compared to non­
responders. This study of London et a l is the first to suggest CV outcome can be 
improved via regression of LVH in dialysis patients but as yet there is still no major 
evidence base to support the hypothesis that aggressive risk factor targeting and 
regression of LV abnormalities will impact upon either CV or all cause mortality in this 
population.
Part of the problem with using LV abnormalities as targets in interventional studies in 
patients with ESRF is the inaccuracy of echocardiography as the method of measurement 
in this population. However, several other problems also exist. Firstly, LV abnormalities 
of structure and function are interrelated and often coexist together giving a ‘chicken and
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egg’ scenario once established. Secondly, LV abnormalities are also a risk factor for CV 
outcome and a disease state themselves, further complicating the issue and finally, the 
relationship of LV abnormalities to CAD is not clearly defined in this population due to 
the difficulties of non-invasive characterization of CAD and a high prevalence of 
symptoms such as chest pain and breathlessness, which although suggestive of 
underlying CAD, may be due to other conditions such as volume overload and anaemia. 
Anaemia has been consistently listed as a risk factor for both CVD and cardiomyopathy 
in patients on RRT and the majority of interventional trials targeting LV abnormalities 
have been via treatment of anaemia in this population. However, there are no trials 
showing that reversal of anaemia alone improves CV outcome or produces regression of 
LVH in patients with renal failure and the association of haemoglobin with LVH in this 
population may be because of inaccuracies in the current methods used for calculation of 
LV mass.
1.5 Haemoglobin and Left Ventricular abnormalities
There are several explanations for the anaemia found in association with CRF, including 
inhibition of marrow erythropoiesis by humoral toxins, bleeding, shortened life span of 
erythrocytes and malnutrition, but the primary cause is a decline of erythropoietin 
production by the failing kidney (96). The anaemia associated with renal failure is 
typically normochromic and normocytic and the severity increases with decreasing GFR. 
Anaemia develops when GFR falls to between 25-50ml/min (97) and, with the discovery 
of erythropoietin and eventual manufacture of recombinant human erythropoietin,
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treatment of anaemia in patients with CRF changed dramatically, with the need for 
recurrent blood transfusion significantly reduced (96).
However, a significant proportion of patients with CRF, especially those with ESRF, 
remain anaemic and current guidelines suggest a target haemoglobin concentration of 
more than llg/dL in such patients (98). At tissue level, anaemia leads to hypoxia, 
vasodilatation and increased venous return (99). This in turn affects measured end- 
diastolic volume (EDV) and anaemia has been associated with LVDil in several previous 
echocardiographic studies (42,71,74,100). It is postulated that initial LVDil caused by 
anaemia in CRF will lead to eccentric LVH and thus anaemia is also associated with 
LVH in ESRF. Anaemia in CRF is associated with increased morbidity and mortality 
(101-102). Large retrospective studies of patients on haemodialysis programmes have 
suggested an increase in mortality rate as haemoglobin declines and that patients with 
haemoglobin concentrations of <8g/dL have twice the rate of mortality of those with 
concentrations of between 10-llg/dL (101). Treatment of anaemia with erythropoietin is 
associated with outcomes such as improvements in quality of life (103), exercise 
tolerance (104), immunity (105) and sexual function (106) and decreases frequency of 
hospitalization (12). However, the degree of anaemia correction conferring optimal 
mortality benefit is less certain and anaemia correction has not directly been shown to 
confer mortality benefit in either CRF or ESRF (107-108).
In a recent study published by Singh et al. (107), 1432 patients with CRF were 
randomised to receive erythropoietin targeted to achieve either a haemoglobin 
concentration of 13.5g/dL or 11.3g/dL and had a composite end-point of death, 
myocardial infarction or hospitalisation for CHF and stroke. They found no benefit to
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targeting haemoglobin concentration to the higher level and the number of adverse events 
was actually higher in the group whose target haemoglobin concentration was 13.5g/dL. 
Another study by Drueke et al. (108) targeted those with a GFR of between 15-35ml/min 
and mild anaemia (11.0-12.5g/dL) to either a target haemoglobin concentration of 13.0- 
15.0g/dL or 10.5-11.5g/dL. The primary end-point was a composite of 8 CV end-points 
with a secondary end-point of LVH regression. Again, at the end of this 3 year study no 
improvement in CV outcome was found and no differences in LV mass between groups. 
In both studies quality of life and general function improved. Other studies such as the 
Normalisation of Haematocrit Trial (109) included patients on haemodialysis with the 
presence of IHD or CHF. Patients were targeted to a higher (42%) or lower haematocrit 
(30%) level and again no benefit was found with regard to mortality or CV events and the 
trial was stopped early due to an excess of vascular access thrombosis in those targeted 
to a higher haematocrit level.
The association of anaemia directly with LV abnormalities such as LVH has come 
mainly from observational trials (42,71,100) and several of these have found anaemia to 
be a risk factor for LVDil and LVH as well as new onset CHF. Thus the hypothesis in 
many subsequent articles involving anaemia and patients with ESRF (110-112) has been 
as follows; LVH defined by echocardiography is common in patients with ESRF and is 
associated with increased CV mortality; anaemia is a risk factor for LVH and de novo 
CHF; regression of LVH in patients with hypertension results in a reduction in CV events 
in patients without renal failure; anaemia correction will lead to regression of LVH and 
therefore, CV outcome will be improved in patients with ESRF by anaemia correction. 
This hypothesis supposes that LVH and LV dilation are mechanisms via which anaemia
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affects mortality and that LVH is an attractive surrogate end-point for CV outcome in 
trials of anaemia correction. This strategy is questionable due to the lack of interventional 
studies demonstrating that anaemia correction improves clinical events in parallel with a 
predictable change in LV geometry or function.
There have been several small, uncontrolled interventional trials targeting anaemia which 
suggested variable reduction of LV mass or LV dilation (113-115). However, in a larger 
double blind randomised controlled trial, Parfrey et al.{ 116) randomised haemodialysis 
patients with echocardiographically defined cardiomyopathy to a targeted haemoglobin 
concentration of either 9.5-10.5g/dL or 11-13g/dL. No regression of concentric LVH or 
LVDil was found resulting from normalisation of haemoglobin, although it was 
suggested that reversal of anaemia may prevent new LVDil. It was commented upon by 
the authors that patients on haemodialysis with evidence of cardiomyopathy may be at a 
too advanced stage to benefit from anaemia correction.
There is little data supporting the relationship of correction of anaemia and LVH in 
patients with CRF either. Two studies totalling 20 patients reported LVH regression in 
association with erythropoietin treatment but as these studies were uncontrolled, the 
effect of other parallel processes cannot be dismissed (117-118). In a larger randomised 
trial involving 153 patients with a GFR of between 15-20ml/min, patients were assigned 
to target haemoglobin concentrations of either 9.0-10.0g/dL or 11.0-12.0g/dL (119). 
Follow up was over 2 years and the primary end-point was a change in LV mass index 
(LVMI), measured using echocardiography. No significant differences were found 
between the 2 treatment arms at the end of the study with regard to LV mass or volumes 
and a small increase in LVMI in those found to have no LVH at the commencement of
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the study showed no relationship to haemoglobin. Similar findings were observed in a 
recent study by MacDougall et a l (120) who studied 197 patients with a serum creatinine 
of <500mmol/L. Patients were treated early when they first developed anaemia (Hb 
<11.0g/dL) and compared to a group who were not treated until haemoglobin fell below 
9.5g/dL. Again, there was no significant difference found with regard to the primary end­
point of LV mass between the two groups after three years follow up.
However, the use of LVH in patients as a surrogate end point of CV outcome in this 
population still remains an attractive one in light of the results of the previously 
mentioned interventional trial by London et al. (75). This study assessed the impact of 
targeting both anaemia and BP on LVH. This strategy produced partial but significant 
regression of LVH which conferred a mortality benefit. However, it is unclear how much 
BP reduction influenced the results and perceivable, in light of other evidence, that BP 
reduction resulted in all of the positive findings. It is important to ascertain how much of 
an impact each of these reversible risk factors has on end-points such as LVH, as 
treatment of anaemia with erythropoietin can elevate BP. The findings of London et al. 
also do not support the argument of Parfrey et al. that regression of LV abnormalities in 
patients on haemodialysis may not be possible due to the advanced stage of 
cardiomyopathy.
Despite the consistent association of anaemia with LVH, there is no reliable evidence that 
reversal of anaemia either improves LV abnormalities or patient outcome. It is likely that 
this ‘mismatch’ in evidence base is partly due to the inaccuracies associated with 
echocardiographic measurements of LV mass and volumes and the relationship between
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anaemia and LV abnormalities may be better understood using more accurate 
measurement techniques.
1.6 Brain Natriuretic Peptide and Left Ventricular 
abnormalities in ESRF
The natriuretic peptides are a family of peptides, discovered in 1981, with a potent 
natriuretic, diuretic and vasorelaxant activity, the physiological effects of which are 
shown schematically in Figure 1.2 (121). The family consist of three peptides; atrial 
natriuretic peptide (ANP), BNP and C-type natriuretic peptide (CNP). ANP, produced 
primarily in the cardiac atria and BNP, produced mainly in the cardiac ventricles, are 
released in response to increased myocyte stretch with an increase in atrial and 
ventricular wall tension respectively, both reflecting increased intravascular volume 
( 121).
Both ANP and BNP are initially produced in a pre-cursor protein form and are cleaved to 
the active form and inactive NT-proANP and NT-proBNP. Both the active and inactive 
forms of ANP and BNP circulate in the plasma and can be measured. ANP and BNP as 
well as NT-proANP and NT-proBNP have been shown to have elevated levels in patients 
with LVSD (122-123), LVH (124-125) and CAD (126) and are strong predictors of CV 
morbidity and mortality in such patients (126-127). Furthermore these peptides, 
particularly BNP and NT-proBNP can be used to help diagnose heart failure in the 
general population due to the very high negative predictive value (NPV) of this test 
(123,128) and it has been suggested that levels can be used in the tailoring of medical 
therapy in heart failure to improve prognosis (129).
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Recently, the use of BNP and NT pro-BNP has been examined in patients with advanced 
heart failure awaiting cardiac transplant and in patients after transplant. Gardner et a l
(130) studied 26 consecutive patients undergoing cardiac transplantation, measuring NT 
pro-BNP level at the time of listing for transplant and 1 week post transplant. They found 
that NT pro-BNP level was predictive of mortality post cardiac transplant and previous 
work by the same group suggests NT pro-BNP is also a strong independent predictor of 
mortality in patients whilst awaiting cardiac transplant. An earlier study by Mehra et al.
(131) measured BNP in 62 patients who had undergone cardiac transplant more than 12 
months previously. Patients were followed up for 24 months and BNP as well as a low 
EF were found to be independent predictors of poor survival.
It therefore follows, that in view of the association of LV abnormalities with outcome in 
patients with ESRF and the fact that CVD is the most common cause of death both whilst 
patients are awaiting renal transplant and post-transplant, natriuretic peptides could form 
a useful adjunct in the investigation of CVD in such patients. However, the measurement 
of these peptides is more complex in patients with renal failure for several reasons. 
Firstly, fluid retention and increased intravascular volume and therefore venous return, 
will cause stretch of the atria and ventricles increasing the production of ANP and BNP. 
Secondly, the kidney is in part responsible for excretion of these peptides and both ANP 
and BNP circulate in higher levels in the plasma in patients with CRF than in patients 
with normal renal function and levels progressively increase with a decrease in GFR 
(132-136). Thirdly, in patients on haemodialysis levels of ANP and BNP change 
depending on the time the sample is taken with regard to dialysis cycle (134,137) and 
depending on whether high or low flux dialysis membranes are used (137) and finally
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levels are further elevated in patients with ESRF who have LVSD, LVH or CAD 
(129,138-139). It has also been suggested that there are also other confounding factors in 
patients with renal failure which influence natriuretic peptide levels including 
haemoglobin levels and albumin (136).
In renal failure, several studies have shown that BNP is a more sensitive and specific 
marker than ANP for the assessment of LV abnormalities (137,140). BNP is a 32 amino 
acid structure and has a molecular weight of 3472Da. Most dialysis membranes will clear 
mid-molecular weight molecules including BNP but high-flux membranes will give a 
higher rate of clearance (138). Several studies have suggested that BNP levels do not 
change after dialysis (141-142) but others have found that levels decrease (133,137,143). 
Recently Zeng et al. (134) performed a study in 56 patients on long term haemodialysis, 
measuring BNP levels pre-dialysis, immediately post dialysis and again at 3hours, 6hours 
and 24hours post dialysis. They found that levels of BNP were elevated from pre-dialysis 
level immediately post-dialysis and then fell below pre-dialysis level for the remaining 
test times. In another study, Nishikimi et al. (138) found that levels of BNP fell after 
dialysis except on a Monday, after the patients had an extra 24 hours without dialysis 
compared to other times of the week. However, despite these differences in levels of 
natriuretic peptides at differing times between dialysis sessions Zeng et al. found that the 
timing of sampling did not significantly change the sensitivity and specificity of BNP to 
predict LV abnormalities.
Recently, it has been suggested that in patients with normal renal function NT-proBNP is 
more sensitive and specific than BNP for identifying LV systolic and diastolic 
dysfunction and a more powerful predictor of outcome (144). NT-proBNP is a much
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larger molecule than BNP with a molecular weight of 85 Da, and also has differing 
methods of excretion. In addition to glomerular filtration, BNP is eliminated from plasma 
mainly through natriuretic peptide receptors NPR-C, and degraded by neutral 
endopeptidases (145-146). In contrast, NT pro-BNP is largely eliminated by glomerular 
filtration only (147). In our own population, we performed a pilot study to assess the 
potential use of NT-proBNP as a marker of LV abnormalities in dialysis dependant renal 
failure. We studied 25 patients on haemodialysis and measured levels of NT-proBNP 
immediately before, halfway through and immediately after haemodialysis. The normal 
level of NT-proBNP is <90picomoles/L and we found grossly elevated levels of NT- 
proBNP at all three time stages. Mean NT-proBNP level was 88,164 picomoles/L, the 
range of NT-proBNP was very large and levels further increased after dialysis. This 
finding has been shown in other studies of NT-pro BNP in patients on dialysis (147) and 
NT pro-BNP is eliminated by high flux dialysis membranes but not by low flux dialysis 
membranes. In view of the added potential problems with NT pro-BNP and a seemingly 
superior sensitivity and specificity of BNP compared to ANP in detecting LV 
abnormalities in patients on haemodialysis we elected to measure BNP in our cohort of 
patients.
However, not all patients awaiting renal transplantation use haemodialysis as mode of 
RRT and a significant proportion use continuous ambulatory PD (CAPD) or ambulatory 
PD (APD). There is little data on levels of natriuretic peptides in patients on CAPD or 
APD but one small study comparing 32 patients on CAPD to 63 patients on 
haemodialysis suggested that BNP and ANP levels are significantly lower in patients on 
CAPD after patients with IHD had been excluded. The authors suggested that this may be
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due to the lower haemodynamic load in patients on CAPD and BNP correlated with 
positively with LVMI and negatively with EF in both subsets of patients (148).
It is unsurprising in view of the numerous confounding factors contributing to the 
circulation of these peptides in patients with renal failure that their usefulness in the 
diagnosis of LV abnormalities in this population, as well as their potential role in 
monitoring disease and as a marker for prognosis is unclear. Previous studies assessing 
the role of these peptides in CRF have all used echocardiography as the method of 
measurement of LV abnormalities. CMR imaging is now the accepted standard of 
reference for measurement of LV mass, volumes and function (149) and the relationship 
between BNP and LV abnormalities in patients with ESRF may be better defined using 
CMR measurements of LV structure and function.
1.7 Left Ventricular abnormalities and Coronary
Artery Disease
The mode of cardiac death in patients with ESRF is different to that of the normal 
population. Whereas the majority of deaths in the normal population are due to 
obstructive CAD, only around 20% of cardiac deaths are due to the direct consequences 
of AMI in patients with ESRF (150). The majority of the mortality in this population is 
due to sudden, presumed arrhythmic death (150) explained partially by large electrolyte 
shifts associated with dialysis, abnormal physiological loading conditions (151) and 
reduced subendocardial capillary density with resultant relative hypoperfusion secondary 
to LVH (79). However, it is also likely that a proportion of arrhythmic death in this 
population is due to underlying ‘silent’ CAD.
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There are other differences between CAD found in the normal population and that in 
patients with renal failure. The composition of coronary plaque may be different in 
patients with ESRF, with increased media thickness and more marked calcification of the 
affected coronary arteries compared to those of the normal population, in whom plaque 
morphology tends to be fibroatheromatous (152-153). An increase in media thickness is 
not confined to the coronary conduit arteries in patients with CRF but is widespread from 
small resistance arteries to the aorta (80-81,154), in part, resulting in an increase in 
vascular stiffness and non-compliance.
Angiographic studies of patients with ESRF suggest that up to 50% have significant and 
often silent CAD and defining those patients with CAD is important as it affects 
treatment and prognosis (155-157). AMI is an early hazard in patients starting dialysis 
with 29% sustaining an AMI within the first year of dialysis and 52% within two years of 
initiation of dialysis (158) and in this population AMI is an event that is associated with a 
very poor long term survival (158-160). Several studies have shown that mortality rate at 
12 months post AMI in this population is as high as 60% and two year mortality up to 
73% (158). Patients have a better outcome after renal transplantation but mortality is still 
significantly higher than that of the normal population with a two year mortality rate of 
34% (159) and around 45% of deaths in the first 12 months after renal transplant are due 
to AMI (1,161). The very poor outcome in patients on dialysis is felt to be, in part, due to 
a combination of under diagnosis, as many patients may present atypically with 
symptoms that could also be attributable to fluid overload, and under treatment or 
‘therapeutic nihilism’ (162-163). Patients established on RRT are less likely to receive 
thrombolysis (164) in the event of an AMI even though outcome is even more dismal if
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thrombolysis is not administered in this population (165) and patients with ESRF are also 
less likely to undergo percutaneous intervention (PCI), receive glycoprotein Ilb/IIIa 
receptor antagonists or be discharged on optimal secondary prevention with beta-blockers 
or statins (163,166-167). Again, this is despite the fact there is evidence to suggest that 
administration of glycoprotein Ilb/IIIa inhibitors provide similar benefits in patients with 
renal failure (168-169), at the cost of a moderately increased risk of non-fatal 
haemorrhage, and that patients with ESRF have a better long term outcome after AMI if 
prescribed aspirin, beta-blockers and ACEI’s (166,170).
LV abnormalities, defined by echocardiography, are generally considered and 
investigated separately to CAD in patients with renal failure in nephrology literature and 
there are few studies comparing the findings of coronary angiography to those of resting 
echocardiography and LV abnormalities. Longitudinal studies investigating LV 
abnormalities tend to use a history of angina or previous AMI as a marker of CAD 
(17,29), as repeated coronary angiography would be impractical and unethical, and the 
few studies using coronary angiography to investigate CAD in this population that also 
involve resting echocardiography, have incomplete echocardiographic data as 
echocardiography was carried out at the discretion of the referring physician (171).
Several studies investigating the risk factors for the development of de novo IHD suggest 
an echocardiographic finding of LVSD was the strongest predictor of developing 
symptoms of IHD (29). A finding of LVH or LV dilation (LVDil) was also associated 
with an increased risk of developing IHD (29) but as previously mentioned, IHD was 
defined clinically and it is well recognised that patients with renal failure and LVH may
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develop typical symptoms of angina with normal coronary arteries due to relative 
hypoperfusion of the subendocardial layer of the myocardium.
The non-invasive identification of LV abnormalities is relatively straightforward in this 
population compared to the non-invasive identification of CAD. The ability of non- 
invasive stress imaging modalities to both identify reversible myocardial ischaemia and 
predict prognosis in this population has been generally disappointing. Exercise tolerance 
testing (ETT) in patients with ESRF is unsatisfactory as patients have poor exercise 
tolerance secondary to factors such as anaemia, PVD and general deconditioning and 
there is a high prevalence of abnormalities found on the resting electrocardiogram (ECG) 
making interpretation difficult (33,172). The accuracy of single-photon emission 
computed tomography (SPECT) nuclear stress perfusion imaging in renal transplant 
candidates, compared to quantitative coronary angiography (QCA), is better than that of 
conventional ETT but still does not reliably provide a sensitivity or specificity of over 
80% (173-174) and there are no studies using positron emission tomography (PET) 
scanning in this population, which is widely regarded as the standard of reference for the 
non-invasive detection of CAD in the normal population. There are relatively few studies 
using dobutamine stress echocardiography (DSE) in patients with ESRF with mixed 
results. In a study of 50 renal transplant candidates, Herzog et al. (175) found a 
sensitivity of 75% and specificity of 76% for DSE to detect a >70% coronary stenosis 
defined using QCA and more recently, Sharma et al. (33) found the sensitivity of DSE to 
detect a coronary stenosis of >70% to be 88% with a specificity of 94% in a cohort of 125 
renal transplant candidates. However, other groups have not found DSE to be predictive 
of coronary anatomy or future cardiac events in renal transplant candidates and many
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found difficulty in interpreting the wall motion of the LV due to LVH and suboptimal 
achievement of adequate stress due to the need for early termination of the test by a 
markedly hypertensive response to dobutamine (171). Although observational studies 
have suggested there is no predictive value of non-invasive testing in patients awaiting 
renal transplantation (13), a meta analysis of 8 nuclear and 4 stress echo studies did show 
that a the finding of a positive test increased the relative risk of both future AMI and of 
cardiac death (176).
Several groups have argued that patients with ESRF should undergo coronary 
angiography to define CAD if being considered for renal transplant (155,171). This 
strategy is also problematic. Firstly, this is an invasive procedure with a risk of 
cerebrovascular event, AMI and death. The majority of patients with ESRF will have this 
procedure performed via the femoral approach due to the presence or potential need of 
arterio-venous fistulae and with the femoral approach there is a potential higher risk of 
dissection, pseudo-aneurysm or significant haemorrhage than that of the normal 
population due to the vasculopathy of renal failure. Secondly, contrast nephropathy is a 
real risk to patients not yet established on RRT or those with residual renal function on 
PD. Thirdly, if significant CAD is found, then what is the correct treatment strategy? 
Many of these patients are asymptomatic and the benefit of revascularization in 
asymptomatic patients is unknown. Recent evidence in a study of 2287 patients with 
CAD randomised to either medical therapy or medical therapy plus PCI showed no 
additional morbidity or mortality benefit of PCI over medical therapy after almost 5 years 
of follow-up (177). There is scant data comparing optimal medical management to PCI 
in patients with ESRF for the treatment of CAD and patients with ESRF undergoing PCI
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have twice the restenosis rate of the general population and almost ten times the mortality 
(178). Data comparing PCI to coronary artery bypass grafting (CABG) in this population 
favours CABG (179-180). Finally, there are potential flaws in the use of QCA in the 
assessment of significant, physiological ‘flow limiting’ stenoses of the coronary arteries. 
A recent meta-analysis of 31 studies comparing QCA to measurements made using 
fractional flow reserve (FFR), which is now considered the standard of reference for 
physiological significance of a coronary stenosis, suggests that QCA does not predict the 
functional significance of CAD and that non-invasive methods of measurement such as 
DSE and PET actually compare better with FFR than QCA (181). As yet, there are no 
studies using FFR in this population and future studies utilizing coronary angiography 
should be wary of using QCA as the standard of reference for the functional significance 
of a coronary stenosis. However, the presence of CAD at angiography using QCA does 
give information regarding prognosis in patients awaiting renal transplant (171).
A more accurate non-invasive, combined assessment of both LV abnormalities and of 
underlying CAD would therefore be attractive for the CV investigation of patients with 
renal failure both to better define the relationship between LV abnormalities and CAD 
and to potentially negate the need for invasive coronary angiography, especially in 
asymptomatic patients.
1.8 Echocardiography and the Uraemic Heart
Echocardiography is a widely available, inexpensive and easily performed method of 
assessment of cardiac structure and function allowing direct visualisation of the 
myocardium and real time imaging (Figure 1.3). It has been utilised extensively in
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longitudinal and cross sectional studies of LV abnormalities in patients with ESRF (69- 
76) and undoubtedly gives valuable information regarding prognosis (71-72,75-76,86- 
87). However, problems regarding both image acquisition and the geometric assumptions 
required for calculation of LV mass and volumes from one and two dimensional images 
of a 3-dimensional structure introduce error and affect both the accuracy and 
reproducibility of this method. The resulting wide range of variability raises questions 
regarding the utility of echocardiography to accurately detect progression or regression of 
LV abnormalities over time unless study sample sizes are very large (182-183).
Obtaining good quality images depends on a skilled operator, patient position and 
anatomy, obesity and angle of the transducer beam. Therefore, the first problem with 
echocardiography is obtaining images of sufficient quality for analysis which may 
exclude up to 25% patients (184-185). For example, in the study by Foley et al. (69) one 
of the entry criteria to the study was a satisfactory echocardiogram within 6 months of 
starting haemodialysis. Despite this, a further 16% of the initial cohort was excluded 
from the study on follow up due to inability to gain adequate images from 
echocardi ography.
Both M-mode (one-dimensional) and two-dimensional imaging can be employed to 
calculate LV mass. M-mode imaging allows better endocardial border definition as it has 
greater resolution due to a higher frame rate, as long as adequate beam positioning is 
ensured and ventricular shape is normal. Two-dimensional imaging on the other hand 
depicts the ‘real’ ventricular shape and identifies regional wall motion abnormalities. 
However, the quality of two-dimensional imaging may be limited due to both lower 
lateral resolution and frame rate. Additionally, this option is more time consuming and in
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all but the most recent studies in patients with ESRF, M-mode measurements have been 
used to calculate LV mass, volumes and function.
M-mode measurements of ventricular wall thickness and chamber dimensions and the 
method of cubed formulae, incorporates only one dimension of the LV cavity and 
assumes an ellipsoid geometry. Therefore any inaccuracy is amplified even in normal 
ventricles, such that a difference of 5% in the M-mode measurement will translate to a 
difference in LV mass of 8-15% (186).
Further problems arise due to the fact there are several formulae or measurement 
conventions for the calculation of LV mass and although more recently the American 
Society of Echocardiography (ASE) convention (187) has become the most widely used 
in epidemiological studies, earlier studies used any one of 3 conventions which are not 
interchangeable and can lead to differences in mass estimation by up to 18% (188). These 
conventions differ on the inclusion or exclusion of echoes from interfaces of the LV 
cavity or myocardial wall. These echoes are created by the fact that ultrasound signals are 
reinforced where surfaces change density and this allows the definition of limits between 
surface layers (Figure 1.4).
Initial M-mode standard convention recommended inclusion of the edges as part of the 
interventricular septum (IVS) but exclusion of the posterior wall epicardial edge and was 
calculated thus (189);
LV mass = 1.05 ([LVIDD + PWTD + IVSTD]3 - [LVIDD]3 g
LVH)D= LV internal diameter in diastole, PWTD= Posterior wall thickness in diastole, 
IVSTD= Interventricular septum thickness in diastole
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Subsequently Devereux suggested a modified regression equation derived from the post­
mortem findings of 34 patients using the Penn convention as border definition where all 
edges are considered part of the ventricular cavity (Figure 1.4) thus (190);
LV mass = 1.04 ([LVIDD + PWTD + IVSTD]3 - [LVIDD]3 - 13.6g 
Finally the ASE convention was proposed (187) and has become the most accepted 
border definition criteria using the leading edge of each layer (Figure 1.4) . Devereux et 
al. (191) then proposed a new adjusted equation using the ASE convention based on the 
post mortem specimens of 54 patients thus;
LV Mass = 0.8 (1.04 ([LVIDD + PWTD + IVSTD]3 - [LVIDD]3)) + 0.6g 
Therefore, employing different conventions and formulae will result in differing 
calculations of mass from the same M-mode image and using the Penn as opposed to the 
ASE convention will result in a difference in calculated LV mass of 15% in men and 18% 
in women (188). This makes comparison of LVH studies using different methods of 
measurement difficult (192) and each can lead to different cut point values for LVH. 
Furthermore, the post-mortem validation studies had limited sample sizes and evaluate 
heterogeneous ventricular configurations and another post mortem study revealed only 
moderate correlation between echocardiographic and post mortem findings (193).
The problems associated with image acquisition and geometric assumptions apply to all 
patients undergoing echocardiography but additional problems exist when performing 
echocardiography in patients with renal failure. The calculation of LV mass from M- 
mode measurements is critically dependant on LVIDD and changes in loading conditions 
will temporally affect ventricular volumes and therefore also affect the measurement of 
LVIDD. The unique problem of the assessment of LV volumes and function in patients
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with ESRF was demonstrated very simply by Nixon et al. (194). They studied 5 patients 
who were not on cardiac medication and in whom initial echocardiography demonstrated 
a normal ventricle and therefore the inaccuracies inherent to the geometric formulae 
minimised. They performed echocardiography after three different dialysis regimes were 
performed in each patient; haemodialysis with volume loss, ultrafiltration with volume 
loss only and haemodialysis without volume loss. Echocardiography was performed in 
each patient before and after each type of dialysis and the results analysed by two 
independent cardiologists who were blinded to patient name and type of dialysis. They 
found that even in dialysis patients with normal ventricles both EDV and end-systolic 
volume (ESV) altered significantly depending on type of haemodialysis therapy as did 
FS. In patients who had volume loss only, there were significant decreases in EDV and 
ESV with a decrease in EF of around 20% due to a downward shift on the Frank-Starling 
curve. This contrasted to the findings in the other two groups were EF increased with 
differing degrees of change of EDV and ESV.
Further work by Harnett et a l (195) found that due to the dependency of the calculation 
of LV mass on LVIDD, mass measurements could change by 20% in the same patient 
from images taken before and after a single dialysis session and thus patients with ESRF 
undergoing echocardiography should be studied on a post-dialysis day. However, this 
will not abolish the inaccuracies completely and as LV volume is calculated from M- 
mode measurements using the formula;
(LVIDD)3 x 0.001047/Body Surface Area (BSA) 
and FS is calculated using the formula
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[LVTDD-LVESD/LVESD] x 100, there will also be inaccuracies in the calculation of 
volumes and function of the LV.
It is therefore unsurprising that the reproducibility of echocardiographic measurements 
are variable and whilst interstudy reproducibility (test, retest variability) has a standard 
deviation (SD) of 22-40g (95% Cl 45-78g) (183,191,196-198), interobserver variability 
has a standard error of estimation (SEE) of 28-41g (95% Cl 55-80g) (191,197-198). This 
wide range of variability affects accuracy, which for M-mode imaging has a SEE of 29- 
97g (95% Cl 57-190g) (190-191,199-200) and in a clinical setting this means that in an 
individual patient, M-mode echocardiography cannot detect a change unless it is more 
than +/-45-78g, with any certainty. It is also likely that the high variability of 
measurements produced by echocardiography is largely responsible for the lack of 
reliable evidence in patients with ESRF that LV abnormalities are reversible and that 
regression of these abnormalities translates into improved outcome.
These problems with echocardiography, along with the emergence of CMR imaging have 
led to questions being raised about the accuracy and utility of echocardiography in 
longitudinal and interventional studies in the hypertensive population (183,196,201) and 
several studies have suggested that, in the presence of an abnormal ventricle, 
echocardiography can both underestimate and overestimate LV mass (202-203).
Recent developments such as the use of contrast and 3-dimensional echocardiography 
have led to improvements in the accuracy associated with this technique but problems 
remain with acoustic windows and the standard of reference for the measurement of LV 
structure and function is now CMR imaging. Indeed, studies assessing these more recent
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developments in echocardiographic technique have used CMR as the ‘gold standard’ 
comparison (204-205).
1.9 Cardiovascular Magnetic Resonance Imaging
Over the last 10 years CMR imaging has become well established in clinical practice and 
is now the accepted standard of reference for the measurement of left and right 
ventricular function, mass and volumes (206-208). Its superiority with regard to accuracy 
and reproducibility is due to a combination of high spatial and temporal resolution and 
the ability to image in any desired orthogonal plane giving 3-dimensional coverage of the 
heart. Initially, a fast low angle shot (FLASH) imaging sequence was used but more 
recently a steady-state free precession (SSFP) sequence has become the routine method 
for cine imaging as this provides better contrast between myocardium and blood pool, 
although both sequences have similar reproducibility (209).
For a CMR 3-dimensional volume and mass assessment, a set of contiguous short axis 
slices covering the entire ventricle from base to apex is acquired, which is planned from 
the horizontal long axis (HLA) view. The ventricular volume is the sum of the 
endocardial areas multiplied by the interslice distance, calculated at end-diastole and end- 
systole, and the ventricular mass is the area occupied between the endocardial and 
epicardial border multiplied by the interslice distance. Thus, CMR measurements of mass 
and function take into account any regional abnormalities of the ventricle and are 
independent of any geometric assumptions.
The accuracy of CMR measurements of LV mass has been validated on post mortem 
specimens in vivo in animal studies (210-211) and ex vivo in human studies (196,212).
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These showed good agreement between CMR measured mass and the actual LV mass 
with a SD of difference of 8g (95% CI+/-15g) in human studies and lOg (+/-19g) in 
animal studies (dogs). Reproducibility of CMR measurements is also superior to that of 
echocardiography. Interstudy variability has a mean weighted SD of difference of 7.8g 
(95% Cl +/-15.3g) (182,196,198,212-215) and the mean weighted intra and interobserver 
variability’s are 4.8g and 9.0g respectively (213,216). By comparison the corresponding 
mean weighted interstudy SD of the difference for M-mode and two-dimensional 
echocardiography is 27.7g (183,196-199,201,217) and 19.2g (217-218) respectively.
The improved reproducibility of CMR means that in group studies much smaller sample 
sizes can be used to detect change in LV mass or, using the same sample size, smaller 
degrees of change can be detected. Bellenger et a l (213) showed that in order to detect a 
change of lOg in absolute LV mass with 90% power, 13 patients would be required using 
CMR, whereas 162 patients would be required using M-mode echocardiography, 
resulting in a 95% decrease in the sample size needed. It is now therefore recommended 
that CMR is used in studies targeting LV mass.
CMR has now become established as a Class 1 indication for the investigation of cardiac 
disease in several other areas (206). Due to its superior spatial resolution and three 
dimensional visualization, it has become the investigation of choice for cardiomyopathies 
such as apical hypertrophic cardiomyopathy and those affecting the anterolateral free 
wall which are difficult to diagnose with echocardiography, especially in the early stages 
of the disease and difficult to exclude by echocardiography in relatives of affected 
patients (219-221).
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More recently, the assessment of cardiomyopathy has been revolutionised by a CMR 
technique called ia te  gadolinium contrast enhancement’ (LGCE) which allows non- 
invasive identification of abnormal myocardial tissue (222-223). This technique uses a 
gadolinium based magnetic contrast media to visualise myocardial fibrosis and necrosis 
and put simply, the T1 weighted images acquired after intravenous administration of 
gadolinium chelates show the damaged myocardium as bright areas (Figure 1.5). The 
mechanism of myocardial hyperenhancement is demonstrated in Figure 1.6 (224). The 
mechanism is based on two facts. Firstly, gadolinium chelates are extracellular and freely 
distribute in extracellular water but cannot cross intact cell membranes. Secondly, in 
normal myocardium, myocytes are densely packed and thus myocyte intracellular space 
forms the majority (85%) of the space. Therefore the volume of distribution of 
gadolinium in normal myocardium is very small and no hyperenhancement is visualised. 
In the setting of, for example, AMI there is myocyte membrane rupture which allows 
additional gadolinium to diffuse into what was previously intracellular space. This, in 
combination with delayed washout kinetics, results in an increased gadolinium 
concentration and hyperenhancement. In the setting of chronic infarction, myocytes are 
replaced with collagenous scar. In this situation the interstitial space is expanded which 
again leads to increased gadolinium concentration and hyperenhancement.
Expanded extracellular space in the myocardium can also be caused by pathological 
processes other than MI such as fibrosis, protein infiltration and possibly myocardial 
disarray with disordered myocardial fibre packing, allowing tissue characterization of 
non-ischaemic cardiomyopathy (NICM) as well as ICM. Studies have demonstrated that 
in the context of ICM, a combination of cine and LGCE CMR imaging is effective in
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detecting the presence, location and extent of myocardial infarction and predicting 
improvement in contractile function following revascularisation in both the acute and 
chronic setting (225-232).
The combination of LGCE and cine CMR can also differentiate ICM from NICM with an 
accuracy of over 90% (225-226). Wu et a l (232) were the first group to report that LGCE 
could differentiate ICM from NICM. In their study almost all patients with ICM, 
diagnosed by QCA, displayed the typical hyperenhancement pattern associated with ICM 
whereas none of the patients with NICM had hyperenhancement. Several studies have 
followed including that of McCrohon et a l (225) of 90 patients with LVSD made up of 
27 with ICM and 63 with NICM, defined on the basis of QCA. Again, all patients with 
ICM had typical hyperenhancement whereas only 13% of those with NICM displayed 
hyperenhancement. This group was made up of a proportion with mid-wall LGCE not 
typical of that observed with ICM and a small number that did display the typical pattern 
of LGCE observed with ICM. The assumption was that these patients did indeed have 
ICM due to previous coronary artery plaque rupture with recanalisation post event and 
thus no significant CAD observed at angiography. Finally Patel et a l (226) recently 
investigated 234 consecutive patients presenting with LVSD, with an EF of less than 30% 
and an unclear aetiology for the cardiomyopathy. Patients underwent both CMR with 
LGCE and coronary angiography and the authors found that the diagnosis of ICM could 
be diagnosed using LGCE with a sensitivity of 92% and a specificity of 93% compared to 
the reference standard of QCA.
In ICM, LGCE is distributed in the territory of the supplying coronary artery and always 
involves the subendocardium (227-228) (Figure 1.5T LGCE can differentiate
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subendocardial from transmural infarction which is the basis for defining the viability of 
the myocardium supplied by the diseased coronary artery. With NICM, typically, there is 
an absence of LGCE or it is found in the mid-part of the myocardium (229). The majority 
of the studies differentiating ICM from NICM exclude patients with forms of 
cardiomyopathy other than idiopathic dilated cardiomyopathy, such as hypertrophic 
cardiomyopathy (HCM) or that caused by myocarditis or infiltrative disease. LGCE can 
also help differentiate these types of cardiomyopathy from other forms due to distinct 
patterns of LGCE and underlying morphology of the LV (230). For example, extensive 
work by Moon et al. has shown that information regarding the aetiology and subsequent 
prognosis can be gained when using this technique in HCM, where the pattern of LGCE 
is typically confined to the ventricular septum (233) (Figure 1.7V LGCE in patients with 
HCM is associated with more severe forms of the disease such as those with LVSD and 
its presence confers adverse prognosis and an increased risk of ventricular arrhythmias 
and sudden death. The technique of LGCE has been shown to be accurate when 
compared to autopsy and histological specimens in animal models (234) and humans 
(235) and is more accurate than SPECT imaging (236) with comparable accuracy to PET 
imaging (237-238) for the assessment of myocardial viability. Such has been the success 
of this non-invasive imaging technique that it has now been established as a Class 1 
indication for the assessment of myocardial viability in ICM, the differentiation of ICM 
from NICM and in the assessment of both aetiology and prognosis of NICM (206,238). 
CMR is thus an accurate technique for the diagnosis and assessment of LV 
morphological abnormalities, gives unique insight into the underlying aetiology of any 
identified LV abnormality and can identify ICM without the need for invasive coronary
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angiography. It would therefore seem ideally suited to aid the investigation of LV 
abnormalities and their association with CAD in patients with ESRF.
1.10 Aims of this Thesis
With the expansion of dialysis programmes, demand for renal transplantation continues 
to increase and CVD is now the most common cause of death in both patients awaiting 
renal transplantation and in those with a functioning renal allograft. It therefore follows 
that to further improve the benefits of renal transplantation, better diagnosis and 
treatment of CVD is mandatory.
LV abnormalities are the strongest independent predictors of CV outcome in this 
population. Although it is known that LV abnormalities, especially LVH, are prevalent in 
patients on RRT, the current methods of assessment of such abnormalities are inaccurate, 
especially in this population and thus it is unknown whether targeting LVH or other LV 
abnormalities confers improved outcome to patients with ESRF and the relationship of 
LV abnormalities and CAD is poorly defined. CMR is now an established imaging 
modality in clinical cardiology and the standard of reference for the measurement of LV 
structure and function. As yet, CMR has not been used in the investigation of LV 
abnormalities and IHD in patients with ESRF. The aims of this thesis are therefore as 
follows;
• To identify the prevalence of LV abnormalities in patients awaiting renal 
transplantation using CMR.
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• To identify the clinical correlates and potential determinants of LV abnormalities 
identified using CMR in order to identify opportunities for future interventional 
trials.
• To study the natural history of LV abnormalities whilst patients wait for renal 
transplant with CMR.
• To examine the relationship between LV abnormalities and anaemia in patients 
with ESRF using CMR
• To assess the usefulness of BNP in identifying patients with LV abnormalities 
defined by CMR
• To investigate the relationship between CAD and LV abnormalities using a 
combination of LGCE and cine CMR.
• To assess the strength of LV abnormalities defined by CMR to predict the 
outcome of patients awaiting renal transplantation
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Graph 1.1 CV mortality rates of US dialysis patients compared to that of the normal 
population (17)
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Graph 1.2 Adjusted relative risk of death among recipients of a first cadaveric renal 
transplant compared to those remaining on the waiting list (1)
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Table 1.1 Traditional and non-traditional risk factors for CVD in patients with 
progressive renal failure (37)
Traditional Risk Factors Non-traditional Risk Factors
Older age Albuminuria
Male sex Hyperhomocysteinaemia
Hypertension Anaemia
High total cholesterol Abnormal calcium/phosphate metabolism
High LDL cholesterol Extracellular fluid volume overload
Low HDL cholesterol Oxidative stress
High triglycerides Inflammation
Diabetes Malnutrition
Smoking Thrombogenic factors
Family history of premature IHD Altered nitric oxide/endothelin imbalance
Physical inactivity Lp(a) lipoprotein
Left ventricular hypertrophy
Table 1.2 Prevalence and pattern of dyslipidaemia at varying stages and types of 
progressive renal failure (53)
Total Choi 
>240mg/dl
LDL Choi 
>130mg/dl
HDL Choi 
<35mg/dl
Trigs
>200 mg/dl
General
population
20% 40% 15% 15%
CRF Stage 1-4 
+nephrotic syn
90% 85% 50% 60%
CRF Stage 1-4 
-nephrotic syn
30% 10% 35% 40%
CRF Stage 1-4 
+ renal 
transplant
60% 60% 14% 35%
CRF Stage 5 on 
HD
20% 30% 50% 45%
CRF Stage 5 on 
PD
25% 45% 20% 50%
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Graph 1.3 Mortality rate of diabetic (dashed line) and non-diabetic (solid line) patients 
commencing RRT (64)
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Figure 1.1 Piechart demonstrating the prevalence o f  LV abnormalities in 433 patients 
comm encing RRT, defined using echocardiography (69)
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Figure 1.2 Actions and physiological effects o f  natriuretic peptides (121)
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Figure 1.3 Typical 4-chamber and parasternal long axis views using 2-dimensional 
echocardiography in a patient on RRT with LV SD  (Dashed line depicts correct placement 
o f  M -m ode cursor)
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Figure 1.4 Echocardiographic M -mode images and demonstration o f  m easurem ent o f  LV 
parameters for Troy and Pom bo (Standard), Penn and ASE conventions in a normal 
subject
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Figure 1.5 Typical subendocardial pattern o f  late gadolinium contrast enhancem ent 
associated with myocardial infarction in a patient post septal myocardial infarction
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Figure 1.6 Basis for contrast enhancement with gadolinium chelates in damaged 
myocardium, imaged using CM R (224)
Nonnal myocardium Acute infarction Scar
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Figure 1.7 Patchy septal distribution o f  LG CE in a patient with genetic hypertrophic 
cardiomyopathy
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Chapter 2
Methods
2.1 The study population- Sampling and Invitation process
All patients with ESRF on the West of Scotland renal transplant waiting list in January 
2001, were invited to participate in the study by letter. Those who initially did not 
respond were contacted by a second letter. There were 55 patients on the waiting list at 
that time, of which 44 attended for screening. Thus 80% of the waiting list attended for 
screening and the major reason for the 11 patients declining screening was the distance 
involved in travelling to the Western Infirmary for screening. The remainder of the 
patients entering the study were recruited from the renal transplant assessment clinic at 
the Western Infirmary, Glasgow between January 2001 and August 2002. All patients 
gave informed consent and signed the consent form approved by the local Ethics 
Committee.
A total of 154 patients were screened for the study. Three patients could not undergo 
CMR scanning due to contraindications regarding ferromagnetic objects (one patient had 
previous surgery and clipping for subarachnoid haemorrhage, one patient had a 
ventriculo-peritoneal shunt for hydrocephalus and one patient had a foreign body from a 
previous accident. Three patients could not tolerate the scan due to claustrophobia and 
therefore in total 4% of patients could not undergo CMR scanning. The study cohort 
therefore consisted of 148 patients.
73
2.2 Basic protocol
Patients attended for screening on a post dialysis day, if using haemodialysis as mode of 
RRT, and patients using PD were studied at their ‘dry weight’ according to clinical 
charts. The screening protocol followed is displayed in Flowchart 2.1 and apart from 
CMR imaging is the protocol in place for CV screening for the West of Scotland 
transplant assessment clinic. Patients initially filled in a questionnaire to obtain details of 
past renal and other medical history, medication taken, standard CV risk factors 
(hypertension, hyperlipidaemia, diabetes, smoking history, family history), CV co­
morbidity and the presence of any symptoms suggestive of CVD. 1HD was defined as a 
history of angina for which regular medication was taken, a previous history of AMI, PCI 
or CABG or previously documented CAD at angiography. CHF was defined as 
previously documented LVSD. If the patient was unable to remember any of the required 
information, this data was obtained from the West of Scotland renal database with the 
patient’s consent.
The patients then underwent physical examination. Pulse rate and BP were recorded as 
well as auscultation of heart and lungs and clinical assessment of peripheral pulses.
A 12-lead ECG was obtained and blood samples were taken after the patient had been 
recumbent for 20 minutes, followed by a CMR scan. After CMR scanning the patients 
underwent exercise tolerance testing (ETT).
If a patient was found to have LVSD or had a high risk treadmill test, they were referred 
for coronary angiography. If the patient did not perform adequately on treadmill testing 
or the test was inconclusive, they were referred for nuclear stress perfusion imaging.
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Again, if the nuclear perfusion scan showed a reversible perfusion defect, the patient was 
referred for coronary angiography (Figure 2.1).
Patients reattended after at least 6 months for repeat CMR scanning. Patients were 
excluded from repeat scanning if they had undergone renal transplantation in the 
preceding 6 months. Repeat BP measurement and blood sampling were performed and a 
proportion of patients had a more detailed CMR scan with LGCE. Patients gave informed 
consent to the more detailed CMR study and signed the consent form approved by the 
local Ethics Committee.
Patients were thereafter followed up for 4 years to detail all cause mortality. Patient 
outcome was monitored via the West of Scotland renal database.
2.3 Pulse and blood pressure measurement
Pulse rate and rhythm were assessed both clinically and by resting 12-lead ECG. BP was 
taken after 20 minutes in the recumbent position, before blood sampling, using an 
automatic Critikon Dinamap Plus Vital Signs Monitor. BP was monitored during and 
after ETT and was again measured at the end of the screening visit. The mean BP from 
the initial BP check and that at the end of the study visit was used for subsequent 
analysis.
2.4 Blood Sampling
Venous blood was sampled after the patient was recumbent for 20 minutes. Blood was 
taken for the analysis of urea and electrolytes, full blood count, glucose, total cholesterol, 
CRP and BNP. All analysis except for BNP measurement was carried out by the clinical
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biochemistry and haematology laboratories in the Western Infirmary. The venous blood 
sample taken for BNP was collected in chilled tube containing trasylol (50u/ml). It was 
then centrifuged at 3000g for 10 minutes at 4C to obtain separated plasma which was 
stored at -80C until batch analysis. This was carried out in the University of Glasgow 
biochemistry department using a commercial BNP assay kit (Shionoria BNP kit, 
Shionogi, Japan). The limit of detection of this kit is lpg/ml (0.29 pmol/L) and the co­
efficient of variance for within assay and between assay variation was <2.7% and <4.2% 
respectively.
2  5 Electrocardiogram
A 12-lead ECG was acquired prior to ETT. This was acquired using a Siemens Megacart 
ECG system (Siemens Medical Systems, Erlangen, Germany) and the ECG was recorded 
at 22mm/sec and lmV/cm standardization. Heart rate and rhythm was recorded and the 
presence or absence of pathological Q waves and ST changes. Pathological Q waves were 
defined as Q waves more than 1mm width and 3mm depth and ST shift was defined as 
any resting ST depression.
The ECG criteria used to define LVH was the Cornell product (240-241). The Cornell 
voltage (242) is calculated by multiplying the voltage of the R wave in lead aVL by the 
voltage of the S wave in lead V3 thus; RaVL x SV3. The Cornell Product is calculated by 
multiplying the Cornell voltage by the QRS duration in milliseconds 
([RaVLxSV3]xQRS). The partition coefficient used to define LVH from the ECG was 
>2592mV.ms for males and >2610mV.ms for females (241).
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2.6 Exercise Tolerance Testing
All patients were asked to undergo ETT. This was carried out on a Marquette CASE 15 
ETT system treadmill machine using a standard Full Bruce protocol which was first 
published in 1963. This protocol is conducted in up to 7 stages each lasting 3 minutes. 
Stage 1 is the equivalent of 4.6 metabolic equivalents of work (METS), where one MET 
is the amount of oxygen consumed at rest. (At rest 1 MET= 3.5ml of oxygen/Kg/min). 
Stage 1 is conducted at a speed of 1.7mph and a gradient of 10 degrees. Each stage 
thereafter increases in speed and grade.
Patients had continuous 12-lead ECG monitoring during and after exercise and BP was 
recorded at the end of each stage during the test and every two minutes after the test until 
BP returned to baseline. Symptoms of chest pain and breathlessness were recorded during 
the test as was heart rate achieved and total exercise time. Patients were asked to exercise 
until 85% of target heart rate was achieved (calculated as 220-age of patient) and to 
exercise for at least 6 minutes and 30 seconds. The test was considered high risk if there 
were >2mm of horizontal or down sloping ST depression in 2 or more contiguous leads, a 
positive response within 6 minutes or exertional hypotension. The test was considered 
intermediate risk if the patient developed symptoms of chest pain during the procedure 
without ECG changes and the test was considered inconclusive if the patient did not 
reach target heart rate and/or did not exercise for 6 minutes 30 seconds.
2.7 Cardiovascular Magnetic Resonance Imaging
All patients in the study underwent CMR scanning on at least one occasion. This was 
carried out on a 1.5 Tesla Siemens, Sonata whole body system (Siemens Medical
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Systems, Erlangen, Germany), equipped with a circularly polarized phased-array body 
coil. Images were obtained using retrospective ECG gating and imaging sequence was 
triggered on the R wave.
An initial series of scout images were obtained using a true fast imaging with steady state 
precession (TRUE FISP) pulse sequence in the coronal, transverse and oblique-sagittal 
views. These scout images were used for planning an initial vertical long axis (VLA) 
pilot image and using this VLA pilot, a horizontal long axis (HLA) pilot was planned. 
Using the VLA and HLA pilots a series of three short axis (SA) pilots were obtained and 
using this set of pilot images, TRUE FISP breath hold cine images in the HLA, VLA and 
3-chamber views were obtained. The HLA/4-chamber view (Figure 2.2) and the VLA/2- 
chamber view in the end-diastolic frame were used to position the complete stack of short 
axis, TRUE FISP, breath hold, cine images from the base of the LV to the apex (Figure 
2.3) and this short axis stack was used in the analysis of LV mass, volumes and function. 
The most basal image plane was positioned close to the transition of the LV myocardium 
to the mitral valve leaflets thus covering the most basal part of the LV.
The images were acquired using a standardized protocol of 8mm slices with 2mm gap 
between slices and number of images depended on length and size of ventricle (Range of 
8-13 slices). TRUE FISP sequences rephrase the transverse magnetization (instead of 
spoiling it) after phase encoding and readout. This results in an improved blood- 
myocardium contrast, being dependant mainly on the tissue to blood T1/T2 ratio and not 
on through plane blood flow. Thus, the following standardized system parameters were 
used;
• repetition time (TR) = 3.14ms
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• echo time (TE) = 1,6ms
• flip angle (a) = 60°
• voxel size = 2.2x1.1x8.0mm
• Field of View (FoV) = 340mm
The duration of the CMR scan was on average 20 minutes.
A proportion of patients also underwent an extended scanning protocol involving the 
administration of a 0.2mmol/Kg bolus of Gd-DTPA, which is a gadolinium based 
extracellular contrast agent. Patients undergoing the extended scan protocol had a 16 
gauge venflon inserted into a suitable vein in the antecubital fossa prior to scanning. 
Further images were acquired 10 minutes after administration of Gd-DTPA using a 
breath hold, segmented, turbo fast low angle shot (FLASH) gradient-echo pulse sequence 
technique with an initial inversion pre-pulse (180°). The pre-pulse delay (inversion time) 
was chosen so there was no/minimal longitudinal magnetization in the normal 
myocardium which therefore appeared dark (nulled). Any remaining contrast agent in the 
myocardium due to delayed wash-in and wash-out kinetics through infarcted or fibrotic 
myocardium, exhibited a faster T1 relaxation and therefore appeared bright.
For this sequence the following standardized system parameters were used;
• TR = 11.6ms
• TE = 4.3ms
• a = 20°
• voxel size = 2.2x1.1x8.0mm
• FoV = 300mm
Inversion time was chosen on an individual patient basis.
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Image analysis was carried out on ARGUS software (Siemens, Erlangen, Germany). 
Patients underwent initial screening echocardiography to ensure there was no significant 
valvular heart disease, which may have affected results for LV mass and volumes. For the 
analysis of mass and volumes, end-diastole (ED) was defined as the first temporal frame 
directly after the R wave of the ECG. End-systole (ES) was defined as the temporal frame 
at which the image showed the smallest LV cavity and was typically 240-320ms after the 
R wave. LV epi- and endocardial contours were manually traced around the ED frame 
and the ES frame for each of the short axis slices encompassing the LV. The papillary 
muscles were included in the mass calculation and excluded from the volume calculation. 
EDV and ESV were calculated by the summation of the product [area x slice distance] 
for all slices.
Stroke volume (SV) was calculated using the formula; SV=EDV- ESV 
EF was calculated using the formula; EF = (SV/EDV) x 100%.
CO was calculated by multiplying SV and heart rate.
The LV ED mass was obtained by multiplying the volume of LV muscle by the specific 
weight of muscle tissue, which is 1.05g/cm3.
The global LV measures were indexed for BSA thus;
BSA (g/m2) = Weight 0.425 x Height 0.725 x 0.007184
A proportion of the images (10 scans) were analysed by a second observer for the 
calculation of inter-observer variability and 10 scans were analysed on two separate 
occasions in a random order by the first observer for calculation of intra-observer
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variability. Both were found to be within published ranges at 7.4% and 5.8% respectively 
(213,216).
Analysis of the LGCE images was carried out on ARGUS software by two blinded 
observers (John Foster, CMR physicist and Tracey Steedman, CMR radiographer). The 
presence of myocardial fibrosis was indicated by the presence of LGCE. Images were 
obtained in long-axis in the HLA, VLA and 3-chamber view and in the SA orientation 
using the same slice positions as the cine SA images obtained for functional analysis. 
Images were assessed initially for the presence or absence of LGCE and in those patients 
that displayed LGCE the pattern of enhancement was divided into either ‘patchy’ LGCE, 
not consistent with coronary artery disease (CAD) or ‘discrete’ LGCE consistent with 
CAD.
Patients were classed as having LGCE if two or more contiguous SA slices showed 
evidence of LGCE and the corresponding area on either the routine long axis images or a 
further long axis image planned through the area of LGCE on the SA slices. If artefact 
was suspected on any of the images, the phase-encoding direction was changed and if the 
area of LGCE persisted, it was regarded as true LGCE.
2.8 Nuclear stress perfusion scanning
Patients who were classed as requiring further non-invasive assessment for reversible 
ischaemia, if treadmill testing was inconclusive or not possible, were placed on the 
waiting list for out-patient nuclear stress perfusion (SPECT) scanning at the Western 
Infirmary. The scans were carried out on a 3000 XP triple headed gamma camera with 
attenuation correction facility, using technetium Tc-99m (tetrofosmin) as the radioactive
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perfusion agent and dipyridamole as the stress agent in combination with bike exercise if 
possible. Dipyridamole was administered as a bolus injection with a dose of 0.56mg/Kg 
over 4 minutes. In patients for whom dipyridamole was contra-indicated (i.e. those with 
reversible obstructive airways disease) dobutamine was administered as the stress agent. 
Dobutamine infusion was commenced at lOpg/kg/min and increased in increments of 
lOpg/kg/min every 3 minutes up to a total of 40pg/kg/min or until target heart rate was 
achieved.
Images were analysed by the single physician responsible for reporting nuclear stress 
perfusion scans for the hospital and were graded initially as a normal stress perfusion 
scan or an abnormal stress perfusion scan. Those that had an abnormal scan were divided 
into those with a fixed perfusion defect or a reversible perfusion defect. Those that had 
both a fixed and stress perfusion defect were placed in the reversible defect category. The 
scans were carried out within six months of the original screening visit.
2,9 Coronary angiography
Patients who were classed as requiring coronary angiography were placed on the waiting 
list for out-patient coronary angiography at the Western Infirmary. The angiograms were 
carried out by a single operator via the femoral route and the patients undergoing 
coronary angiography were classified as having normal coronary arteries, mild/moderate 
CAD (defined as the presence of coronary atheroma but no single coronary plaque 
stenosis of more than 70%) and those with and stenosis over 70% were considered to 
have severe CAD.
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Figure 2.1 Screening protocol for CV risk assessment in renal transplant candidates
LVSD
High risk Low risk
Nuclear stress perfusion 
scan
Low risk/ 
Fixed defect
Coronary
angiography
Clinical
PCI/
CABG follow-up
Severe CAD Normal/ 
Mild CAD
Reversible defect
CMR
ETT
Intermediate risk/ 
Inconclusive
Cardiovascular screening 
History, examination 
ECG
83
Figure 2.2 Horizontal long axis CM R image and planned short axis slices
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Figure 2.3 Corresponding short axis stack used for calculation o f  LV mass, volumes and 
function with endocardial (red) and epicardial (green) contours used in analysis o f  LV 
mass, volumes and function
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Chapter 3
Characteristics of the Study Population and the 
Risk Factors for Cardiovascular Disease
3.1 Introduction
Applying current European Best Practice Guidelines (243) to the selection of patients 
suitable for renal transplantation, results in substantial selection of healthier patients 
compared to those remaining on RRT. Candidates who undergo transplantation are 
younger, more likely to be male, have non-diabetic renal failure and have less co­
morbidity than patients on RRT who are not considered suitable for transplantation (1,3). 
In the UK, Oniscu et al. (3) studied 1736 patients listed for renal transplant in Scotland 
over a 10 year period between 1989 and 1999. Average age of patients was 46.6+/-14.1 
years, 20% had a prior history of IHD and the proportion of diabetic patients was 14.6%. 
More recently Sharma et a l (87) studied 203 transplant candidates between 1996 and 
2001. Average age of this London based cohort was 47+/-12 years, the proportion of 
patients with a history of IHD was 4% and the proportion of diabetics was 21%. 
Guidelines also exist for the assessment of CVD in patients being considered for 
transplantation and for the treatment of CV risk factors such as hypertension and 
hyperlipidaemia in all patients with ESRF. In the UK, the Renal Association have 
published guidelines stating that patients over the age of 49, in addition to patients with a 
history of diabetes, previous IHD, other vascular disease or CHF should be considered at 
high CV risk and undergo stress testing prior to listing for transplantation (244). 
Furthermore, the Renal Association also advise that risk factors such as hypertension,
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hyperlipidaemia and smoking should be aggressively targeted in patients on RRT and 
those patients with a history of IHD should be on secondary preventative therapy as 
recommended for the general population (245).
Despite similar advice from renal associations in other countries (246-247), it is well 
recognised that with regard to standard CV risk factors, patients with renal failure and 
especially those on RRT are under treated and the prescription of medications such as 
aspirin, beta-blockers and statins, even after AMI is low(162-163). One could presume 
that with regard to patients selected for renal transplantation, treatment of CV risk factors 
and instigation of primary and secondary preventative therapy for CVD should be even 
more aggressive than that in patients not selected for transplant but whilst there is data 
available on the baseline demographics, morbidity and mortality of patients listed for 
renal transplant, there is little information detailing the treatment of CV risk factors and 
the use of cardioprotective medication in this group of patients.
The aim of this chapter is to describe the baseline demographics of this population of 148 
patients with ESRF in the West of Scotland considered suitable for renal transplantation, 
in addition to assessing the treatment of standard, reversible CV risk factors and the use 
of cardioprotective medication, both in the primary and secondary prevention of CVD in 
this population.
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3.2 Methods
3.2.1 Subjects and procedure
Patients were recruited from the West of Scotland renal transplant waiting list or from the 
transplant assessment clinic at the Western Infirmary, Glasgow. All patients gave 
informed consent and the study had approval from the local ethics committee. The full 
screening protocol and description of methods used are described in Chapter 2. Patients 
were recruited between January 2001 and August 2002.
3.2.2 Statistics
Statistical analysis was performed using SPSS Version 11.5 software (SPSS inc. Chicago 
IL, USA). Baseline data are expressed as mean +/- standard deviation (SD) if normally 
distributed or median, if not normally distributed. Categorical variables were examined 
using the Chi-squared test. Differences between two groups were assessed using a two- 
sample, unpaired t-test (parametric data) or Mann Whitney U test (nonparametric data). A 
p-value of less than 0.05 was considered significant.
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3.3 Results
3.3.1 Age and sex differences
The cohort totalled 148 patients and consisted of 101 men (68%) and 47 women. The age 
distribution of the cohort is displayed in Graph 3.1. The mean age of the cohort was 50 
years with a median of 50 years and age ranged from 24-70 years. One fifth of the cohort 
(30 patients) was over 60 years of age. Baseline demographics for the whole cohort are 
shown in Table 3.1.
3.3.2 Aetiology of renal failure
The proportions of patients with different primary causes of renal failure are shown in 
Figure 3.1. The proportion of patients with glomerulonephritis was 22% and this was the 
most common individual cause of renal failure in the cohort. Diabetic nephropathy 
accounted for 17% of ESRF and thereafter adult polycystic kidney disease (11%), 
chronic pyelonephritis (12%) and nephrosclerosis/hypertensive renal disease (8%) made 
up smaller proportions. The remaining 30% patients either had an unknown cause of 
ESRF or the primary cause of ESRF was rare, such as multisystem diseases or pulmonary 
vascular syndromes.
3.3.3 Length of renal failure and time on renal replacement therapy
As patients in the study were recruited from either the transplant waiting list or from the 
renal transplant assessment clinic, the ranges for length of renal failure, from point of 
diagnosis, were large. Times ranged from 2 months to 39 years, with a mean of 99
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months and a median of 60 months. The length of time on RRT ranged from 0 months, in 
those patients assessed for renal transplant at or just prior to inception of RRT, to 12 
years in a patient with a previous renal transplant. The mean length of time spent on RRT 
was 31 months and the median 22 months.
The majority of the cohort (81%) had never undergone previous renal transplantation but 
19 patients (13%) had 1 previous failed allograft, 7 patients (4.7%) had 2 previous 
allografts and 1 patient had previously had 3 transplants.
3.3.4 Type of renal replacement therapy
Similar to other dialysis programmes in the United Kingdom, 60% of the cohort used 
haemodialysis as mode of RRT and 40% PD. Those using haemodialysis were either 
attending thrice weekly sessions of 4 hours per session or thrice weekly overnight or 
Tong time’ sessions of 6 hours per session. Patients using PD were either using CAPD or 
overnight APD. The proportions of each of these 4 modalities are displayed in Figure 3.2. 
In this cohort of patients, no significant differences were found between those using PD 
or haemodialysis with regard to CV morbidity, medication taken or renal history. 
Similarly, there were no significant age or sex differences between those using peritoneal 
or haemodialysis. For example, the proportion of patients with diabetes using 
haemodialysis was 17% and using PD 21% (p= 0.490) and the proportion of patients with 
a history of IHD using PD was 23% compared to 18% using haemodialysis (p= 0.450).
3.3.5 Standard cardiovascular risk factors
Table 3.1 shows the proportions of patients in the cohort with standard CV risk factors 
and CV co-morbidity. A relatively low proportion of patients had a history of previous 
AMI (9.7%) and just under one fifth of the cohort (19.3%) had a history of IHD. A much 
smaller proportion of patients had a history of CHF (7.6%), and 5.5% of patients had a 
history of previous cerebrovascular event. Similarly, 5.5% patients had a history of PVD 
defined as claudication at less than 100 yards or previous documented disease on X-ray 
angiography or magnetic resonance angiography.
With regard to standard risk factors for IHD, unsurprisingly, the majority of the cohort 
had a history of hypertension (94.5%). High proportions (36%) also had a history of 
hyperlipidaemia, defined as those established on statin therapy, 29.2% of patients were 
current smokers and a further 25% were ex-smokers. Over one quarter of the cohort had a 
family history of IHD (26.4%) and 18.6% of patients were diabetic.
Diabetic patients had a similar prevalence of IHD (18.5% vs. 19.5%, p=0.908) and 
previous MI (7.4% vs. 10.2%, p=0.662) than non-diabetic patients and similar 
proportions of patients in each group had a history of CHF (7.4% vs. 7.6%, p=0.969) 
(Table 3.2). However, higher proportions of diabetic patients had other forms of vascular 
disease. A higher but non-significant proportion of diabetic patients had a history of a 
prior cerebrovascular event (11.1% vs. 4.2%, p=0.160) and diabetic patients were 
significantly more likely to have a history of PVD (14.8% vs. 3.4%, p=0.019).
With regard to renal history, diabetic patients had spent less time on RRT (20+/-21.3 vs. 
34+/-30.2, p=0.007) and had a relatively shorter period of renal failure (45+/-39.1 vs. 
112+/-99, p<0.001) than those without diabetes and non-diabetic patients were more
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likely to undergo reassessment after a previous failed transplant (22% vs. 3.7%, 
p=0.026). Only one diabetic patient had undergone prior renal transplantation.
3.3.6 Drug therapy
The proportion of patients prescribed different medications is shown in Table 3.3 and 
total number of antihypertensives taken by patients is displayed in Figure 3.3. 
Erythropoietin was the most commonly prescribed drug with 73.6% patients receiving 
regular erythropoietin therapy. Thereafter, just over one third of the cohort was taking a 
beta-blocker (36.4%) and 28.7% were taking an ACEI or an angiotensin receptor blocker 
(ARB). Unsurprisingly, similar proportions of patients were taking aspirin (31.5%) or a 
statin (31.5%).
With regard to antihypertensive therapy, 33% of the cohort was not prescribed any 
antihypertensive medication. This is surprising as 95% had a history of hypertension but 
on the day of screening 49% of patients in the cohort had a normal BP reading. However, 
19.4% patients with a hypertensive BP reading (>150/80mmHg) on the day of screening 
were not taking any antihypertensive medication. Of the remaining 77%, the highest 
proportion was prescribed one antihypertensive medication and 3% of the total cohort 
was prescribed 4 antihypertensives.
With regard to other therapy, 12% patients not receiving regular erythropoietin, had 
haemoglobin concentrations of <llg/dL and a much higher proportion of 49.5% of 
patients not taking a statin had a total cholesterol of >5.5mmol/L.
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3.3.7 Drug therapy in ‘high ’ risk patients
Following the guidelines of the Renal Association (244), 109 of the 148 patients in this 
cohort should be considered at higher CV risk and undergo formal stress testing and 
echocardiography for CVD prior to listing for transplantation. It follows that this group of 
patients should therefore be considered for primary prevention of CVD and prescription 
of statins and aspirin. This group of patients also includes the subgroups of patients with 
diabetes, a history of IHD and those who have previously sustained an AMI. Medication 
prescription for these subgroups of patients is shown in Table 3.4.
A higher proportion of patients in the ‘high’ risk group were taking cardiac medication 
compared to the cohort as a whole but overall, the prescription of cardiac medication was 
still relatively low. The prescription of ACEI or ARB and beta-blockers in diabetic 
patients was particularly low at 36% and 32% respectively, and apart from the 
prescription of aspirin, there was a low proportion of patients on secondary prevention 
after a previous AMI. Only 57.4% of the group of patients who had a previous AMI were 
taking a statin or were on an ACEI or ARB.
3.3.7 Prevalence of reversible risk factors in ‘high’ risk patients
The proportions of patients with an elevated BP on the day of screening 
(>150/80mmHg), a total cholesterol of >5.0mmol/L and a current smoking practice are 
shown in Table 3.5. The prevalence of all three potentially reversible risk factors was 
high in patients considered at high CV risk. Even in patients with an established history 
of IHD and previous AMI, the proportion with a high total cholesterol was over 50% and 
over 40% of these patients had a hypertensive BP reading on the day of screening.
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3.4 Discussion
Advancing age and co-morbidity are well recognised factors influencing selection of 
patients with ESRF for renal transplantation (10-11). Oniscu et al. (11) reported on 
access to the transplant waiting list for 4523 patients in Scotland starting RRT between 
1989 and 1999. The study found that older patients and diabetics were much less likely to 
be listed for renal transplant. Patients over 60 years old were 80% less likely to be listed 
compared to patients aged between 18 and 34 and diabetics were 50% less likely to be 
listed than non-diabetics. Similar results have been observed in American studies but the 
proportion of diabetic patients both starting RRT and undergoing transplantation in 
America is higher than that in the UK (13-14). Similarly in this cohort, the proportion of 
patients over 60 years of age was much lower than that previously reported for patients 
starting RRT in Scotland. In the study of Oniscu et a l  42% of patients commencing RRT 
were older than 65 and in the later study of Metcalfe et a l i l l )  the proportion of patients 
over 65 starting RRT was even higher at 48.5%. However, the proportion of older 
patients being listed for transplant in Scotland does seem to be increasing. Between 1989 
and 1999, 10% of the patients listed for transplant in Scotland were over 60 whereas in 
our cohort, recruited between 2001 and 2002, 20% of patients were over 60.
It is well documented that diabetic patients with ESRF have both a higher CV risk profile 
and higher CV morbidity compared to those without diabetes (63-64). It is therefore 
unsurprising that a low proportion of diabetic patients are listed for transplant. Whereas 
around 24% of patients commencing RRT in Scotland are diabetic, we found that diabetic 
patients account for only 18% of those on the waiting list. However, this again is a 
slightly higher proportion than that of previous studies suggesting that higher risk patients
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may now be gaining access to transplantation in Scotland. Despite this finding, patients 
with diabetes in this cohort actually had a slightly lower prevalence of both IHD and MI 
compared to those without diabetes suggesting that there is still a significant selection 
bias but suitable diabetic patients seem to be identified earlier in the course of renal 
failure and once selected, may be listed sooner.
Patients on haemodialysis have a higher level of co morbidity compared to those on PD 
(32), and older patients with a history of IHD or CHF are more likely to be placed on 
haemodialysis programmes. In this cohort there was no difference in any aspect of past 
renal or CV history between those on haemodialysis or PD. This may reflect the long 
time overnight dialysis programme in the West of Scotland which tends to be attractive to 
younger fitter patients with ESRF who still work or may reflect a selection bias for fitter 
patients on haemodialysis to be selected for transplant.
The majority of guidelines regarding the management of CVD in patients with ESRF 
advise that patients should be regarded to be at high CV risk and that standard CV risk 
factors should be treated according to guidelines for the general population. However, the 
underpresciption of cardiac medications such as beta-blockers and statins in patients with 
ESRF is well recognised. There are several explanations for this phenomenon of 
‘therapeutic nihilism’ including a lack of evidence of the benefits of cardioprotective 
medication in patients with ESRF due to under representation of such patients in 
interventional randomised controlled CV trials and concerns regarding drug safety. Since 
this study was conducted, two other studies have been published detailing the use of 
cardiac medication in patients awaiting transplant. In 2005 Gill et a l (13) reported an 
extremely low prescription of beta-blockers (30%), ACEI (35%) and statins (28%) in 604
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patients listed for transplant in Canada. Sharma et a l  (33) reported a slightly higher 
prescription rate in 203 patients listed in London and the proportion of patients taking 
cardioprotective medication ranged from 35.2% prescribed a beta-blocker to 56.8% 
prescribed a statin. In our cohort of patients the percentage of patients taking 
cardioprotective medication was slightly higher than that of the Canadian study but 
prescription rates were much lower than that of the UK study, apart from beta-blocker 
prescription which was similar in the two groups. When the cohort was split into higher 
risk subgroups, the prescription rate increased but alarmingly, less than half of patients 
with a documented history of IHD were taking aspirin and only one-third of diabetics 
were prescribed an ACEI or ARB.
The treatment of reversible risk factors was also low. We found that 20% patients who 
were hypertensive on day of screening were not prescribed any medication to control BP 
and 50% patients not prescribed a statin had an elevated cholesterol concentration, in 
what should be regarded as a high risk population. Patients regarded to be at higher CV 
risk had a high observed prevalence of hyperlipidaemia and hypertension (Table 3.51 and 
around one fifth were current smokers, including those with a previous AMI. It should be 
noted however, that BP in this study was a single measurement and 24 hour monitoring 
may have given a more accurate assessment of mean BP. However, screening was carried 
out on a post-dialysis day so patients should have been relatively euvolemic.
A major concern with regard to the prescription of drugs such as aspirin and statins in 
patients with ESRF has been safety, especially the risk of rhabdomyolosis caused by 
statins and worsening of anaemia in those taking aspirin. Recently the UK-HARP study 
(248) reported on the safety of the use of simvastatin and aspirin in patients with CRF
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including a proportion on RRT and found that both were safe to use in this population of 
patients. Patients with ESRF have also been shown to benefit from secondary 
preventative medication after AMI (163,167,170) and carvedilol has been shown to 
confer mortality benefits in patients on RRT with LVSD (249). However, evidence of 
mortality benefit as a result of primary prevention of CVD with drugs such as aspirin and 
statins in this population is still lacking.
Another reason for the underprescription of anti-hypertensive medication in patients on 
RRT, especially haemodialysis, are the problems of hypotension during dialysis and of 
hyperkalaemia in patients prescribed ACEI or ARB’s. With regard to the former problem, 
it should be remembered that any form of haemodynamic instability should raise 
suspicion of underlying cardiomyopathy or CAD and prompt further cardiac investigation 
as these patients may be the ones to benefit most from cardioprotective medication but 
hyperkalaemia does limit the use of ACEI in some patients.
Patients in this cohort have many similar characteristics to those of previous studies, both 
in Scotland and the UK but the proportion of older patients and diabetics gaining access 
to the waiting list may be increasing in Scotland. Patients listed for transplant have a high 
prevalence of untreated, potentially reversible standard CV risk factors. The use of 
cardioprotective medication is low in this population, even in high risk groups and an 
obvious initial strategy to improve CV morbidity and mortality in this population would 
be to aggressively control reversible risk factors and to increase the prescribing practice 
of cardioprotective medication as per current guidelines. Strategies such as specific 
cardiac risk or cardio-renal clinics for patients with CRF may offer a way of achieving 
this.
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Table 3.1 Baseline demographics in a cohort of 148 patients with ESRF felt suitable for
renal transplantation
Baseline Variable
Age (years +/-SD) 50+/-10
Sex (%male) 68.2
Patients using haemodialysis (%) 60
Length of time on RRT (months/range) 31.6(0-144)
Length of renal failure (years/range) 8.2 (0.2-39)
Previous renal transplant (%) 18.2
History of Ischaemic Heart Disease (%) 19.3
Previous myocardial infarction (%) 9.7
History of chronic heart failure (%) 7.6
Diabetic (%) 18.6
History of hypertension (%) 94.5
History of hyperlipidaemia (%) 36
Current smoker (%) 29.2
Family history of IHD (%) 26.4
Cerebrovascular disease (%) 5.5
Peripheral vascular disease (%) 5.5
Systolic blood pressure (mmHg+/-SD) 136+/-24
Diastolic blood pressure (mmHg+/-SD) 80+/-12
Cholesterol level (mmol/L+/-SD) 5.6+/-1.7
Haemoglobin (g/dL+/-SD) 11.5+/-1.6
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Figure 3 .1 Primary causes o f  renal failure
renal diagnosis
□  diabetic
□  polycystic
□  glomerulonephritis
■  chronic pyelonephritis
□  nephrosclerosis
□  other
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Figure 3 .2 Types o f  dialysis therapy
13.19%
13.89%
47.22%
25.69%
type of dialysis
□  haemodialysis
□  CAPD
□  APD
□  long time dialysis
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Table 3.2 Differences between diabetic and non-diabetic patient baseline demographics 
and standard CV risk factor profile
Variable Diabetic
n=25
Non-diabetic
n=123
p-value
Age (years) 48+/-10.9 50+/-10.1 p=0.395
Sex (% male) 77.8 65.3 p=0.211
Length of renal 
failure (months)
45+/-39.1 112+/-99 p<0.001*
Time on RRT 
(months)
20+/-21.3 34+/-30.2 p=0.007*
Type of RRT 
(% using HD)
53.8 61.2 p=0.490
Previous transplant 
(%)
3.7 22.0 p=0.026*
Previous MI (%) 7.4 10.2 p=0.662
Ischaemic heart 
disease (%)
18.5 19.5 p=0.908
Chronic heart 
failure (%)
7.4 7.6 p=0.969
Cerebrovascular 
disease (%)
11.1 4.2 p=0.160
Peripheral vascular 
disease (%)
14.8 3.4 p=0.019*
Hypertension (%) 100 93.2 p=0.165
Hyperlipidaemia
(%>
48.1 33.1 II o i—i
Family history of 
IHD (%)
14.8 29.1 p=0.131
Current smoker (%) 22.2 30.8 T3 II O VO
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Table 3.3 Prescribed medication for total cohort
Medication Proportion of patients (%)
Erythropoietin 73.6
Aspirin 31.5
Beta-blocker 36.4
ACEI or ARB 28.7
Calcium channel blocker 21.0
Doxasosin 11.2
Nitrate 7.7
Diuretic 32.2
Statin 31.5
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Figure 3.3 Num ber o f  antihypertensive medications prescribed per patient
number of 
antihypertensives 
■  none
□  one
□  two
□  three
□  four
32.87%
17.48%
29.37%
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Table 3.4 Cardioprotective medication prescription in high CV risk subgroups
Drug A l l (high ’ risk
patients
n=109
Diabetes
n-25
IHD
n=29
AMI
n=15
Aspirin 42.3% 52% 42.9% 85.7%
Beta-blocker 40.4% 32% 71.4% 64.3%
ACEI/ARB 33.6% 36% 53% 57.1%
Statin 39.4% 52% 60.7% 57.1%
Table 3.5 Prevalence of potentially reversible standard CV risk factors in high risk 
subgroups
Risk Factor All ‘high ’ risk
patients
n=109
Diabetes
n=25
IHD
n=29
AMI
n=15
Hypertension 52.3% 55.6% 42.9% 42.9%
High chol 62.9% 59.1% 56.0% 58.3%
smoker 31.4% 22.2% 25.9% 21.4%
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Chapter 4
Prevalence, Pattern and Determinants of Left 
Ventricular Abnormalities
4.1 Introduction
The finding of an abnormal LV in a patient with ESRF confers an adverse prognosis for 
that patient compared to a patient with ESRF and a normal LV (37,71). Furthermore, 
such a finding also implies that patient is more likely to develop IHD or CHF (29,30,37). 
The pattern of the LV abnormalities identified will provide information regarding how 
soon the patient can expect to develop symptoms of CHF or IHD and how long they are 
likely to survive (17,71). High systolic BP has been most consistently associated with the 
most common LV abnormality, concentric LVH, whereas IHD is more often associated 
with the LV abnormality that confers the poorest outcome, LVSD (29,30,47,71,76). 
Other potential risk factors for LV abnormalities include older age, diabetes and anaemia. 
However, what is not established is whether consistent improvement or regression of 
such ventricular abnormalities is possible in this population and whether regression will 
result in an improved outcome for the patient. In other words, although we know that the 
patient sitting in front of us at the clinic with LVH and LVSD will have a poor outcome 
we don’t know if we can improve that outcome. Furthermore, as LV abnormalities are so 
prevalent in this population we therefore do not know if we can improve the outcome of 
up to 85% of patients with ESRF (69).
This is not the case for the general population, where large adequately powered 
interventional trials have shown that regression of LVH and improvement of LVEF is
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possible by targeting BP with antihypertensive medication in the case of the former and 
the use of ACEI and beta-blocker therapy in the latter. Both strategies result in 
improvements in outcome (250-252).
Although echocardiography is, and will remain, an invaluable tool for the assessment of 
cardiac structure and function there has been a move away from its use in studies 
targeting LV mass or function because of the large ranges of variability of measurement 
associated with the technique (183). This means large sample sizes are required and 
whilst previous studies in the normal population recruited several thousand patients, the 
largest interventional study targeting LVH in patients with ESRF to date involved only 
150 patients (75). Echocardiography poses additional problems in patients with ESRF 
and previous studies have suggested that echocardiography overestimates LV mass 
compared to CMR imaging (202). As CMR is a more direct method of measuring LV 
mass and volumes, with a much higher spatial resolution compared to echocardiography, 
the range of variability is much smaller and a reduction of sample size of over 90% can 
be expected when using CMR imaging as opposed to echocardiography in either 
longitudinal or interventional studies targeting LV function (213).
We therefore aimed to assess the utility of CMR imaging in patients with ESRF awaiting 
transplant and to measure the prevalence and pattern of LV abnormalities using a method 
of measurement which is not dependant on EDV for the calculation of LV mass. We also 
aimed to identify the determinants of LV abnormalities defined by CMR in order to 
design future interventional trials to investigate whether regression of LV abnormalities 
is possible and if so, whether it confers improved outcome for patients with ESRF.
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4.2 Methods
4.2.1 Subjects
Patients were recruited from the West of Scotland renal transplant waiting list or from the 
transplant assessment clinic at the Western Infirmary, Glasgow. All patients gave 
informed consent and the study had approval from the local ethics committee. The full 
screening protocol and description of methods used are described in Chapter 2.
4.2.2 Procedure
148 patients attended for an initial screening visit as described in Chapter 2. Measured 
LV volumes and mass were corrected for BSA. The normal ranges for LV parameters in 
males and females are shown in Table 4.1(253).
4.2.3 Statistics
Statistical analysis was performed using SPSS Version 11.5 software (SPSS inc. Chicago 
IL, USA). Baseline data are expressed as mean +/- SD or median, if not normally 
distributed. Differences between the groups were assessed using a two-sample t test 
(normally distributed data) or Mann Whitney U test (non-parametric data). A p-value of 
less than 0.05 was considered significant. 95% confidence intervals for differences 
between groups in mean percentage change from baseline are given. Correlations 
between continuous values were assessed using Pearson’s correlation coefficient for 
parametric data. The determinants of LV abnormalities were identified using multivariate 
linear regression analysis using a stepwise paradigm.
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4.3 Results
4.3.1 Baseline Characteristics
Data was available for 148 patients for the initial analysis on prevalence of LV 
abnormalities. Baseline demographics, including CV risk factors, for the whole cohort are 
discussed in Chapter 3 and shown in Table 3.1. Average systolic BP for the cohort was 
136+/-24mmHg and average diastolic BP was 80+/-12mmHg. Average haemoglobin 
level was relatively high for a group of patients with ESRF at 11.5+/-1.6g/dL.
4.3.2 Baseline left ventricular anatomy and function and prevalence of left 
ventricular abnormalities
Baseline measurements for LV function, mass and volumes are found in Table 4.2 with 
the corresponding normal ranges for men and women using CMR imaging (253). In the 
baseline cohort of 148 patients, 29% had a normal LV as defined by CMR imaging. In 
keeping with previous studies the most common LV abnormality was elevated LV mass 
with a total of 70% of patients being identified with LVH. LVDil was found in 17% of 
patients and 15% had LVSD. Unsurprisingly, a particular patient could have more than 
one LV abnormality and 11% of the cohort (16 patients) had a combination of all three 
LV abnormalities. The relationship of these LV abnormalities to each other is shown in 
Figure 4.1. LVH was ubiquitous in those with LV abnormalities and only 1 patient with 
an abnormal LV did not have LVH. LVDil did not occur in isolation and was always 
associated with LVH with or without LVSD. Similarly, LVSD was usually observed in 
association with LVH and LVDil with a small number associated only with LVH.
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Categorising the LV abnormalities observed into the previously described patterns of 
cardiomyopathy in patients with ESRF, 50% of patients had concentric LVH, 6% had 
eccentric LVH and 15% had LVSD (Figure 4.2V Thus the pattern of differing types of 
cardiomyopathy in this cohort measured using CMR is different to that previously 
described by other groups using echocardiography (Figure 1.1T
4.3.3 Baseline correlates of left ventricular anatomy and function
The relationship between systolic BP and the baseline LV abnormalities is demonstrated 
in Graphs 4.1-4.4. Systolic and diastolic BP correlated well with LV mass (p<0.001, 
r=0.410), (p=0.001, r=0.412) and EDV (p<0.001, r=0.374), (p=0.009, r=0.215) but not 
with ESV (p=0.023, r=0.201) (p=0.187, r=0.117) and neither correlated significantly with 
Ejection Fraction (p=0.586), (p=0.687). There was no correlation with any baseline LV 
abnormality and age but there was a significant correlation between sex and LVMI and a 
weak but significant negative correlation between heart rate and Ejection Fraction 
(p=0.003, r=0.283).
4.3.4 Characteristics of patients with left ventricular abnormalities
The differences between patients who had normal left ventricles (control group) defined 
by CMR and those who had abnormal ventricles are shown in Table 4.3 and the 
differences found in LV measurements in Table 4.4. There was no significant difference 
between the groups with regard to age or sex. With regard to history of renal disease, 
there was no difference between the groups with regard to length of CRF (p=0.333), 
length of time on RRT (p=0.807) or number of previous transplants (p=0.914). There was
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however, a significant difference between those with a normal ventricle and an abnormal 
ventricle and mode of RRT. Patients who had an abnormal LV were more likely to be on 
haemodialysis (61%) compared to those with a normal ventricle (45%) p=0.038.
With regard to standard CV risk factors there were significant differences between the 
groups with regard to both systolic and diastolic BP. Patients with an abnormal LV were 
more likely to have both a higher systolic BP (141.0+/-22.7mmHg vs. 124.3+/- 
24.3mmHg, p<0.001) and diastolic BP (82.5+/-11.5mmHg vs. 74.0+/-11.2mmHg, 
p<0.001) than those with a normal LV. Similar to findings in previous echocardiographic 
studies there were no significant differences between the groups with regard to other 
standard CV risk factors. Patients with an abnormal LV were no more likely to have a 
past history of IHD (p=0.959), diabetes (p=0.073) or a past history of other vascular 
disease (p=0.064). There were no significant differences between the groups with regard 
to a history of hypertension, smoking or family history of IHD.
Interestingly, despite the differences in BP between the two groups, there were no 
significant differences between those with a normal LV and an abnormal LV with regard 
to type of antihypertensive medication (Table 4.5) such as beta-blockers (p=0.104) or 
ACE inhibitors (p=0.292), number of prescribed antihypertensive drugs (p=0.063) or the 
use of aspirin (p=0.205) or statins (p=0.482).
Finally, turning to biochemical markers there were no differences between the groups 
with regard to haemoglobin (p=0.214), CRP (p=0.254) or cholesterol level (p=0.066) but 
the patients with an abnormal ventricle had significantly higher levels of BNP (p<0.001).
I l l
4.3.5 Characteristics of patients with isolated left ventricular hypertrophy
Turning to the individual LV abnormalities, each group of abnormalities were compared 
to the patients in the cohort with a ‘normal’ LV to ascertain any potential differences 
between patients with findings of isolated LVH, LVDil and LVSD and are shown in 
Table 4.3.
LVH was the most common LV abnormality in the cohort and 70% patients were found 
to have this abnormality. Of those patients with an abnormal LV, 68% of these had 
isolated LVH (50% of total cohort) and this group was compared to those patients with a 
normal LV. With regard to baseline characteristics there were no age or sex differences 
between the groups and no significant differences were seen with regard to total length of 
renal failure or length of time on RRT. The only significant difference with regard to 
renal history between the groups was type of RRT, and 65.7% patients with concentric 
LVH were established on haemodialysis compared to 45% patients with normal left 
ventricles (p=0.047).
Patients with concentric LVH had a significantly higher systolic (140.7+/-23.6mmHg vs. 
124.3+/-24.3mmHg, p=0.001) and diastolic (82.8+/-11.9mmHg vs. 74.0+/-11.2mmHg, 
p<0.001) BP than those in the control group and similar to the initial analysis of all 
patients with an abnormal LV there were no significant differences between the groups 
with regard to previous history of IHD (p=0.241), diabetes (p=0.383) or other vascular 
disease (p=0.122). Patients with concentric LVH were no more likely to be on a beta- 
blocker (p=0.154) or ACE inhibitor (p=0.870) and were not taking a higher number of 
antihypertensive medications (p=0.203) than those with normal ventricles, although the
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proportions on these medications in the group with concentric LVH was higher (Table
4J).
Finally, there were no significant differences with regard to haemoglobin level (11.6+/- 
1.5g/dL vs. 11.9+/-1.6g/dL, p=0.489) or cholesterol level (5.7+/-1.6mmol/L vs. 6.0+/- 
1.7mmol/L) but lgBNP was significantly higher in those with concentric LVH (2.9 vs.
1.4, p<0.001).
4.3.6 Characteristics of patients with left ventricular dilation
A total of 17% patients in the cohort had LVDil defined by CMR imaging. It should be 
noted that patients who had LVDil consisted of a small number categorised as eccentric 
LVH (9 patients) and the rest had associated LVSD which may confound results for this 
group. There were no differences with regard to sex and age between patients with LVDil 
and those with normal ventricles but once again there were significant differences in BP 
between the two groups. (Table 4.3). Systolic BP was significantly higher in the patients 
with LVDil (144.3+/-19.9mmHg vs. 124.3+/-24.3mmHg, p=0.011) as was diastolic BP 
(87.0+/-8.2mmHg vs. 74.0+/-11.2mmHg, p<0.001) when compared to patients with 
normal ventricles.
In contrast to the findings in the group analysis of all those with LV abnormalities and 
that of patients with LVH, patients with LVDil were no more likely to be on 
haemodialysis than those with a normal ventricle (p=0.443). With regard to vascular 
disease and diabetes, patients with LVDil did not have a significantly higher prevalence 
of IHD (p=0.553) or diabetes (p=0.965), than those with normal ventricles but did have a
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significantly higher prevalence of other vascular disease (p<0.001) and a significantly 
higher proportion of those with LVDil had a previous history of CHF (p=0.006)
Turning to medication, the use of ACE inhibitors was significantly higher in patients with 
LVDil (p=0.044) as was use of calcium channel blockers (p=0.044). There were no other 
significant differences between the two groups with regard to medication type or number 
of antihypertensive medications taken (Table 4.5).
As expected, patients with LVDil had similar haemoglobin levels to those with normal 
ventricles (11.2g/dL vs. 11.9g/dL, p=0.284) and the only biochemical abnormality that 
was significantly different between the two groups was BNP with a significantly higher 
lgBNP observed in the patients with dilated ventricles (3.2 vs. 1.4, p=0.016).
4.3.7 Characteristics of patients with left ventricular systolic dysfunction
Although only 7.6% patients had a documented history of LVSD prior to screening, 15% 
patients had LVSD as defined by CMR. This group also includes all patients with a 
combination of all three LV abnormalities as 70% patients with LVSD also had 
associated LVH and LVDil.
Although there were no significant differences with regard to age between patients who 
had LVSD and those in the control group, this was the only group patients with LV 
abnormalities to have a significant difference in sex and 87% of those with LVSD were 
male (p=0.015). In contrast to the other groups of patients with LV abnormalities there 
were much smaller differences between those with LVSD and those with normal 
ventricles with regard to BP. Systolic BP was significantly higher in those with LVSD 
(136.9mmHg+/-22.2mmHg vs. 124.3+/-24.3mmHg, p=0.043) but there was no
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significant difference with regard to diastolic BP (78.7+/-10.6mmHg vs. 74.0+/-
11.2mmHg, p=0.104) and no significant differences in any aspect of renal history, 
including type of dialysis therapy.
What was significantly different however, was a previous history of AMI (p=0.010), IHD 
(p=0.027), other vascular disease (p=0.005) and CHF (p=0.009). A prior history of any of 
these conditions was significantly more likely in the group of patients with LVSD, as was 
a history of diabetes (p<0.001) (Table 4.31. In view of this it is unsurprising that patients 
with LVSD were more likely to be taking aspirin (p<0.001) and ACE inhibitors 
(p<0.010) but they were not more likely to be taking a beta-blocker (p=0.184) or a statin 
than those patients with a normal LV (p=0.854) (Table 4.5).
With regard to haematological and biochemical markers there was no difference in 
haemoglobin level between those with LVSD and those with a normal LV (11.2+/-
1.5mmol/dL vs. 11.8+/-1.6mmol/dL, p=0.127) but lgBNP was significantly higher (4.5 
vs. 1.4, p<0.001) and cholesterol levels were significantly lower in patients with LVSD 
(4.7+/-1.6 vs. 6.0+/-1.6mmol/L, p<0.001).
4.3.8 Relationship between left ventricular abnormalities and the ECG
Differences in ECG findings between the groups are displayed in Table 4.6 Patients with 
LV abnormalities were more likely to have an abnormal ECG with regard to criteria of 
LVH (14.3% vs. 47%, p=0.001), ST changes (7.1% vs. 37%, p=0.001) and the presence 
of Q waves (2.4% vs. 6.8%, p=0.025) and patients with history of IHD and prior AMI 
were more likely to have Q-waves on their ECG (p<0.001).
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However, the sensitivity of the ECG to detect abnormalities of LV anatomy and function 
was generally unsatisfactory with a sensitivity of 39.0% and a specificity of 81.0%. The 
NPV of the ECG to exclude those with LV abnormalities was also poor at 65% with a 
PPV of 83%.
4.3.9 The determinants of left ventricular abnormalities defined by CMR
Finally, the determinants of LV abnormalities were identified using multivariate linear 
regression analysis and results are displayed in Table 4.7. The continuous variables of 
LVMI, EDV corrected to BSA, ESV corrected to BSA and LVEF were tested as outcome 
variables for the whole cohort. A set of independent variables consisting of age, sex, 
systolic and diastolic BP, a history of IHD, diabetes or CHF, length of renal failure, type 
of dialysis therapy and haemoglobin were examined as potential determinants in a 
backward elimination strategy.
Significant independent determinants of LV mass were sex (p=0.002), diastolic BP 
(p<0.001), haemodialysis as mode of RRT (p=0.014) and a history of diabetes (p=0.004). 
A history of IHD was not an independent determinant of LV mass.
Similarly to LV mass, diastolic BP (p<0.001) and haemodialysis as mode of RRT 
(p=0.019) were independent predictors of EDV and a history of CHF was also a predictor 
of EDV (p=0.003). However, BP and mode of RRT were not predictors of ESV, whereas 
a history of IHD (p=0.030), CHF (p=0.037) and diabetes (p=0.007) were predictors of 
ESV. Finally, Ejection Fraction was not dependant on any measure of BP but was 
dependant on a history of prior IHD (p=0.022) or CHF (p=0.006) and a history of 
diabetes (p=0.001).
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When BNP was included in the regression model it was found to be an independent 
predictor of all parameters of LV mass, volumes and function measured and was found to 
be most strongly associated with LV mass.
4.3.10 The concept of LV concentric remodelling
In the original LV geometry trials in hypertensive patients, a fourth pattern of LV 
geometry was identified in addition to normal geometry, concentric LVH and eccentric 
LVH; that of concentric remodelling (Figure 4.3Y This is described as normal LV mass 
and increased relative wall thickness of the LV resulting in a small cavity LV and has not 
been included in previous echocardiographic classification of uraemic cardiomyopathy. 
Using the definition criteria for concentric remodelling, a further 17 patients (10 men) or
11.5% of the cohort would be categorised in this group from the normal LV group 
leaving only 17.5% of the total cohort with a normal LV.
This group interestingly, had a significantly lower mean BP than that in either patients 
with a normal LV or the rest of the cohort taken as a whole. Mean BP for patients with 
concentric remodelling was 112+/-20mmHg and 71+/-13mmHg for systolic and diastolic 
BP respectively. Patients who had a normal LV had a significantly higher systolic BP 
(132+/-23mmHg, p=0.006) but diastolic BP was not significantly different.
Both systolic BP and diastolic BP were significantly lower in patients in the concentric 
remodelling group when compared to the rest of the cohort who had a systolic BP of 
139+/-23mmHg, p<0.001) and diastolic BP of 81+/-llmmHg, p=0.001)
The significance if any, in this patient group of concentric remodelling is unknown and 
has not previously been investigated. In view of this we elected to simply describe the
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pattern of concentric remodelling, rather than include it in the main analysis, as it would 
introduce a further confounding effect and used the previously defined types of uraemic 
cardiomyopathy from earlier echocardiographic studies in patients with ESRF.
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4.4 Discussion
Previous echocardiographic studies have established that LV abnormalities such as LVH, 
LVDil and LVSD are common in patients with ESRF and are associated with a poor 
outcome (14,16-17,29,42,69,74). In this study of 148 patients with ESRF suitable for 
renal transplantation, 29% were found to have a normal LV as defined by CMR imaging. 
This is almost twice that found in previous echocardiographic studies of patients with 
ESRF (69,72-73) and may reflect the fact that patients assessed for renal transplant have 
less co-morbidity than the unselected groups of dialysis patients in previous studies. For 
example, this cohort of patients included a relatively low proportion of diabetics at 18% 
whereas in the study of Parfrey et al. (69), the proportion of diabetics was higher at 27% 
However, in contrast to the higher prevalence of normal ventricles, similar proportions of 
patients were found to have LVSD in our study, compared to the studies of Parfrey et al. 
at 15%. The pattern of LV abnormalities was also different. Concentric LVH was the 
predominant LV abnormality but unlike previous studies we found a lower total 
prevalence of LVDil (16%) and a higher proportion of those who had LVDil, had this in 
association with LVSD (Figure 4. IT Only 6% of the cohort were found to have eccentric 
LVH. Thus, whilst a fitter population of patients may explain why fewer have an 
abnormal LV compared to echocardiographic studies of unselected haemodialysis 
patients, it does not explain the difference in the pattern of LV abnormalities found.
Ganau et al. (254) described 4 different patterns of LV geometry in patients with 
essential hypertension; normal, concentric LVH, eccentric LVH and concentric 
remodelling (Figure 4.2). Although we are familiar with the first 3 patterns the fourth 
pattern is not often described as total LV mass is normal. However relative wall thickness
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is increased due to a decrease in LV cavity size. This pattern of LV geometry is felt to 
reflect remodelling from concentric LVH or a pattern of geometry that develops in 
response to pressure overload in some patients and the mortality rate in patients 
displaying this type of geometric pattern is lower than that of eccentric and concentric 
LVH but higher than that of normal geometry. Concentric remodelling may imply 
additional problems in patients on haemodialysis as CO is decreased and chamber size is 
small and therefore this group of patients may be particularly sensitive to abrupt changes 
in preload during dialysis and be at high risk of dialysis induced hypotension (255).
When considering together the prevalence of concentric LVH and concentric remodelling 
it is felt that pressure overload is the fundamental abnormality in patients with arterial 
hypertension although in most circumstances it is associated with some volume 
component. In hypertensive patients without CAD, regression of concentric LVH to 
eccentric LVH confers a favourable prognosis (256). However, in cross sectional studies, 
hypertensive patients with eccentric LV geometry are more likely to have underlying 
CAD than patients with concentric LVH (257). Thus the natural history seems to be a 
high prevalence of concentric LVH during the natural progression of arterial 
hypertension toward overt CVD and a higher prevalence of eccentric LVH once C VD has 
occurred, as a consequence of post infarction remodelling which will lead to systolic 
dysfunction.
Although volume overload will be more predominant in patients with CRF compared to 
those with essential hypertension, the pattern of abnormalities found in our study fit well 
with the pattern observed in patients with essential hypertension. The predominant LV 
abnormality found was concentric LVH (50% of whole cohort), which was associated
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with BP and a much smaller proportion had eccentric LVH (6% of whole cohort). A 
dilated LV was more likely to be observed in association with LVSD (10.1%) and this 
group were observed to have a higher prevalence of IHD and diabetes. This is in contrast 
to the study of Parfrey et a l where 28% of patients were classified as having eccentric 
LVH.
The higher prevalence of eccentric LVH in echocardiographic studies in patients with 
ESRF may reflect differences in the technique used to measure the LV, namely 
echocardiography and CMR. The difficulty in classifying LVH into either a concentric or 
eccentric type in haemodialysis patients is well recognised when using echocardiography 
because of cyclical variations in extracellular fluid volume (194-195). The internal 
dimensions of the LV are influenced by volume status and therefore LV diameter will be 
different at any given time point in relation to dialysis cycle (194-195). This induces 
‘acute’ changes in relative LV wall thickness and the same patient could be characterised 
to having either eccentric or concentric hypertrophy depending on the time point of 
echocardiography. It should be noted that this is a younger, more motivated population, 
more likely to adhere to fluid restriction and our group as a whole had higher 
haemoglobin levels than other studies and so these findings do need to be interpreted with 
caution in comparison to other cohorts. In the recent echocardiographic study of 
transplant candidates by Sharma et a l 11% of patients were found to have eccentric 
LVH. This study used more accurate 2-D methods of measurement for LV volumes and 
harmonic imaging, neither of which were used in earlier studies and therefore the lower 
proportion of eccentric LVH may reflect either more accurate measurement of true LV 
volumes and mass or reflect a fitter population (patients with known LVSD were
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excluded from this study). However, despite this the proportion of patients with eccentric 
LVH in the study of Sharma et a l was still nearly twice that of our study.
LV abnormalities often overlap and co-exist making analysis of individual abnormalities 
difficult but the pattern of LV abnormalities observed in this study does not support the 
generally accepted hypothesis that ‘uraemic cardiomyopathy’ initially exists as either 
concentric or eccentric LV hypertrophy (79) but rather LVDil may be an intermediate 
disease stage between LVH and LVSD as observed in the hypertensive population as we 
did not observe LVDil in isolation. This hypothesis is partly supported by the recent 
study of Aoki et al.(258) They studied the pathological ventricular characteristics of 40 
patients on haemodialysis found to have dilated cardiomyopathy and normal coronary 
arteries. LV biopsies were taken at catheterisation and compared to biopsies in a group of 
patients with dilated cardiomyopathy and normal coronary arteries who did not have a 
history of renal failure. On histological examination severe myocyte hypertrophy and 
disarray was observed in patients on dialysis compared to the control group and the 
pattern observed in the dialysis group was typical of that associated with the dilated phase 
of hypertrophic cardiomyopathy.
Despite overlap of LV abnormalities, when groups of patients with each LV abnormality 
were compared to those with normal ventricles, specific differences were found between 
groups especially between those with LVH and those with LVSD. Overall, BP correlated 
well with LV mass and EDV for all patients in the cohort but did not correlate with EF. 
This was reflected in the finding that both systolic and diastolic BP were significantly 
higher in the group of patients with elevated LV mass but no such difference were found 
in the group with LVSD.
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The other major difference between the groups was with regard to a history of IHD. 
Whereas patients with LVSD had a much higher prevalence of IHD than those with 
normal ventricles, those with LVH did not and the proportion of patients with IHD 
increased from 11% to 27% to 45% with findings of hypertrophy, dilation and systolic 
dysfunction.
Thus, in patients with concentric LVH, BP and mode of dialysis therapy determined LV 
abnormalities when compared to those with normal ventricles, whereas in those with 
LVSD a history of EHD and diabetes determined LV abnormalities. This finding has been 
observed in other studies. Foley et al. found consistently in studies of their cohort of 433 
patients that IHD was associated with LVSD, but not with dilation or hypertrophy 
(17,69,29) but with follow up, no association between serial echocardiographic changes 
to LV abnormalities and IHD was found (70).
These findings suggest that although LVH and LVSD are interrelated, the major 
mechanisms for the development of LVH and LVSD are different. LVH is more 
dependant on BP and haemodynamic influences such as haemodialysis and LVSD is 
more dependant on the effects of pre-existing IHD and diabetes. It could therefore be 
proposed that the two major types of uraemic cardiomyopathy are in fact concentric 
hypertrophic cardiomyopathy and ICM both of which maybe associated with LV dilation. 
With regards to targeting risk factors, BP was the only reversible risk factor identified in 
patients with concentric LVH and LVDil and no traditional reversible risk factors were 
identified to target in those with LVSD.
Unusually in studies in patients with ESRF, diastolic BP showed a stronger relationship 
to LVMI in this study. Whereas both systolic and diastolic BP were significantly higher
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in patients with LVH, only diastolic BP was independently associated with LVMI and the 
reasons for this are unclear but may reflect the greater range of variability observed with 
systolic BP and the fact the only a single measurement of BP was used rather than mean 
24 hour values.
Although only 7.6% of patients in the study had a preceding history of heart failure, twice 
as many were found to have LVSD, a finding which implies worsened prognosis when 
compared to that of LVH or LVDil (17,70,88). This suggests that either LVSD is under 
detected prior to patient assessment for renal transplant or is not detected in those who 
develop LVSD whilst on the waiting list. In either case, if these high risk patients are to 
be identified prior to undergoing renal transplantation, improved screening for systolic 
dysfunction is required so that attempts can be made to modify and minimise risk both 
pre-transplant and in the peri and post-transplant period.
The use of the standard 12 lead ECG to detect LV abnormalities is not a sensitive enough 
tool to be used in clinical practice in this population. Although an abnormal ECG was a 
relatively specific sign of LV abnormalities the finding of a normal ECG does not 
exclude LV abnormalities reliably and therefore other additional non-invasive methods 
are required to identify LV abnormalities when assessing patients for renal 
transplantation.
The aim of this study was to determine the prevalence of LV abnormalities of patients 
with ESRF suitable for renal transplantation using CMR and to identify the determinants 
of these LV abnormalities. CMR was well tolerated by patients and 71% of patients had 
an abnormal ventricle which is a smaller proportion than observed in previous 
echocardiographic studies of transplant candidates. The predominant abnormality was
124
concentric LVH, found in 50% of the cohort and the proportion of patients with eccentric 
LVH was very small compared to previous studies. BP and haemodialysis as choice of 
dialysis therapy were independent predictors of LVH, suggesting a relationship with 
pressure and volume overload and future interventional studies should target BP control 
via antihypertensive therapy and manipulation of dialysis programmes in those with 
concentric LVH.
Patients with LVSD displayed a strong relationship with IHD and diabetes, neither of 
which are reversible. However, future studies in patients with LVSD and ESRF could 
assess ischaemic burden, especially the degree of reversible ischaemia which could 
provide an interventional target in this population of patients with ESRF and poor 
prognosis.
Further studies are required; both larger studies in patients undergoing assessment for 
renal transplantation and in unselected patients on RRT using CMR to provide further 
evidence that ischaemic cardiomyopathy rather than eccentric hypertrophy is the main 
type of uraemic cardiomyopathy after concentric hypertrophy in patients with ESRF.
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Table 4.1 Normal ranges for LV parameters using CMR with SSFP sequence and
baseline LV parameters in a cohort of 148 patients with ESRF felt suitable for renal
transplantation, defined by CMR
MEN ESRF cohort
PARAMETER ABSOLUTE NORMALIZED TO BSA
LVEDV 168+/-33(102-
235)ml
82+/-15(53-l 12)ml/m2 82(+/-31)ml/m2
LVESV 60+/-16(28-92)ml 29+/-7(15-43)ml/m2 31 (+/- 23)ml/m2
LVSV 107+/-21(65-149)ml 52+/-10(32-72)ml/m2 49(+/-17)ml/rn2
LVEF 64+/-5(54-74)% 63 (+/-12)%
LVM 133+/-24(85-181)g 65+/-9(47-83)g/m2 114(+/-34)g/m2
WOMEN
LVEDV 135+/-19(96-174)ml 77+/-10(57-97)ml/m2 67(+/-25)ml/m2
LVESV 49+/-1 l(27-71)ml 24+/-5(14-34)ml/m2 22(+/-2I)ml/m2
LVSV 86+/-12(62-110)ml 42+/-6(30-54)ml/m2 45(+/-13)ml/m2
LVEF 64+/-5(54-74)% 69(+/-ll)%
LVM 90+/-12(66-114)g 52+/-8(36-68)g/m2 85(+/-27)g/m2
LVEDV- left ventricular end-diastolic volume 
LVESV- left ventricular end-systolic volume 
LVSV- left ventricular stroke volume 
LVEF- left ventricular ejection fraction 
LVM- left ventricular mass
Alfakih K, Plein S, Thiele H, Jones T, Ridgeway J, Sivananthan M. Normal human left 
and right ventricular dimensions for MRI as assessed by turbo gradient and steady state 
free precession imaging sequences. Jnl Magn Res Imaging 17:323-329 (2003)
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Figure 4.1 Relationship o f LV abnormalities in 148 patients with ESRF, felt suitable for
renal transplantation, defined by CMR
Normal-43
LVSD
Dilated LV LVH
n=148
LVH- left ventricular hypertrophy 
LVSD- left ventricular systolic dysfunction 
Dilated LV- dilated left ventricle
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Figure 4.2 Piechart dem onstrating prevalence o f LV abnorm alities in 148 patients 
w ith ESRF, felt suitable for renal transplantation, defined by CM R
concentric LVH 
50%
LVSD
15% eccentric LVH
6%
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Graph 4.1 Scatterplot dem onstrating correlation betw een systolic BP and LV mass
corrected to BSA (p<0.001, r=0.410)
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G raph 4.2 Scatterplot dem onstrating correlation betw een systolic BP and ED V
corrected to BSA (p<0.001, r=0.374)
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G raph 4.3 Scatterplot dem onstrating correlation betw een systolic BP and ESV
corrected to BSA (p=0.023, r=0.201)
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G raph 4.4 Scatterplot dem onstrating correlation betw een systolic BP and Ejection
Fraction (p=0.586, r=-0.046)
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Chapter 5 
Natural history of Left Ventricular abnormalities 
in patients with ESRF awaiting Renal Transplant
5.1 Introduction
Several previous echocardiographic studies have suggested that LV abnormalities 
progress after instigation of dialysis (70,93,95). In the studies of Foley et al. (70), follow 
up of an initial cohort of 433 patients commencing RRT produced data on serial 
echocardiograms over 4 years for 29 patients. It was found that the natural history in this 
self-selected group was a continued increase in LVH and LVDil over time and that the 
mass:volume ratio remained constant suggesting the dominant evolutionary picture was 
one of progressive eccentric cardiomyopathy. It was also observed that most of the 
dilation took place in the first year of dialysis therapy and that haemodialysis as mode of 
RRT and anaemia were associated with ventricular enlargement. However, they did not 
find any significant deterioration of ventricular function, expressed as FS. In patients with 
predominant concentric LVH, progressive hypertrophy was the main finding and in those 
with eccentric LVH, continued LVDil occurred. These findings were in contrast to the 
study of Covic et al. (73) who found that concentric LVH rather than eccentric LVH was 
the main progressive pattern.
Subsequent to this Foley et al. have published further data on the serial changes of 
echocardiographic abnormalities in patients with ESRF (95). From the initial study, a 
cohort of 227 patients had baseline echocardiography at the instigation of dialysis and 
follow up echocardiography at a median interval of 13 months after the initial study and
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were followed up for almost 4 years. Overall, a mean increase of LVMI mass was 
observed but patients were divided into groups depending on whether they showed 
individual increases or decreases in LVMI. Those that showed progression of LV mass 
had an increased incidence of new onset CHF compared to those whose LV parameters 
improved. Interestingly, no such differences were observed with LVDil and the authors 
concluded that serial echocardiograms added prognostic information over that of a single 
study and that a lag period of 2 years occurred before baseline LV abnormalities found at 
inception of dialysis therapy translated into the adverse outcome measure of CHF. 
Subsequent work by Zoccalli et a l (93) has also shown that, in general, LV mass and 
LVDil progress in patients with ESRF on haemodialysis but that ventricular systolic 
function does not change significantly. Echocardiography was performed for 161 patients 
at baseline and after 18 months, with a further period of 29 months of follow up. 
Progression of LV mass was associated with an increased risk of death or incident CV 
event, independent of baseline LV mass and other risk factors.
Observational data therefore now suggests that, in general, LV mass progresses in 
patients on haemodialysis and that progression of LV mass implies a poorer outcome for 
that patient. However, why some patients on dialysis show progression of LV 
abnormalities and some show regression is unknown, although this is presumed to be due 
to an excess of risk factors associated with the initial development of LV abnormalities 
such as uncontrolled hypertension.
There are no studies detailing the natural history of LV abnormalities for the subgroup of 
patients on RRT awaiting renal transplant and whilst it is advised that patients undergoing
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assessment for transplant should have yearly screening for IHD, no such guidelines exist 
for how often patients should have an assessment of LV structure and function.
Recently, the validity of longitudinal follow up studies using echocardiography has been 
brought into question with the establishment of CMR imaging (182-183,186,193,196- 
197). It has been suggested that studies requiring repeated measurements of LV mass or 
function in an individual should use CMR (203,259) as it has a superior inter and intra­
observer variability and is more accurate than echocardiography. The use of CMR also 
means that either smaller sample sizes can be used to detect similar change or that 
changes can be detected over a shorter period of time in a similar sample size as that 
required for echocardiography. We therefore obtained 2 consecutive CMR scans, at least 
6 months apart, with follow up data on LV mass, volumes and function in a cohort of 84 
patients involved in our original study to investigate the natural history of LV 
abnormalities in patients awaiting renal transplant.
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5.2 Methods
5.2.1 Subjects and Procedure
Patients were recruited from the West of Scotland renal transplant waiting list or directly 
from the renal transplant assessment clinic at the Western Infirmary, Glasgow. All 
patients gave informed consent and the study had approval from the local ethics 
committee. Screening procedure and methods are described in Chapter 2. Patients were 
contacted again 6 months after the date of initial screening and a further appointment was 
made for repeat scanning at the patient’s convenience.
5.2.2 Statistics
Statistical analysis was performed using SPSS Version 11.5 software (SPSS inc. Chicago 
IL, USA). Baseline data are expressed as mean +/- SD or median, if not normally 
distributed. Differences between the groups were assessed using a two-sample t test 
(normally distributed data) or Mann Whitney U test (nonparametric data). A p-value of 
less than 0.05 was considered significant. 95% confidence intervals for differences 
between groups in mean percentage change from baseline are given. Correlations 
between continuous values were assessed using Pearson’s correlation coefficient for 
parametric data.
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5.3 Results
5.3.1 Baseline characteristics and prevalence of baseline left ventricular 
abnormalities
Data from two consecutive CMR scans at least six months apart were available for 84 
patients and baseline characteristics are displayed in Table 5.1. Mean time of follow up 
scan was 8 months +/-1.2 months. Baseline characteristics were very similar to the initial 
cohort of 148 patients described in Chapter 3 and there were no significant differences in 
baseline data found between patients who attended for 2 scans and the initial cohort. 
Patients in the follow-up cohort were more likely to have undergone previous renal 
transplantation and had a slightly lower prevalence of heart failure than those in the initial 
cohort but these differences were not statistically significant.
Similarly, the prevalence and pattern of LV abnormalities at baseline was similar in the 
follow-up cohort as the initial group. LVH was the most frequently observed LV 
abnormality and was present in 66% of patients. LVSD was found in 15% of patients as 
was LVDil and 33% patients had a normal LV. Although the proportion of patients with 
normal ventricles was slightly higher in this smaller follow-up group compared to the 
baseline group, again this difference was not statistically significant and thus it was felt 
these 85 patients were representative of the initial cohort
5.3.2 Left ventricular abnormalities and follow up
The correlation between individual LV parameters at baseline and follow-up was good 
for all 4 parameters of Ejection Fraction (EF) (p<0.001, r=0.769), LV mass (p<0.001,
143
r=0.723), EDV (p<0.001, r=0.685) and ESV (p<0.001, r=0.842) and are shown in Graphs 
5.1-5.3.
Initially LV abnormalities at baseline were compared with those on follow up for the 
entire cohort and are displayed in Table 5.2. Overall, there were no significant differences 
in any LV parameter at baseline and on follow up. The patients were then split into 
groups depending on whether a normal LV or an abnormal LV was found at baseline to 
ascertain whether there were any significant changes in LV parameters within these 
groups over time.
5.3.3 Follow-up changes in patients with normal left ventricles at baseline
Just over one third of patients (29 patients) in the cohort had a normal LV on baseline 
scan and data on LV parameters at baseline and follow-up are displayed in Table 5.3. 
Interestingly, although EF (p=0.322), ESV (p=0.618) and EDV (p=0.979) did not change 
significantly on follow up, LV mass did increase significantly from 76.8+/-14.9g/m2 to 
84.0+/-18.6g/m2 (p=0.009) in those with an initially normal LV (Graph 5.81.
5.3.4 Follow-up changes in patients with an abnormal LV at baseline
Again, LVH was the most frequent LV abnormality observed and a total of 66% of 
patients had LVH on baseline CMR scan. Almost all patients with an abnormal LV in the 
cohort had LVH and therefore this includes those patients with associated LVSD and 
LVDil. Results of LV parameters at baseline and follow up are displayed in Table 5.4. In 
contrast to those with normal ventricles at baseline, no significant differences were seen
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on follow-up in those patients who already had an abnormal LV with regard to any of the 
LV parameters measured.
5.3.4 Follow-up changes in patients with isolated LVH at baseline
Concentric LVH was the most common LV abnormality observed in the cohort. Forty 
patients in the cohort had concentric LVH on the baseline scan and made up 46.4% of the 
total cohort. Differences on baseline scan and follow up as shown in Table 5.5. Again, no 
significant differences were observed in LV parameters at baseline and follow up and 
total LV mass actually decreased slightly with follow-up but this difference did not reach 
statistical significance.
5.3.5 Follow-up changes in patients with LVSD
Ten patients were found to have LVSD at baseline scan (12% of cohort) and all of these 
also had a dilated ventricle and associated LVH. With follow-up after at least 6 months, 
no differences were found in LV function, volumes or mass in this group. Results of the 
analysis between baseline and follow-up scan are shown in Table 5.6.
5.3.6 Follow-up changes in LV parameters in individuals
Within the cohort as a whole there were no significant differences observed with any LV 
parameter measured. However, more interesting individual differences in patients at 
baseline and follow up are described in Table 5.7 and displayed in Graphs 5.4-5.6 for EF, 
LV mass corrected to BSA and EDV corrected to BSA respectively.
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The only significant difference observed with follow up was an increase in LV mass in 
those who had a normal LV at baseline. There were 29 patients (34.5%) in the cohort 
with a normal LV at baseline and with follow up 13 of these patients (45% of those with 
an initial normal LV) developed LVH whilst 1 patient with an initially normal ventricle 
developed LVSD after an anterior AMI.
Conversely, 9 patients in the group with initial concentric LVH showed apparent 
regression to normal mass and volumes, although 5 of these patients may actually be 
better categorized into the group of concentric remodelling described by Ganau et a l 
(Tigure 4.2) (253). Four patients with initial concentric LVH progressed to eccentric 
LVH and no changes were observed with regard to patients in the group with LVSD. The 
group with eccentric LVH was small (6 patients), the majority of which showed no 
change.
Individual changes in LV mass in patients with an initial normal LV are displayed in 
Graphs 5.7-8. Baseline characteristics including baseline LV mass, EDV, ESV and EF 
were compared between those who developed LVH on follow up and those whose 
ventricles remained normal. The only significant difference between the 2 groups was the 
prevalence of diabetes (p=0.040). (Table 5.81.
As noted above, 13 patients were observed to undergo progression of LVH to develop 
abnormal ventricles and 10 patients with abnormal ventricles, all of which had initial 
concentric LVH underwent progression of LVH by >/= 10g/m2. In contrast 9 patients 
with abnormal ventricles at baseline underwent regression of LVH by >/=10g/m2. 
Baseline variables of these two groups were also compared and the only significant 
difference between those with progression of LVH and those with regression of LVH was
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baseline LV mass (p=0.017). Those demonstrating regression had a higher LVMI 
compared to those demonstrating progression (117.7+/-28.0g/m2 vs. 90.4+/-24.9g/m2) 
Interestingly, there were no significant differences with regard to baseline BP in either 
patients who developed an abnormal LV or those with initially abnormal ventricles that 
showed progression or regression of LVH.
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5 . 4  D i s c u s s i o n
The number of patients selected for renal transplant continues to rise and includes an 
increasing proportion of older patients and those with additional co-morbidity. As a 
consequence, waiting times for a cadaver donor kidney have become longer and in the 
future a significant proportion of patients will wait 3-5 years for transplant (260). Indeed, 
on average, patients in this cohort had been on dialysis for almost 3 years.
The American Society of Transplantation published guidelines in 2002 (261) suggesting 
those at high risk of CV disease should undergo repeated imaging’ studies to rule out 
progression of overt IHD during the waiting period. This guideline was not more specific 
as it was acknowledged there was a lack of studies addressing patients on the waiting list. 
The presence of LVH was defined in these guidelines as a ‘high risk’ marker and if LVH 
was found in the presence of another risk factor, such as age >45 or male sex, patients 
should undergo annual screening and these guidelines are very similar to those of the UK 
based Renal Association (244-245). However, while progression of LV abnormalities in 
patients on RRT is well described, there is much less data detailing the natural history of 
LV abnormalities in the sub-group waiting for renal transplant and if patients were to 
develop LVH whilst on the waiting list that could convert status from ‘normal’ risk to 
‘high’ risk.
In this study, we acquired data on 84 patients felt suitable for renal transplant and 
followed up a baseline CMR study with another study after a mean period of 8 months. 
Overall, there were no significant changes in LV parameters between baseline and 
follow-up study which is not entirely surprising given the relatively short follow-up time. 
However, when the groups were split into those who had a normal LV at baseline and
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those who had an abnormal LV, an interesting difference did occur. Although LV 
parameters in the group with an abnormal baseline LV did not change significantly with 
follow up, those with an initially normal ventricle showed a significant progression of LV 
mass and 45% patients with an initially normal ventricle developed an abnormal LV 
through development of concentric LVH. Thus, with follow up, degree of CV risk in this 
group increases.
When this group of patients exhibiting progression of LVH was compared to those whose 
ventricles remained normal, the only significant difference between groups was 
prevalence of diabetes. No diabetic patients were found in the group whose ventricle 
remained normal, whereas 25% of patients who showed progression of LVH were 
diabetic. However, the numbers in the groups were small (11 vs. 15) and this result 
should be interpreted with caution as should the lack of difference found in other 
variables such as BP, which although was higher in the group who developed LVH, was 
not statistically significant..
Individual differences with regard to EF and volumes were generally small and as 
mentioned previously, only one patient had a significant drop in EF and increase in 
volumes after a large AMI. This finding is in keeping with the findings of Foley et al. 
(95) and Zocalli et al. (93). However, previous echocardiographic studies have found 
significant individual changes with regard to LV volumes and dilation. In this study we 
found no such differences but the number of patients categorized with eccentric LVH was 
small which may have affected analysis. Our findings suggest that any changes over time 
observed with EF and LVDil occur more slowly than the rate change of LV mass or, in 
the case of EF, produced by events such as AMI. However, with follow-up the
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proportion of patients with normal ventricles fell from 34.5% to 28.5%, although this 
difference was not found to be statistically significant.
Only significant progression or regression of LVMI was observed over a period of 8 
months in this cohort. In the group of patients with concentric LVH, 10 showed 
progression of LVH and 9 showed regression of LVH by >/= 10g/m2. When patients who 
showed progression during the study were compared with those showing regression, the 
only significant difference was baseline LV mass. Patients showing progression of LVH 
were more likely to have a lower LV mass at baseline scan than those showing 
regression. It is unclear why this should be the case but again, small groups and the 
relatively larger variability of those with elevated LV mass may affect these results and 
have led to the phenomenon of regression to the mean.
In the early studies of Foley et a l ventricular enlargement was mainly observed in the 
first 12 months of RRT, with relatively little further change thereafter. This was not the 
case in this cohort. Average time on RRT was almost 3 years and there were no 
significant differences observed with regard to time on RRT between those who 
displayed progression or regression of LV parameters and those who showed no change. 
This suggests that intervention in patients awaiting renal transplantation to reduce LV 
mass is feasible.
Within a relatively short period of follow up, a significant proportion of patients 
developed concentric LVH after an initial low risk screening scan. Apart from a history 
of diabetes, no clear differences existed to identify those who progressed from a normal 
LV to an abnormal LV. Although the numbers in this study are relatively small, the 
patients were representative of the initial larger cohort and suggest that lower risk patients
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can progress to higher risk in under a year. Zoccalli et a l observed that progression of 
LVH in patients on RRT was associated with a higher incidence of CV events and a 
higher mortality after 2 years of follow-up. The findings of this study may have 
implications for management of renal transplant waiting lists, especially as average 
waiting time increases and warrants further study, both to replicate initial findings in a 
larger patient group over a longer time period and to examine whether progression of LV 
mass whilst on the transplant waiting list translates into a poorer long term outcome.
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Table 5.1 Baseline demographics of 84 patients undergoing CMR follow-up
BASELINE VARIABLE Follow-up
cohort
n=84
Initial
cohort
n=148
p value
Age (years) 51 +/-10 50+/-10 0.89
Sex (%male) 62.4 68.2 0.64
Patients on haemodialysis (%) 62 60 0.92
Length of time on RRT (months+range) 34.6 (0-144) 31.6 (0-144) 0.66
Length of renal failure (yrs+range) 12.6 (2-45) 8.2 (0.2-39) 0.63
Previous renal transplant (%) 22.8 18.2 0.12
History of Ischaemic Heart Disease (%) 21.4 19.3 0.43
Previous myocardial infarction (%) 8.6 9.7 0.87
History of chronic heart failure (%) 4.8 7.6 0.69
Diabetic (%) 16.7 18.6 0.48
History of hypertension (%) 91.7 94.5 0.88
History of hyperlipidaemia (%) 36 36 0.98
Current smoker (%) 27.7 29.2 0.58
Systolic blood pressure (mmHg+/-95%CI) 134+/-24 136+/-24 0.64
Diastolic blood pressure (mmHg+/-95%CI) 78+/-12 80+/-12 0.67
Cholesterol level (mmol/L+/-95%CI) 5.6+/-1.5 5.6+/-1.7 0.89
Haemoglobin (g/dL+/-95%CI) 11.6+/-1.4 11.5+/-1.6 0.92
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Table 5.2 LV abnormalities at baseline and follow-up in 84 patients with ESRF, felt
suitable candidates for renal transplantation
Variable Baseline scan Follow-up scan p  value
Ejection Fraction (%) 67+/-11.0 67.7+/-12.0 p=0.527
L V M I (g/m2) 99.7+/-28.3 101.4.1+/-30.1 p=0.428
ESVcorrected to BSA (ml/m2) 25.1+/-19.1 24.7+/-20.1 p=0.825
EDVcorrected to BSA (ml/m2) 75.7+/-27.2 13.9+1-29 3 p=0.419
SVcorrected to BSA (ml/m2) 88.0+/-26.9 86.7+/-26.9 p=0.604
Table 5.3 LV abnormalities at baseline and follow-up in patients with a normal LV at 
baseline CMR scan (* denotes significant p-value at p<0.005). n=29
Variable Baseline scan Follow-up scan p value
Ejection Fraction (%) 69+1-6.2 11+1-93 p=0.322
L V M I (g/m2) 76.8+/-14.9 84.0+/-18.6 p=0.009*
ESVcorrected to BSA (ml/m2) 17.8+/-6.5 18.6+/-9.5 p=0.618
EDVcorrected to BSA (ml/m2) 60.4+/-18.6 603+1-22.1 p=0.979
SVcorrected to BSA (ml/m2) 95.8+/-24.8 91.8+/-25.9 p=0.172
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Table 5.4 LV abnormalities at baseline and follow-up in patients with an abnormal 
LV at baseline CMR scan. n=55
Variable Baseline scan Follow-up scan p  value
Ejection Fraction (%) 66+/-12.8 66+/-13.5 p=0.910
L V M I (g/m2) 111.7+/-26.1 110.9+/-30.7 p=0.777
ESVcorrected to BSA (ml/m2) 28.9+/-22.2 27.9+/-23.3 p=0.713
EDVcorrected to BSA (ml/m2) 83.8+/-27.7 81.1+/-30.0 p=0.345
SVcorrected to BSA (ml/m2) 95.7+/-24.8 91.8+/-25.9 p=0.172
Table 5.5 LV abnormalities at baseline and follow-up in patients with isolated LVH at 
baseline CMR scan. n=40
Variable Baseline scan Follow-up scan p  value
Ejection Fraction (%) 71.9+/-5.2 71.9+/-7.1 p=0.981
L V M I (g/m2) 104.4+/-18.9 101.5+/-25.3 p=0.243
ESVcorrected to BSA (ml/m2) 19.1+/-6.0 18.2+/-8.0 p=0.441
EDVcorrected to BSA (ml/m2) 70.3+/-15.1 67.7+/-18.4 p=0.340
SVcorrected to BSA (ml/m2) 90.1+/-19.8 87.9+/-26.4 p=0.432
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Table 5.6 LV abnormalities at baseline and follow-up in patients with LVSD at
baseline CMR scan. n=10
Variable Baseline scan Follow-up scan p value
Ejection Fraction (%) 47.5+/-12.4 45.9+/-9.1 p=0.245
L V M I (g/m2) 116.6+/-27.9 117.6+/-33.2 p=0.810
ESVcorrected to BSA (ml/m2) 58.3+/-28.9 62.0+/-32.4 p=0.122
EDVcorrected to BSA (ml/m2) 102.2+/-35.7 108.2+/-36.1 p=0.246
SVcorrected to BSA (ml/m2) 85.1+/-21.6 87.1+/-20.7 p=0.620
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Graph 5.4 Changes in Ejection Fraction in individual patients at baseline and follow-up
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Table 5.8 Differences in baseline characteristics between patients who developed LVH 
on follow-up and those whose ventricles remained normal. * denotes p<0.05
Variable Normal LV on 
follow up (n=15)
LVH on follow up 
(n=13)
p  value
Age (years) 49.7+/-12.0 52.6+/-8.1 p=0.473
Sex (%male) 60 58 p=0.943
Patients on haemodialysis (%) 53 58 p=0.683
Time on dialysis (months) 41.5+/-32.3 31.9+/-33.0 p=0.454
Length of renal failure (yrs) 13.5+/-5.6 11.0+/-13.6 p=0.518
History of IHD (%) 20 15 p=0.687
Diabetic (%) 0 25 p=0.044*
History of hypertension (%) 87 92 p=0.829
History of hyperlipidaemia (%) 27 36 p=0.167
Current smoker (%) 13 10 p=0.755
Systolic BP (mmHg) 117.8+/-23.0 138.3+/-31.8 p=0.062
Diastolic BP (mmHg) 74.0+/-12.1 77.0+/-11.9 p=0.525
Cholesterol level (mmol/L) 5.6+/-1.3 6.0+/-2.3 p=0.576
Haemoglobin (g/dL) 12.2+/-0.9 11.5+/-1.8 p=0.233
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Chapter 6 
Haemoglobin and Left Ventricular Abnormalities 
6.1 Introduction
There are numerous observational studies evaluating the relationship between 
haemoglobin and abnormalities of LV structure and function in patients with CRF. 
Almost uniformly, these studies demonstrate that lower haemoglobin values are 
associated with increased LV mass and LVDil and this relationship has been observed in 
patients with pre-dialysis renal failure, ESRF and in those with a functioning renal 
allograft (23,42,69,91,97,100,110-111).
Anaemia results in several adaptive physiological responses designed to improve tissue 
oxygenation. Non-haemodynamic responses include an increase in erythropoietin 
production by the peritubular cells in the cortex-medullary border of the kidney and an 
increase in the intra-erythrocyte concentration of 2,3 diphospoglycerate (DPG) (262). 
Haemodynamic responses to anaemia are more complex and result in an increase in 
cardiac preload, a decrease in systemic vascular resistance leading to a decrease in 
cardiac afterload, all of which result in an increase in CO (99). This CV response to 
anaemia is appropriate and usually reversible but in patients with renal failure it has been 
suggested that this response becomes maladaptive and results in eccentric LVH and LV 
remodelling. Reasons postulated for the response becoming maladaptive include the 
‘hypermetabolic’ state associated with CRF (263).
Despite a consistent association of anaemia with LV mass, results from prospective 
randomised trials such as the CHOIR and CREATE trials (107-108), designed to prove
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the benefit of treatment of anaemia on mortality and via regression of LV mass, have 
been disappointing. Only the study of London et a l has shown that regression of LVH 
with a combined treatment approach for both hypertension and anaemia confers improved 
outcome in patients on RRT (75).
Confounding factors exist in observational studies which may help explain why an 
association between LVH and anaemia was observed. For example, it is well recognised 
that during an acute illness haemoglobin level will fall and may take many months to 
recover and inflammatory mediators may play a role in the anaemia of CRF (264). There 
is also an association between a higher erythropoietin dose and adverse outcome at every 
haematocrit level, including those over 39% (265) and it may be that anaemia is simply a 
marker of disease severity and therefore only indirectly associated with outcome.
Another significant confounding effect is the fact that the increased CO associated with 
anaemia results in an increased diameter of the LV. This in turn will result in the 
calculation of larger ventricular volumes and using M-mode echocardiography, a falsely 
higher LV mass. A direct method of measurement that is independent of loading 
conditions, or more accurately ‘volume status-independent5, is therefore attractive and 
may result in defining a more meaningful relationship between LV mass and anaemia. 
Furthermore, it may demonstrate a weaker association between ventricular mass and 
anaemia and help partly explain why regression of LV mass and improved outcome has 
not been consistently observed in studies thus far.
We therefore aimed to examine the relationship between LV mass and anaemia using a 
direct and relatively loading independent method of measuring LV mass, namely CMR.
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6.2 Methods
6.2.1 Subjects
Patients were recruited from the West of Scotland renal transplant waiting list or directly 
from the renal transplant assessment clinic at the Western Infirmary, Glasgow. All 
patients gave informed consent and the study had approval from the local ethics 
committee.
6.2.2 Procedure
Patients attended on a post dialysis day for screening. The screening procedure carried 
out is described in Chapter 2.
6.2.3 Statistics
Statistical analysis was performed using SPSS Version 11.5 software (SPSS inc. Chicago 
IL, USA). Baseline data are expressed as mean +/- SD or median, if not normally 
distributed. Differences between the groups were assessed using a two-sample t test 
(normally distributed data) or Mann Whitney U test (nonparametric data). A p-value of 
less than 0.05 was considered significant. 95% confidence intervals for differences 
between groups in mean percentage change from baseline are given. Correlations 
between continuous values were assessed using Pearson’s correlation coefficient for 
parametric data.
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6.3 Results
6.3.1 Clinical features and baseline haemoglobin
Data on haemoglobin and LV abnormalities, as well as other screening tests, were 
available for 148 patients. Follow up screening with repeat CMR after at least 6 months 
was carried out in 84 patients and follow up data detailing LV abnormalities and 
haemoglobin value was available for these patients. Haemoglobin values, were available, 
for patients attending a regular clinic in the West of Scotland were averaged over the 
preceding 3 months prior to screening. Haemoglobin values ranged from 8.3g/dL- 
15.9g/dL with an average of 11.5g/dL and are displayed in Graph 6.1 for the whole 
cohort. In this cohort, 47 patients (32%) were defined as anaemic with a haemoglobin 
value consistently less than 1 lg/dL.
The cohort was split into two groups on this basis for examining the relationship between 
haemoglobin and LV abnormalities. The subjects in the anaemic and ‘non-anaemic’ 
groups were well matched at baseline for standard CV risk factors and baseline 
demographics for both groups are displayed in Table 6.1. There were no significant 
differences between the groups, for age (p=0.324) or sex (p=0.100) groups and no 
significant differences between groups in the length of renal failure (p=0.734), length of 
time on dialysis (p=0.785) or aetiology of renal failure (p=0.643).
With regard to medication, the patients who were anaemic were more likely to be taking 
aspirin (39% vs. 24%) but this difference did not reach statistical significance (p= 0.060) 
and there were no significant differences between the groups with regard to any 
medication taken including erythropoietin (p=0.953).
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With regard to co-morbidity, again, there were no significant differences between the 
groups with regard to past medical history of IHD, other atherosclerotic disease or CHF 
and patients with anaemia were no more likely to have high BP (p=0.652), be a smoker 
(p=0.488) or have a history of diabetes (p=0.958).
In keeping with previous reports of decreased exercise tolerance in patients with anaemia 
in ESRF, anaemic patients performed less well during ETT, managing an average of 
6.2+/-2.4 minutes compared to 7.4+/-2.4 minutes in the non-anaemic group (p=0.039). 
However, they were no more likely to have an abnormal or ischaemic ETT.
6.3.2 Haemoglobin and erythropoietin
Almost three quarters of the cohort (73.6%) were established on erythropoietin. There 
was no significant difference in haemoglobin value between the patients on 
erythropoietin and those not on erythropoietin (11.6 +/-1.54g/dL vs. 11.6+/-1.69g/dL, 
p=0.969). There was no significant difference in systolic BP between those on 
erythropoietin and those not on erythropoietin (135+/-25mmHg vs. 137+/-22mmHg, 
p=0.59) and no difference in diastolic BP (79+/-12mmHg vs. 81.3+/-11 mmHg, p=0.45). 
Patients on erythropoietin were not prescribed a higher number of antihypertensive 
medications than those not on erythropoietin (1.2+/-1.1 vs. 1.5+/-1.4, p=0.23) and were 
not more likely to be prescribed any particular antihypertensive.
6.3.3 Haemoglobin and left ventricular abnormalities
With initial analysis involving the complete cohort, haemoglobin only correlated 
significantly with EDV (p=0.027, r=-0.188) (Graph 6.21. There was no correlation
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between haemoglobin and LV mass (p=0.627, r=-0.042) (Graph 6.3). EF (p=0.198, 
r=0.110), ESV (p=0.142, r=-0.134) or stroke volume (p=0.067, r=-0.157).
Results of the differences in LV parameters between anaemic and non anaemic patients 
are listed in Table 6.2. The anaemic group had a significantly higher EDV compared to 
the non anaemic group (84.0+/-31.4 vs. 72.5+/-28.5, p=0.038) (Graph 6.4). There was a 
smaller non-significant difference in ESV between the groups and this relative difference 
resulted in a significantly higher stroke volume in the anaemic group. This was reflected 
in a significantly higher CO in patients with low haemoglobin values (p=0.020). This 
however did not translate into a difference in EF between the two groups. Notably, 
although there was a difference in EDV between groups, there was no difference in LV 
mass (Graph 6.5)
When specific LV abnormalities were examined individually, no significant differences 
were found between those with LV abnormalities and those with normal ventricles. Of 
the total cohort, 15% were found to have LVSD as defined as EF of less than 56% (33). 
Those with LVSD had a lower mean haemoglobin value to those with a normal LV 
although this did not reach statistical significance (10.9+/-1.5g/dL vs. 11.9+/-1.7g/dL, 
p=0.054). Turning to those patients with LVH, 70% of the cohort had LVH as defined as 
a LVMI of >68g/m2 for women and >83g/m2 for men (33). Again, there was no 
significant difference in haemoglobin levels between those with LVH and those without 
LVH (11.5+/-1,6g/dL vs. 11.9+/-1,6g/dL, p=0.169. The group of patients with LVDil was 
relatively small compared to previous echocardiographic studies in patients with ESRF 
and LVDil was not observed in isolation from other LV abnormalities. A total of 16% of 
the cohort had LVDil and although EDV was observed to be higher in those who were
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anaemic, patients with LVDil did not have a significantly lower haemoglobin value 
compared to those with a normal LV (11.2+/-1.8 vs. 11.9+/-1.7, p=0.149)
6.3.4 Haemoglobin and the development of left ventricular abnormalities
As discussed in Chapter 5, 84 patients had two CMR scans more than six months apart. 
No significant changes were observed across the cohort with regard to progression of LV 
volumes or function but a significant number of patients with initially normal ventricles 
progressed to develop concentric LVH. When these patients were compared to those 
whose ventricles remained normal no difference in haemoglobin value was found 
(11.5+/-1.8g/dL vs. 12.1+/-0.8g/dL, p=0.233) between groups.
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6.4 Discussion
The physiological response mechanisms of the body to anaemia include increased venous 
return to the heart, an increased heart rate and a resultant increase in CO (99). An 
increase in CO has been confirmed indirectly in several studies in patients with renal 
anaemia and it has been shown that an increase in haematocrit from 20% at baseline to 
31% after epoetin treatment is associated with a reduction in CO from 4.4L/min to 
3.4L.min (266). CO is the product of heart rate and stroke volume of the heart and in 
normal physiological circumstances stroke volume depends on EDV. This is known as 
the Frank-Starling mechanism which states that the ‘output of the heart is determined by 
the amount of blood flowing into the heart’. In this study, patients with a low 
haemoglobin value were found to have a significantly higher CO compared to those with 
higher haemoglobin concentrations. This was due to mainly an higher EDV with a 
relatively preserved ESV and resultant higher stroke volume in patients with lower 
haemoglobin values. There was no difference in heart rate between the two groups. EF 
was not significantly different as EDV was not elevated sufficiently in comparison to 
ESV to alter the value of calculation of EF= EDV-ESV/EDV significantly.
In patients with normal renal function the majority of the CV responses to anaemia, such 
as vasodilatation and increased CO are adaptive and reversible. However, in patients with 
CRF it has been postulated that the normal physiological adaptive processes become 
maladaptive, and this results in stimulation of LVH via eccentric remodelling (110). Once 
established, echocardiographic evidence suggests this LVH is not reversible and 
contributes to the increased mortality observed in this population. Although we found 
anaemic patients to have higher circulating volumes than those with haemoglobin values
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above llg/dL, we did not find any associated difference in LV mass between the two 
groups. This finding may reflect the fact that this cohort of patients had relatively high 
haemoglobin values compared to previous observational studies or the relatively small 
proportion of patients in this cohort with eccentric LVH in comparison to concentric 
LVH. However, it may also reflect the fact that when measurements of LV diameter are 
not used in the calculation of LV mass, as is the case with M-mode echocardiography, 
LV mass is not as strongly associated with haemoglobin values as previously thought. 
This lack of association between LV mass and haemoglobin values has also been shown 
in a previous CMR study by our group in a cohort of 35 patients on RRT (202) but is in 
contrast to another study by our group in 44 patients on haemodialysis where CMR 
measurements of LV mass did showed a weak negative correlation with haemoglobin 
(267).
When haemoglobin values in patients with individual LV abnormalities were examined in 
comparison to haemoglobin values in those with normal ventricles, no significant 
differences were found for any specific LV abnormality. Mean haemoglobin values were 
lower in those patients with LV abnormalities, most marked in those with LVSD, but 
these differences did not reach statistical significance. This again is in contrast to 
previous echocardiographic studies but again may reflect a fitter population or a 
population with a low prevalence of eccentric LVH.
The fact that patients with anaemia in this cohort had a significantly increased CO 
compared to those with a haemoglobin concentration of > llg/dL  but no significant 
difference in BP suggest those with anaemia have a relatively lower systemic vascular 
resistance (SVR=MAP/CO). This is a usual physiological response to anaemia of hypoxic
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dilatation (99). Studies of anaemic renal patients have shown a decrease in forearm blood 
flow and a marked increase in SVR in response to oxygen supplementation and it has 
been suggested that an exaggerated increase in SVR in response to erythropoietin 
administration is partly responsible for the rise in BP observed in 30% patients (268). The 
increase in SVR and blood viscosity associated with reversal of anaemia would usually 
result in release of nitric oxide from the vascular endothelium causing vascular relaxation 
and antithrombotic effects but it has been observed in hypertensive patients that nitric 
oxide mediated endothelial function is impaired (269) and it is thought that these 
mechanisms may help explain the adverse outcome in the treatment arms of trials 
targeting anaemia especially those trials aiming for a high haemoglobin value in patients 
with CRF (107,116).
The dominant ventricular abnormality in this cohort is concentric LVH and putting the 
arguments of methods of measurement aside, it is interesting that the prevalence of 
concentric LVH is so high in all studies of patients with ESRF given the substantial 
volume overload. It is well documented that anaemia is associated with adverse CV 
morbidity and mortality in this population (100-101) and this could partly be explained 
by the combination of a stiff hypertrophied LV and an increase in CO. The increase of 
myocardial thickness and associated fibrosis that ensues leads to a non-compliant 
ventricle poorly able to accommodate an increased venous return. This further increases 
already high end-diastolic pressure thereby increasing cardiac work and myocardial 
oxygen demand and potentially inducing ischaemia and arrhythmias.
In addition to adverse outcome several studies have reported that anaemic patients with 
ESRF perform less well during exercise than those who are not anaemic (104). In keeping
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with this finding, of the 120 patients (80%) in our study who underwent ETT, those who 
were anaemic only managed 80% of the total exercise time that those with a haemoglobin 
concentration of > llg/dL  achieved, although it should be remembered that anaemia is 
associated with other chronic conditions which could influence exercise tolerance.
The lack of association between anaemia and LVH in patients who have been established 
on RRT for several years could potentially be explained by the fact that any effect of 
anaemia on the LV may have already have taken place. We therefore examined the 
relationship between the development of new LVH and anaemia. Although the numbers 
were small (13 patients), we found no significant difference in mean haemoglobin value 
between those who developed LVH and those in whom ventricular anatomy remained 
normal. This is in contrast to previous echocardiographic studies that have suggested that 
degree of anaemia and a progressive decline in haemoglobin level are associated with 
progressive LVDil and hypertrophy in the form of eccentric LVH (69-70).
The relationship between anaemia and LV abnormalities, especially LVH, remains 
unclear. Anaemia is an almost universal finding in patients with ESRF, as is LVH and 
both are associated with an adverse outcome. The fact that controversy regarding the 
favourable impact of the treatment of anaemia with regard to mortaltiy still remains 
almost 20 years after the introduction of erythropoietin is shocking. It may be that part of 
the explanation for this may lie with the inaccuracy in the currently used methods of 
measuring LV mass and volumes and the inability of these methods to be ‘volume 
loading-independent’ in a volume loaded setting, exacerbated further by anaemia. It may 
be that using M-mode echocardiography has led to anaemia incorrectly being associated 
with LV mass in the first place or alternatively failing to identify a true impact of the
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treatment of anaemia on LVMt. Combining observations of both the failure of treatment 
of anaemia to regress LVH and the lack of improvement in outcome in apparently 
adequately powered studies makes the former statement the more likely and the results of 
this study would support that hypothesis. Using the relatively load independent technique 
of CMR, with direct measurement of LV mass and volumes we did not demonstrate a 
relationship between anaemia and LV mass, although anaemic patients had a 
physiologically appropriate higher CO. Further studies are required to confirm these 
initial findings but we suggest that targeting regression of LVMI, measured by M-mode 
echocardiography, as an end-point in trials of the treatment of anaemia in patients with 
ESRF is questionable.
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Table 6.1 Differences in baseline characteristics between anaemic and non-anaemic 
patients
Variable Anaemic
Hb<llg/dL
n=47
Non-anaemic
Hb>llg/dL
n=101
p value
Age (years) 51.3+/-10.3 49.5+/-10.3 p=0.324
Sex (%men) 57 71 p=0.100
Duration of RRT (months) 27.2+/-24.7 34.8+/-31.6 p=0.785
Systolic BP (mmHg) 140.3+/-24.6 132.6+/-23.1 p=0.079
Diastolic BP (mmHg) 80.5+/-11.2 79.5+/-12.6 p=0.652
PMH of IHD (%) 19.1 17.8 p=0.844
PMH of Diabetes (%) 17 17 p=0.958
PMH of CHF (%) 6.4 8.9 p=0.610
Smokers (%) 34 28 p=0.488
No. of HBP drugs 1.2 1.1 p=0.875
On erythropoietin (%) 72 72 p=0.953
On aspirin (%) 39 24 p=0.060
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G raph 6.2 Scatterplot dem onstrating correlation between haem oglobin level and ED V  for
total cohort (p=0.027, r=-0.188)
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G raph 6.3 Scatterplot dem onstrating correlation betw een haem oglobin level and LV M I
for total cohort (p=0.627, r=-0.042)
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Table 6.2 Differences in LV parameters between anaemic and non-anaemic patients
Variable Anaemic
Hb<11.0g/dL
n=47
Non-anaemic
Hb>11.0g/dL
n=101
p  value
Ejection fraction (% ) 64.9+/-12.1 65.9+/-12.9 p=0.646
End-diastolic volume * (ml/m2) 84.0+/-31.4 72.5+/-28.5 p=0.038**
End-systolic volume *(ml/m2) 52.3+/-21.0 45.4+/-23.6 p=0.607
Stroke volume (mls/m2) 52.3+/-17.3 45.4+/-15.0 p=0.022**
Cardiac Output (L/min) 7.1+/-2.4 6.1+/-2.1 p=0.020**
L V  mass * (g/m2) 104.5+/-36.1 103.2+/-33.8 p=0.836
Heart Rate (beats per min) 75+/-14 74+/-15 p=0.815)
* corrected to BSA
**signiflcant result at p<0.05.
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Chapter 7
Brain Natriuretic Peptide and Left Ventricular
Abnormalities
7.1 Introduction
The diagnostic, prognostic, screening and therapeutic monitoring roles of natriuretic 
peptides in CVD continue to expand and with the introduction of nesiritide in the US, a 
recombinant form of human BNP, natriuretic peptides may also have a therapeutic role in 
CHF themselves (270). The original and probably still the most robust use of serum BNP, 
is for the diagnosis of LVSD in patients from the normal population presenting with 
breathlessness or other symptoms suggestive of heart failure and due to the high NPV of 
BNP, a diagnosis of LVSD can be reliably excluded in a breathless patient with a low 
BNP value (122-123).
Patients with ESRF have a high prevalence of symptoms suggestive of CHF such as 
breathlessness and ankle oedema and previous studies have shown that the prevalence of 
CHF in patients commencing RRT is as high as 40% (14). Assessing the diagnostic utility 
of BNP for the diagnosis of LVSD or other structural abnormalities in the context of 
ESRF is fraught with difficulties but despite these problems, several studies have found 
that BNP has a potentially diagnostic role for patients with uraemic cardiomyopathy. 
However in contrast to studies in the normal population, BNP seems to correlate more 
strongly with LVMI than EF in patients with ESRF.
In a study of 246 patients on RRT (86% on haemodialysis) by Mallimaci et al. (139), 
serum BNP level was found to detect echocardiographically determined LVH with a
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sensitivity of 88% and a PPV of 87% but with a disappointingly low NPV of 31%. The 
corresponding values for the detection of LVSD included a sensitivity of 94% and a high 
NPV of 96% but the PPV was very low at 15%. Other studies have shown similar 
findings and in the study ofNishikimi T etal. (138), the additional influence of CAD was 
assessed and patients with LV abnormalities and CAD had higher levels of BNP than 
those with LV abnormalities and no CAD.
The reasons for a stronger correlation of BNP with LVMI in these studies are unclear but 
it may be partly explained by the confounding effect of a higher prevalence of CAD in 
patients with LVSD compared to those with concentric LVH. Furthermore, many of these 
studies have excluded patients with known IHD and therefore the group of patients with 
LVSD are small. However, if BNP is going to be considered as a potential diagnostic tool 
for patients undergoing assessment for renal transplantation, it needs to be sensitive and 
specific enough to reliably identify uraemic cardiomyopathy in any patient considered for 
transplantation.
Biomarkers such as natriuretic peptides are easily measured, can predict outcome in 
patients undergoing cardiac transplant and reliably exclude LVSD in patients in the 
general population. A similar tool in the assessment of patients assessed for renal 
transplant would therefore be invaluable. Previous studies in patients with ESRF have 
been carried out using echocardiography and CMR imaging is now the established 
standard of reference for the measurement of LV abnormalities. We hypothesized that 
serum BNP levels may correlate more strongly with CMR measurements of LV structure 
and function than previous echocardiographic studies, thus improving the sensitivity, 
specificity and overall accuracy of BNP to detect LV abnormalities in this population.
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7.2 Methods
7.2.1 Subjects
Patients were recruited from the West of Scotland renal transplant waiting list or directly 
from the renal transplant assessment clinic at the Western Infirmary, Glasgow. All 
patients gave informed consent and the study had approval from the local ethics 
committee.
7.2.2 Procedure
Patients attended on a post dialysis day for screening. The screening procedure described 
in Chapter 2 was carried out for each patient.
7.2.3 Statistics
Statistical analysis was performed using SPSS Version 11.5 software (SPSS inc. Chicago 
EL, USA). Results are expressed as mean with standard deviation for normally distributed 
data. Correlations between continuous values were assessed using Pearson’s correlation 
coefficient for parametric data. Comparisons between groups were made by the student’s 
T test for normally distributed and the Wilcoxon rank-sums tests for non-normally 
distributed data. Logarithmic transformation was used for BNP levels due to skewed 
distribution. The determinants of BNP levels were investigated by multivariate regression 
analysis using a stepwise paradigm.
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7.3 Results
7.3.1 Baseline demographics of cohort
Data on BNP level and LV abnormalities measured using CMR imaging as well as other 
screening tests were available for 126 patients. Baseline demographics were similar to 
that of the total initial cohort (Table 3.1) and there were no significant differences 
between the BNP cohort and the total cohort with regard to baseline demographics. Age 
range of the BNP cohort was 26-70 with a mean age of 51 (+/-9.8) years old and 83 
patients in the cohort (66%) were men. Average length of renal failure was 8.3 years with 
a range of 0.5-15 years and patients had been on dialysis for an average of 2.8 years with 
a range of 0.5-12 years. A higher proportion of patients were established on 
haemodialysis (60%) with the rest established on PD. Of the patients established on 
haemodialysis, 20% were using overnight or Tong time’ dialysis and of the patients 
established on PD, 62% were using CAPD and the rest APD. Almost one fifth (19%) of 
the cohort had undergone previous renal transplantation.
7.3.2 Left ventricular abnormalities
Normal ranges for LV abnormalities measured using CMR are shown in Table 4 1 At 
baseline screening, the average EF of the cohort was 65% (+/-12.7%) with a range of 16- 
85%. In the BNP cohort, 19 patients (15%) had LVSD defined as an EF of <56% 
measured by CMR imaging. Average LV mass corrected to BSA was 113.8g/m2 (+/- 
34.5g/m2) for men and 86.7g/m2 (+/-26.2g/m2) for women. The majority of patients 
(71%) had elevated LV mass. Average EDV corrected to BSA and ESV corrected 1o BSA 
were 81.8ml/m2 (+/-31.6ml/m2) and 30.4ml/m2 (+/-23.6ml/m2) respectively for man and
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68.9ml/m2 (+/-28.5ml/m2) and 22.8ml/m2 (+/-22.1ml/m2) respectively for women. 22 
patients (17%) had a dilated ventricle. Just over one quarter of the cohort (28%) had a 
normal ventricle defined by CMR imaging and 16 patients (13%) had all three LV 
abnormalities of ‘uraemic cardiomyopathy’. All patients with LVSD had an elevated 
ventricular mass and a dilated ventricle. Thus this BNP cohort had no significnat 
differences with regard to LV parameters compared to the total initial cohort (Table 4.2).
7.3.3 Standard cardiovascular risk factors.
Mean systolic BP was 135mmHg (+/-22.3mmHg) and mean diastolic BP was 80mmHg 
(+/- 11.1 mmHg). The majority (95%) of patients had a history of hypertension. There 
was a history of IHD in 16.7% (21 patients) of the cohort and 8.7% had sustained a 
previous AMI (11 patients).There was a family history of premature IHD in 28%. 
Diabetes was present in 15.9% (20 patients) of the cohort and 33.3% of patients had a 
previous history of hyperlipidaemia. With regard to smoking, 28.8% of patients were 
current smokers and a further 26.4% were ex-smokers.
7.3.4 Drug therapy.
At baseline screening, 70% of the cohort was receiving erythropoietin regularly. Two- 
thirds of patients were on at least one anti-hypertensive medication with 30.6% on a 
single medication for hypertension, 16.1% on dual antihypertensive medication with 
17.7% and 2.2% of patients on three and four anti-hypertensives respectively. Beta- 
blockers were used as an anti-hypertensive medication in 33.2% of patients and ACEI in
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21.1%. A significant proportion of patients were on oral diuretics (32.2%) and 28.8% 
patients were on a statin.
7.3.6 BNP and baseline left ventricular abnormalities.
Initially the relationship between BNP level and baseline LV abnormalities for the whole 
cohort was examined. As BNP has a skewed distribution logarithmic transformation was 
performed prior to analysis. For the total cohort, mean serum BNP was 127pmol/L with a 
range of 0-2093pmol/L. There were significant correlations between serum BNP levels 
and all LV measurements and these are illustrated in Graphs 7.1-7.4. The strongest 
correlation between BNP and LV abnormalities was with LVMI (p<0.001, r=0.585). 
Thereafter, BNP also correlated positively with EDV corrected to BSA (p<0.001, 
r=0.430) and ESV corrected to BSA (p<0.001, r=0.487) and negatively with EF 
(p<0.001, r=-0.455).
7.3.7 Usefulness of BNP to detect left ventricular abnormalities.
Initially the cohort was split into two groups for analysis based on the finding of an 
abnormal LV. Those with a normal ventricle defined by CMR imaging were the ‘control 
group’ and those with an abnormal LV defined by CMR were then examined in 
comparison to the ‘control’ group to examine the diagnostic potential of BNP with regard 
to identifying patients with an abnormal LV.
Patients with an abnormal ventricle had a significantly higher BNP level when compared 
to those with a normal ventricle (26pmol/L+/-66.1pmol/L vs. 166.6pmol/L+/-367pmol/L, 
p=0.002). The significant baseline differences between the two groups are shown in
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Table 7.1 and differences in LV abnormalities between the two groups are shown in 
Table 7.2. Those with an abnormal LV had a significantly higher systolic BP (p=0.023), 
were more likely to be on haemodialysis (p=0.001) and have a history of diabetes 
(p=0.029). Patients with an abnormal LV were no more likely to be on an ACE inhibitor, 
beta-blocker or diuretic than those with a normal LV.
Initially, a range of BNP values were trialled to identify which level of BNP was the most 
accurate upper limit of ‘normal’ for the cohort. An upper limit of 20picomol/L gave the 
best sensitivity, specificity and overall accuracy through the group values and this was 
used to define ‘normal’ and ‘high’ levels for BNP in the cohort. This is higher than the 
level in the normal population of a cut-off of 5.2picomol/L (35). The sensitivity of BNP 
to detect any abnormality was 65% and the specificity 79%. This gave a PPV for BNP to 
detect any LV abnormality of 88% and a NPV value of 59%. The ROC curve is shown in 
Graph 7.5 with an area under the curve of 0.707.
7.3.8 BNP and left ventricular hypertrophy.
Patients with concentric LVH, measured using CMR imaging, were compared with the 
group of patients with a normal LV to examine the potential utility of BNP to identify 
patients with ESRF who have concentric LVH. BNP level was significantly higher in the 
group of patients with LVH when compared to those with normal ventricles 
(26pmol/L+/-66.1pmol/L vs. 175pmol/L+/-157pmol/L, p=0.030). The sensitivity of BNP 
to detect LVH was 63% and the specificity 79%. The PPV of BNP to detect LVH was 
79% and the NPV 60% (Table7.3). The ROC curve is shown in Graph 7.6 with an area 
under the curve of 0.739.
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7.3.9 BNP and left ventricular dilation.
There were 22 patients in the cohort with a dilated left ventricle (LVDil). This group was 
compared with the 33 patients in the cohort with a normal LV with regard to BNP levels 
and the utility of BNP to detect LVDil. BNP levels were significantly higher in the group 
with LVDil than those with a normal LV (16pmol/L+/-30.1pmol/L vs. 599pmol/L+/- 
122.3pmol/L) p=0.001. The sensitivity of BNP to detect LVDil was 68% with a 
specificity of 79%. The PPV of BNP to detect LVDil was 68% and the NPV of a high 
BNP ruling out LVDil was 80% (Table 7.3T The area under the ROC curve was 0.767.
7.3.10 BNP and left ventricular systolic dysfunction.
Finally, the group of patients with LVSD were compared to the group with a normal LV. 
BNP level in the group was significantly higher in those with LVSD than in those with a 
normal ventricle (16+/-30pmol/L vs. 395+/-534pmol/L, p<0.001). The sensitivity of BNP 
to detect LVSD was 74% and the specificity 79%. The PPV of BNP to detect LVSD was 
67% with a NPV of 90% (TableJ7T). The ROC curve is shown in Graph 7.8 and area 
under the curve is 0.811.
7.3.11 Determinants of BNP in patients awaiting renal transplantation.
The whole cohort was examined using lgBNP as the outcome variable and the set of 
initial independent variables used in a multivariate linear regression model were LVMI, 
EDV corrected to BSA, EF, age, sex, systolic and diastolic BP, length of renal failure, 
mode of RRT, a history of CHF, IHD or diabetes and haemoglobin. These variables were
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then used in a backward elimination strategy to identify independent determinants of 
BNP. Table 7.4 shows univariate and the independent predictors of BNP.
All parameters of LV mass, volumes and EF were significant on univariate testing as 
were systolic BP and a history of diabetes. Interestingly, type of dialysis therapy was not 
significant on univariate analysis nor was length of renal failure or length of time on 
dialysis.
The only independent predictors of BNP found in the regression model were LVMI 
(p<0.001, P=0.435) and EF (p=0.043, P=-0.171). A history of IHD or measures of LV 
volume were not found to be independently associated with BNP level.
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7.4 Discussion
Patients with renal failure, especially those who have ESRF have a high mortality rate 
mainly attributable to CVD. In this population the major predictors of mortality are 
structural LV abnormalities, especially LVSD. A significant proportion of patients with 
ESRF will be considered as potential candidates for renal transplantation and part of the 
assessment should include cardiac risk stratification. Many of these patients will undergo 
echocardiography for assessment of LV abnormalities but waiting times in some centres 
are still long and measurements made often depend on timing of the study in relation to 
dialysis cycle (195) and outwith the setting of clinical trails, a hospital appointment for an 
echocardiogram will not often fall at the optimum time of 4-6 hours post dialysis session. 
Furthermore, echocardiographic images are often sub-optimal due to poor echo windows 
in as many as 40% of adult patients (186).
A screening test such a BNP, that could be carried out at the transplant assessment clinic, 
would therefore be attractive in this population to enable identification of patients with 
LV abnormalities and prompt further plans for cardiac investigation at that time. Previous 
studies have suggested that natriuretic peptides may be useful in this population but that 
other factors such as drug therapy and methods of excretion may affect the accuracy of 
cardiac biomarkers such as BNP in patients with renal disease (132-133,136,138).
At time of writing, this is the first study examining the relationship of the natriuretic 
peptide BNP and LV abnormalities in a group of patients with ESRF using CMR as the 
method of measurement of LV abnormalities and several of our findings were similar to 
previous echocardiographic studies. As in the study of Nakatini et al. (148) we also found 
that BNP level was significantly higher in patients on haemodialysis compared to those
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on CAPD. In our BNP cohort there were no significant differences in prevalence of IHD 
between patients on differing forms of RRT and several explanations exist for the higher 
observed level of BNP in patients on haemodialysis. Nakatini et a l proposed that the 
higher haemodynamic burden on patients of haemodialysis could account for higher 
circulating levels of BNP. However, type of dialysis therapy was not found to be a 
determinant of BNP level in this study and therefore does not support this hypothesis. 
Alternatively, patients on CAPD tend to have greater residual renal function than those 
on haemodialysis and lower BNP levels in patients on CAPD may reflect greater 
clearance. In our cohort, patients on haemodialysis had a higher prevalence of LV 
abnormalities (Table 7.1). mainly in the form of LVH, compared to those on CAPD and it 
is likely that selection bias in choosing mode of RRT plays a major role in the higher 
circulating levels of BNP in patients on haemodialysis.
Using CMR, serum BNP levels correlated strongly with all LV measurements; positively 
with mass and volumes and negatively with systolic function and similar to previous 
echocardiographic studies, BNP correlated most strongly with LV mass. In the study of 
Mallamacci et al. (140), patients with known CHF were excluded and 13% of patients in 
their cohort were found to have LVSD whilst 79% had LVH. In our cohort there was a 
slightly lower prevalence of LVH (71%) and a similar prevalence of LVSD (15%) and 
we found a stronger correlation of BNP measurements with LVMI and LV volumes than 
was observed in the study of Mallamacci et a l Whilst correlation with LV wall thickness 
was strong in the study of Mallamacci et a l (r=0.5, p<0.001) the correlation with LV 
volumes was not, only just reaching statistical significance (r=0.12, p=0.05). In our study 
using CMR we found a stronger correlation of BNP with mass and volumes (Graph 7.1-
195
7.3 and a similar correlation of BNP with EF (Graph 1 A') than the echocardiographic 
study. Whilst it should be remembered the population of patients were different (patients 
on RRT without CHF vs. patients on RRT suitable for transplant), it is tempting to 
speculate that the better correlation of BNP with LV measurements is this study is due the 
improve accuracy of the imaging technique used.
Why LVH is consistently shown to have a stronger relationship with BNP than LVSD in 
patients with ESRF is unclear. It may be that, as we have demonstrated in Chapter 4, 
LVSD and LVDil develop due to underlying CAD which acts as a confounder in analysis 
and patients with IHD were not excluded from either our study or the study of Malamacci 
et a l Also, patients with LVSD may be more likely to be established on medications 
such as beta-blockers and ACEI which may affect BNP levels. Finally, if the 
development of LVH via concentric LVH is the dominant evolutionary pattern in this 
population and additionally is present in the majority of those with LVSD then LVH may 
simply play a more dominant role in triggering the production of BNP, due to the 
increased filling pressures required for adequate filling of a stiff hypertrophied heart, than 
other LV abnormalities.
In the general population it has been found that serum BNP has a sensitivity of 77% and 
specificity of 87% for detecting LV dysfunction (122). Its major benefit in screening for 
LVSD is a high NPV of 93-95% (122,271-272) meaning that a low level of BNP virtually 
rules out a diagnosis of LVSD. Similarly the NPV of BNP for detecting LVSD in patients 
presenting with breathlessness is around 98% (123,272). However, the PPV is not as 
high. This means that where a high level of BNP suggests a diagnosis of LVSD, other 
pathological conditions such as liver failure, renal failure, pulmonary conditions and
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hyperthyroidism also elevate BNP levels (271). A high level of BNP therefore warrants 
further investigation for underlying disease but does not necessarily mean the diagnosis 
will be that of LVSD.
In this study we found a good NPV of BNP for excluding LVSD at 90%. However, the 
NPV was not high when examining the usefulness of BNP to detect any LV abnormality 
(59%) or concentric LVH (60%), although the PPV of BNP to detect an abnormal 
ventricle or concentric LVH was 88% and 79% respectively. This would suggest that 
although lower levels of BNP can help identify patients who do not have the higher risk 
abnormalities of LVDil or LVSD, it is not so valuable in excluding patients with isolated 
LVH or separating those with normal ventricles from those with abnormal ventricles. 
This is not an entirely unexpected finding as the NPV of a test will decrease as the pre­
test probability of the condition being tested increases. The pre-test probability of patients 
with ESRF having an abnormal ventricle or concentric LVH is much higher than the pre­
test probability of having eccentric LVH or LVSD. What is suggested, is that the NPV for 
the patients at highest risk of death is over 90%. It should also be noted that despite the 
lower sensitivity, specificity and predictive values found, compared to those in the 
normal population, the sensitivity and specificity of BNP to detect LV abnormalities is 
much higher than the corresponding sensitivity (31%) and specificity (81%) of the ECG 
to detect LV abnormalities detailed in Chapter 4 and compared to previous 
echocardiographic studies show a an improved combined sensitivity and specificity for 
the detection of both LVH and LVSD.
In this study only LV mass index and EF were found to be an independent predictors of 
BNP level. There did not seem to be any influence on BNP levels of age or sex and it
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may be that the confounding effect of renal failure on circulating BNP levels means that 
the age and sex differences observed in the normal population are not applicable to 
patients with ESRF and this finding has been observed in other studies assessing the use 
of BNP in patients on RRT (139).
In this study we found that BNP correlated strongly and significantly with all LV 
parameters, measured using CMR, in patients with ESRF considered candidates for renal 
transplantation. Furthermore the correlation was stronger than that observed in previous 
echocardiographic studies. The NPV for excluding patients with all three LV 
abnormalities was high, suggesting a low BNP may help exclude those at greatest risk of 
death on the transplant waiting list. In this population the only independent determinants 
of BNP level were LVMI and EF.
Further studies are required in a larger group of patients, especially those with a 
combination of ESRF and LVSD, to confirm these findings and better establish the 
relationship of BNP to LVSD in similar populations. However, these findings suggest 
that measurement of serum BNP in patients with ESRF being assessed for renal 
transplant may be a useful addition to current practice to exclude those at highest risk and 
identify those in whom further investigation is required.
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Graph 7.1 Scatterplot dem onstrating correlation betw een log-transform ed B N P and
LV M I defined by CM R im aging (p<0.001, r=0.585)
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Graph 7.2 Scatterplot dem onstrating correlation betw een log-transform ed BN P and EDV
defined by C M R im aging (p<0.001, r=0.430)
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G raph 7.3 Scatterplot dem onstrating correlation betw een log-transform ed BN P and ESV
defined by C M R im aging (p<0.001, r=0.487)
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Graph 7.4 Scatterplot dem onstrating correlation betw een log-transform ed BNP and EF
defined by C M R im aging (p<0.001, r=-0.455)
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Table 7.1 Baseline characteristics and standard CV risk factors for cohort of patients 
in which BNP measurements available
Variable Normal LV 
n=35
Abnormal LV  
n=91
p  value
Age (years) 53.0+/-9.9 50.0+/-9.8 p=0.070
Sex (%men) 65.6 65.9 p=0.502
Duration of RRT (months) 26.2+/-22.1 33.2+/-31.6 p=0.121
HD VS. PD (% on HD) 34 69 p=0.001*
Systolic BP (mmHg) 126.0+/-18.5 139.4+/-22.6 p=0.023*
Diastolic BP (mmHg) 74.9+/-9.6 82.2+/-11.6 p=0.002*
PMH oflH D  (%) 23 15 p=0.249
PMH of Diabetes (%) 8.6 18.7 p=0.029*
PMH of CHF (%) 5.7 9.9 p=0.321
PMH other vascular (%) 0 8 T3 II O O
Haemoglobin (g/do) 11.8+/-1.5 11.4+/-1.8 p=0.186
Cholesterol (mmol/L) 6.2+/-1.7 5.5+/-1.7 p=0.818
BNP (picomoles/L) 26.0 166.5 p=0.001*
*significant result with p<0.05
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Table 7.2 LV abnormalities measured using CMR imaging in BNP cohort
Variable Normal LV 
n=35
Abnormal LV  
n=91
p  value
Ejection Fraction (%) 68+/-7.6 65+/-14.1 p=0.147
L V M I (g/m2) 74.3+/-12.3 116.1+/-32.9 PC0.0001*
ESVcorrected to BSA (ml/m2) 17.1+/-5.6 31.3+/-25.9 P0.0001*
EDVcorrected to BSA (ml/m2) 57.7+/-18.7 84.9+/-30.4 P0.0001*
*significant result with p<0.05
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G raph 7.5 Receiver-operator characteristic curve dem onstrating ability o f BNP to detect
an abnorm al LV. Area under the curve = 0.707
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Graph 7.6 R eceiver-operator characteristic curve dem onstrating ability o f BNP to detect
LVH. A rea under the curve = 0.739.
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Graph 7.7 R eceiver-operator characteristic curve dem onstrating ability o f  BN P to detect
LV SD . A rea under the curve = 0.845
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Table 7.3 The usefulness o f BNP to detect LV abnormalities in patients with ESRF felt
suitable for renal transplantation
Any LV  
abnormality
LVH LVDil L VSD+L VH+L VDil
sensitivity 65% 63% 68% 11%
specificity 79% 79% 79% 19%
PPV 88% 79% 80% 67%
NPV 59% 60% 68% 90%
Accuracy 71% 74% 76% 80%
Table 7.4 Univariate and multivariate predictors of BNP in patients with ESRF felt 
suitable for renal transplantation. (Adj R square = 0.297 for multivariate regression 
model)
Variable Univariate testing Regression Model
Ejection Fraction p=0.006 p=0.043, p=-0.171
EDV p=0.005 NS
ESV p=0.001 NS
LV mass index p<0.001 p<0.001, p=0.435
Systolic BP p=0.035 NS
Diabetes p=0.043 NS
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Chapter 8 
The Relationship between Left Ventricular 
Abnormalities and Coronary Artery Disease
8.1 Introduction
When considering investigation for a patient with symptoms of heart failure and impaired 
LV systolic or diastolic function, CMR imaging with LGCE is now an established Class 1 
indication for differentiating ICM from NICM. Furthermore, evidence is accumulating 
that this technique identifies patients who have been wrongly labelled as having NICM 
when the diagnosis is in fact ICM. In the study of McCrohon et al. (225), 13% of patients 
who had previously been diagnosed with NICM, on the basis of results from QCA, 
displayed patterns of regional wall thinning and LGCE typical of ICM. It is well 
recognised that recanalisation after an occlusive coronary event or embolization from a 
minimally stenotic but unstable plaque occurs, and post mortem studies have documented 
patterns of fibrosis indistinguishable from myocardial infarction in patients with a pre- 
mortem diagnosis of NICM. Obviously this misclassification has implications for both 
treatment and prognosis for the patient concerned and wider implications regarding the 
need for family screening.
The prevalence of CAD in patients with ESRF is high and angiographic studies of 
patients established on RRT have estimated that 50% have underlying CAD. However, 
patients are often asymptomatic or have non-specific symptoms such as breathlessness 
which could be attributed to CAD, underlying cardiomyopathy, anaemia or fluid 
overload. Furthermore, as the prevalence of CAD and LV abnormalities are high in
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patients with CRF and they both occur early in the course of progressive renal failure, 
defining the relationship between CAD and uraemic cardiomyopathy has been difficult. 
The high prevalence of LV abnormalities in patients with ESRF also affects interpretation 
of non-invasive stress testing, especially ETT and DSE, resulting in a lower sensitivity 
and specificity of these techniques in patients with ESRF compared to the normal 
population. Stress testing forms an important part of cardiac risk assessment when 
considering patients for renal transplant but the inconclusive results that are often 
obtained mean that a high proportion of patients undergo invasive diagnostic coronary 
angiography.
We hypothesised that a CMR study, using a combination of LGCE and standard CMR 
cine imaging would help us gain insight into the relationship of LV abnormalities to CAD 
and that such a CMR study may be a stronger predictor of significant underlying CAD 
than the currently used non-invasive techniques in this population. We therefore studied 
60 patients undergoing assessment for renal transplantation, with no prior history of AMI, 
using a combination of assessment of LV function, mass and volumes, wall motion 
scoring and LGCE in addition to the usual methods of assessment of CAD to test this 
hypothesis.
210
8.2 Methods
8.2.1 Subjects
Patients were recruited from the West of Scotland renal transplant waiting list or directly 
from the renal transplant assessment clinic at the Western Infirmary, Glasgow. All 
patients gave informed consent and the study had approval from the local ethics 
committee.
8.2.2 Procedure
All patients attended for screening on a post-dialysis day. All medications were taken as 
usual. Sixty patients underwent the protocol as described in Chapter 2, along with the 
extended CMR protocol including LGCE. Patients with a prior history of AMI were 
excluded from this part of the study.
8.2.3 Statistics
Statistical analysis was performed using SPSS Version 11.5 software (SPSS inc. Chicago 
IL, USA). Baseline data are expressed as mean +/- SD or median, if not normally 
distributed. Differences between the groups were assessed using a two-sample t test 
(normally distributed data) or Mann Whitney U test (nonparametric data). A p-value of 
less than 0.05 was considered significant. 95% confidence intervals for differences 
between groups in mean percentage change from baseline are given. Correlations 
between continuous values were assessed using Pearson’s correlation coefficient for 
parametric data.
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8.3 Results
8.3.1 Baseline Characteristics
Data was available for 60 patients who underwent the extended CMR protocol involving 
LGCE. Baseline characteristics for this cohort of patients are shown in Table 8.1. 
Average age of the cohort was 52 years of age, ranging from 27-70 years of age. Three- 
quarters of the cohort were men and on average, patients had spent 30 months on dialysis 
and 15% had undergone previous renal transplantation. With regard to standard CV risk 
factors, no patient had a prior history of CHF or AMI and 15.5% had a previous history 
of IHD. Almost one fifth of the cohort were diabetic (19%) and 34.5% had a history of 
hyperlipidaemia. Less than half the cohort had never smoked (44.5%) and 34.5% were 
current smokers. As observed in previous chapters, the majority of the cohort had a 
history of hypertension (91.4%) and 22.4% had a family history of premature IHD. 
Average BP for the cohort was high with an average systolic BP of 138+/-23.2mmHg and 
an average diastolic BP of 81+/-10.1mmHg. Average cholesterol was 5.8+/-1.4mmol/L 
and average haemoglobin concentration for the cohort was 11.5+/-1,5g/dL.
Differences in baseline characteristics between the whole of the initial cohort of 149 
patients and the 60 patients who underwent LGCE are displayed in Table 8.1. Compared 
to the total initial cohort, the only significant difference found with regard to baseline 
characteristics in those who underwent the extended CMR protocol with LGCE, was a 
history of CHF. Patients who were given LGCE, reflecting the fact that patients with 
previous AMI were excluded from this part of the study, had a much lower prevalence of 
previously documented CHF and in fact, excluding those patients with a previously 
documented AMI also resulted in the exclusion of those with previously documented
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LVSD in this cohort. There were no other significant differences with regard to renal 
history, other co-morbidity and standard CV risk factors between the groups.
8.3.2 Left ventricular abnormalities
The results of baseline CMR cine imaging are shown in Table 8.2 along with the normal 
reference ranges. Similar to the initial cohort, there was a high prevalence of LVH and 
73.3% of the cohort (44 patients) had an elevated LVMI. Despite the fact that no patient 
had a history of LVSD before screening, 7 patients (11.7%) were found to have LVSD as 
defined by CMR imaging. These patients had associated LVDil and LVH and overall, 10 
patients (16.7%) had a dilated LV and therefore 3 patients were defined as having 
eccentric LVH.
Average LVMI was much higher in both men and women compared to the normal ranges 
with similar ranges for volumes and function, compared to the sex matched normal 
reference range. Of note, the female group had relatively lower LV volumes than the 
normal reference range and a higher mean EF, a finding most likely associated with the 
high prevalence of LVH, whereas in the male group there was little difference from the 
normal range with regard to LV function or volumes.
8.3.3 Late gadolinium contrast enhancement
Initially the cohort was split into two groups on the basis of presence or absence of LGCE 
during the CMR scan. Of the 60 patients making up the cohort, 16 (26.6%) had evidence 
of LGCE. Differences between the groups with regard to baseline characteristics and 
baseline LV measurements are shown in Table 8.3 and Table 8.4 respectively. There was
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no significant difference in age between the two groups (55+/-8.8 years vs. 52+/-9.3 
years, p=0.214) and no significant differences with regard to past renal history, including 
length of renal failure (p=0.887), length of RRT (p=0.667), type of dialysis therapy 
(p=0.250) and history of a previous renal transplant (p=0.843). Patients who were found 
to have LGCE, indicating myocardial necrosis or fibrosis, were more likely to be male 
(94% vs. 67%, p=0.033), diabetic (40% vs. 11.6%, p=0.017) and have a history of IHD 
(33.0% vs. 9.3%, p=0.028). However, patients with LGCE did not have significantly 
higher systolic (p=0.298) or diastolic (p=0.650) BP compared to those without LGCE and 
similar proportions in both groups had a history of hypertension (93% vs. 91%, p=0.756) 
and were smokers (33% vs. 35%, p=0.667). Although a higher proportion of patients with 
LGCE had a history of hyperlipidaemia (47% vs. 30%, p=0.253), this did not reach 
statistical significance and was likely to reflect a higher level of awareness of 
hyperlipidaemia in this group due to a higher prevalence of IHD.
With regard to biomarkers, although both BNP (lgBNP 4.8 vs. 2.8, p=0.283) and CRP 
levels (27 vs. 7, p=0.089) were higher in the LGCE positive group, neither reached 
statistical significance. Patients with LGCE had a significantly lower total serum 
cholesterol than those without LGCE (5.1+/-1.0mmol/l vs. 6.1+/-1.5mmol/L, p=0.009), 
again reflecting a higher prevalence of IHD (33.0% vs. 9.3%) and statin prescription 
(40% vs. 29%) in the LGCE group, and there was no difference in mean haemoglobin 
values between the two groups (11.6+/-2.0g/dL vs. 11.5+/-1.3g/dL, p=0.732).
The differences between the patients found to have LGCE and those who did not, with 
regard to LV measurements, are displayed in Table 8.4 and Graphs 8.1 -8.4(a). Patients 
who displayed LGCE had significantly higher LVEDV (87.6+/-26.5ml/m2 vs. 72.2 +/-
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20.8ml/m2, p=0.043), LVESV (36.3+/-21.9ml/m2 vs. 20.3+/-7.1ml/m2, p=0.034) and LV 
mass (118.0+/-34.3g/m2 vs. 99.4+/-24.3g/m2, p=0.05) than those without LGCE and 
significantly lower EF (59+/-11.5% vs. 71+/-5.8%, p<0.001).
All 7 patients with LVSD were found to have LGCE on CMR scanning and these patients 
all had associated LVDil. Only 3 of the 10 patients with a dilated LV did not show LGCE 
on CMR scanning and these were the 3 patients who were found to have eccentric LVH. 
This was reflected in the finding that whereas a high proportion of patients in the LGCE 
group had LVSD (43%) and LVDil (43%), the only LV abnormality that was prevalent in 
the group without LGCE was that of LVH and similar proportions of patients in both the 
LGCE positive and negative groups had LVH (76% vs. 72%).
8.3.4 Patterns of late gadolinium contrast enhancement
Within the group of patients displaying LGCE, the distribution of LGCE showed 2 
different patterns. Whereas the majority showed a subendocardial pattern, confined to a 
particular coronary artery territory and typical of that caused by AMI secondary to CAD, 
a smaller proportion showed a more ‘patchy’ distribution not confined to a particular 
coronary artery territory and throughout the myocardium without confinement to the 
subendocardial layer. This pattern of LGCE was more typical of that reported to be 
associated with hypertrophic cardiomyopathy. Of the 16 patients found to have LGCE, 5 
patients (31%) displayed a patchy distribution of LGCE whereas the other 11 patients 
(69%) displayed the more discrete subendocardial pattern of LGCE.
Differences in LV measurements between those displaying the two different types of 
LGCE as well as those with no LGCE are displayed in Table 8.5 and Graphs 8.1-8.4fbY
215
Patients displaying the discrete pattern of LGCE, consistent with ICM, had the lowest 
mean EF (56+/-12.4%) compared to those with patchy LGCE (66+/-5.7%) or no LGCE 
(71+/-5.8%) and patients displaying the patchy pattern of LGCE, consistent with NICM 
had a relatively higher LV mass (126.2+/-34.6g/m2) than either those with discrete LGCE 
(114.6+/-35.3g/m2) or those with no LGCE (99.4+/-24.3g/m2). This finding was reflected 
in the fact that all 5 patients displaying patchy LGCE had LVH and all 7 patients with 
LVSD had focal LGCE. The only significant difference between those patients with 
discrete LGCE and those with patchy LGCE, was EF (p=0.05). Although LV mass was 
higher in those patients with patchy LGCE compared to those with discrete LGCE this 
did not reach statistical significance (p=0.547). This was most likely due to the small 
number of total patients displaying a patchy distribution of LGCE.
With regard to baseline characteristics and standard CV risk factors, no differences were 
found between those with a patchy distribution of LGCE and those without LGCE for 
any variable with regard to past renal history, standard CV risk factors including systolic 
and diastolic BP, age and sex or biomarkers such as BNP and CRP. Again, this was likely 
influenced by the small number of total patients displaying a patchy pattern of LGCE on 
CMR scanning. Patients with a discrete pattern of LGCE, were older (58+/-7.7 years vs. 
52+/-9.3 years, p=0.034), more likely to be male (100% vs. 67%, p=0.023), diabetic 
(45.5% vs. 11.6%, p=0.011) and more likely to have a past medical history of IHD 
(45.5% vs. 9.3%, p=0.004). Patients with discrete LGCE had lower total cholesterol 
levels compared to those with no LGCE (4.7+/-0.8mmol/L vs. 6.1+/-1.5mmol/L, 
p=0.001), again reflecting a higher prevalence of IHD and resultant statin prescription 
(45.5% vs. 29%).
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Finally, there were no significant differences between those with discrete LGCE and 
those with no LGCE with regard to either BNP (lgBNP 3.8 vs. 2.8, p=0.745) or CRP (34 
vs. 7, p=0.128) levels.
8.3.5 Late gadolinium contrast enhancement and natural history of left 
ventricular abnormalities
Of the initial 60 patients who underwent the extended CMR protocol, 54 patients returned 
for a follow up CMR scan at least 6 months after the initial scan. Of these 54 patients, 14 
displayed LGCE. Overall, there was no significant difference between baseline scan and 
that of follow up with regard LV mass, EF or volumes and there were no significant 
differences with regard to LV anatomy or function with follow-up in the group who did 
not display LGCE on CMR scanning. Turning to those patients who did have LGCE on 
CMR scanning, again, overall there was no significant progression or regression of LV 
mass, function or volumes with follow-up. Of the 14 patients who displayed LGCE on 
CMR scanning, 11 of these displayed a focal pattern of LGCE and changes in LV 
parameters with follow-up are displayed in Table 8.6. With follow-up, although the trend 
was towards a fall in EF, with corresponding increase in LV mass and volumes, none of 
these parameters reached statistical significance.
8.3.6 Coronary angiography and left ventricular abnormalities
Within the total cohort of 148 patients, 38 patients underwent coronary angiography. One 
patient developed a significant right femoral pseudoaneurysm requiring vascular surgery. 
There were no other major adverse events recorded as a result of angiography. Of the
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patients undergoing angiography, 15 (41%) were found to have either normal coronary 
arteries or mild disease only. This was despite the fact that referral for angiography was 
only made if patients had a positive stress test, LVSD or at specific request of the 
referring physician.
The differences found for LV parameters and BP between the group of patients who were 
found to have severe CAD at QCA, defined as a coronary artery stenosis of >70%, and 
those who were found to have mild CAD or normal coronary arteries are shown in Table 
8.7. EF was significantly lower in the group of patients with severe CAD (53+/-17% vs. 
67+/-ll% , p=0.013) and ESV was significantly higher (51+/-37ml/m2 vs. 28+/-25ml/m2, 
p=0.049). Although both EDV (99+/-37ml/m2 +/- 77+/-40ml/m2, p=0.116) and LVMI 
(123+/-34g/m2 vs. 112+/-47g/m2, p=0.447) were higher in patients with CAD, neither of 
these reached statistical significance. Interestingly, both systolic BP and diastolic BP 
were lower in patients with severe CAD although the differences observed failed to 
reflect statistical significance. Lower mean BP in patients with severe CAD may reflect 
either a lower EF, or a higher prescription of cardioprotective medication in the group 
found to have severe CAD, or a combination of both.
There were other differences observed between patients with severe CAD and those with 
milder disease or normal coronary arteries. Patients with severe CAD were older 54+/-9 
years vs. 48+/-8 years, p=0.041), more likely to be male (90% vs. 64%, p=0.032) and 
more likely have a history of EHD (62% vs. 21%, p=0.044). There was no difference 
between the groups with regard to length or type of RRT or with regard to haemoglobin 
level. Also, there was no significant difference found between the groups with regard to 
prevalence of diabetes (38% vs. 43%, p=0.459). This may be due to the selection bias of
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diabetic patients undergoing coronary angiography (70% of patients undergoing 
angiography had a history of diabetes)
8.3.7 Coronary angiography and late gadolinium contrast enhancement
Within this cohort of 60 patients who underwent CMR with LGCE, 15 patients had 
coronary angiography (25% of cohort). Within this group, 9 patients were found to have 
severe CAD and of these patients, 8 displayed a discrete pattern of LGCE consistent with 
ICM. One patient with significant CAD did not display any pattern of LGCE and one 
patient did display discrete LGCE and was found to have plaque disease at angiography. 
Two patients displaying a patchy pattern of LGCE underwent coronary angiography and 
were found to have non-obstructive plaque disease. The presence of LGCE significantly 
correlated with severe CAD (p=0.008, r=0.659).
The sensitivity of LGCE pattern on CMR scanning to detect severe CAD was 91% and 
the specificity 75%. The corresponding NPV and PPV were 75% and 91% respectively 
and overall accuracy of the technique was 87% (Table 8.8V
8.3.8 Exercise tolerance testing
Patients also underwent the usual methods of non-invasive assessment for underlying 
CAD prior to renal transplantation in the West of Scotland (Flowchart 2. IT Of the initial 
cohort of 148 patients who were already awaiting renal transplant or undergoing 
assessment for transplant, 119 (82.1%) attempted ETT and 26 patients felt unable to 
attempt even Stage 1 of a Full Bruce protocol. Of the patients who did undergo ETT, the 
average time exercised was 6 minutes and 50 seconds with a range of 1-14 minutes. The
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range of exercise times for men and women are displayed in Graph 8.5. Of the 119 
patients who underwent ETT, 33 patients did not manage to exercise for the minimum 
time period of 6 minutes (7 METS) and therefore had an inconclusive ETT. Thus in total, 
42.5% of the cohort either refused ETT or performed inadequately during exercise for the 
ETT to be of diagnostic use.
Of those patients who did undergo ETT, 24 also had a coronary angiogram and 16 of 
these 24 patients were identified to have severe CAD. No correlation was found between 
whether or not ETT was attempted or total exercise time attained. However, there was a 
significant correlation between the finding of severe CAD at angiography and the 
presence of ST changes during exercise (p=0.001, r=0.644). The sensitivity of ETT to 
detect severe underlying CAD was found to be 42% and the specificity 80%. The 
corresponding NPV and PPV were 30% and 88% respectively reflecting a relatively high 
number of false negative tests and the overall accuracy of the technique was 50% (Table 
8 .8 ).
8.3.9 Radionuclide stress perfusion imaging
Of the total initial cohort, 39 patients underwent radionuclide stress perfusion imaging, 
usually as a result of failure to perform adequately at ETT. Of these patients, 14 went on 
to have a coronary angiogram. Of the patients who underwent angiography, 7 were found 
to have severe CAD. Of the 14 stress perfusion studies carried out only 3 were reported 
as normal. No correlation was found between the finding of a reversible perfusion defect 
and significant CAD. However, there was a significant correlation between the finding of 
a fixed perfusion defect and CAD (p=0.08, r=0.600). The sensitivity of radionuclide
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imaging to detect significant CAD was 87% with a specificity of only 33%, reflecting a 
relatively high number of false positive stress perfusion tests. The NPV and PPV were 
67% and 64% respectively and the overall accuracy of the technique to detect severe 
CAD was 64% (Table 8.8Y
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8.4 Discussion
The technique of CMR imaging with LGCE is now an established sensitive and specific 
method for the non-invasive differentiation of ICM from NICM. Patel et al. (226) 
recently investigated 234 consecutive patients presenting with LVSD, with an EF of less 
than 30% and an unclear aetiology for the cardiomyopathy. Patients underwent both 
CMR with LGCE and coronary angiography, and the authors concluded that a diagnosis 
of ICM could be correctly established by LGCE with a sensitivity of 92% and a 
specificity of 93%, compared to the reference standard of QCA. Furthermore, in the study 
of McCrohon et al. (225), all patients with ICM, defined by QCA, displayed the typical 
pattern of LGCE associated with AMI. An important finding of our study is the fact that 
all patients in this cohort with LVSD and the majority with LVDil had an underlying 
ICM, with evidence of previous AMI. The fact that LVSD was not found without 
evidence of AMI in this study suggests that the aetiology of LVSD in this cohort is CAD 
rather than a dilated form of hypertrophic cardiomyopathy or eccentric cardiomyopathy 
secondary to volume overload. The findings from the previous longitudinal 
echocardiographic study of Parfrey et al. (29), in patients with ESRF and no history of 
IHD, provides supportive evidence of the proposal that LV systolic function is dependant 
on CAD in this population. They identified, in a cohort of 432 patients with ESRF, that 
LVSD was the strongest predictor of the development of de novo IHD during follow-up 
and underlying IHD was also identified as a risk factor for LVDil and LVSD in further 
work by Parfrey et al. (71). It could therefore be proposed that silent CAD and AMI 
preceded the development of LVSD and symptoms of IHD in the former study and that
222
LV remodelling post AMI was responsible for the association between IHD and LVDil in 
the latter study.
Using the technique of LGCE in this cohort of 60 patients with no previous history of 
AMI, we found that 11 (18.3%) patients had evidence of previous AMI, including 6 
(10%) patients who had no prior history of IHD. It is important to identify these patients 
in an attempt to improve the poor prognosis of patients with ESRF after AMI by targeting 
risk factors such as hyperlipidaemia, hypertension and smoking habits as well as 
establishing secondary preventative therapy such as aspirin, beta-blockers and ACEI’s 
which have been shown to improve outcome in this population post AMI (166,170). 
These patients were asymptomatic at the time of screening, and in the case of those with 
preserved LV systolic function, unless they developed symptoms of limiting angina there 
is no evidence that proceeding to coronary angiography and revascularisation will 
improve outcome (177). It is also unclear whether revascularisation of IHD in the 
presence of an associated ICM improves outcome in this population, although in the 
normal population if a patient has significant CAD and hibernating myocardium is 
documented, revascularisation by way of PCI or CABG will be undertaken, although 
trials such as the STICH trial (273) are ongoing to investigate whether revascularisation 
is beneficial versus medical therapy in such patients.
Patients displaying the pattern of LGCE typical of CAD and previous AMI were more 
likely to be older, male, diabetic and have a previous history of IHD. These are typically 
the risk factors previously identified in this population for CAD by several authors 
(29,274). Although these patients were more likely to be on secondary prevention than 
those without focal LGCE, 45% were not prescribed aspirin, 54% were not prescribed a
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statin, 33% were not prescribed a beta-blocker and 42% were not prescribed an ACEI or 
ARB at the time of screening. Overall systolic BP of patients with focal LGCE was 
142+/-28.3mmHg and mean diastolic BP was 80+/-8mmHg. The use of LGCE has 
therefore identified patients with previously unrecognised AMI and therefore those with a 
poorer prognosis on the transplant waiting list and those in whom potential reversible risk 
factors should be more aggressively treated.
A smaller number of patients displayed a different pattern of LGCE, that of ‘patchy’ 
enhancement which was not confined to the subendocardium or to any particular 
epicardial coronary artery territory. This pattern of LGCE was only found in patients with 
LVH and showed similarities to the pattern described in previous studies using LGCE in 
patients with HCM (230,233,235). In the case of HCM, LGCE has been shown to be 
representative of areas of focally increased collagen replacement of myocardial cells, 
rather than myocardial disarray and is proportional to the total LV mass (235). It has also 
been shown that the presence of LGCE may independently predict prognosis in patients 
with HCM, and the presence of LGCE in patients with HCM is associated with the 
clinical markers of sudden death and progression to heart failure (233).
Pathological studies in patients on haemodialysis by means of endomyocardial biopsy 
have shown severe interstitial fibrosis, myocyte hypertrophy and disarray. In a study by 
Aoki et al. (258), 40 patients with LVDil and LVSD but normal coronary arteries 
underwent endomyocardial biopsy. The results showed histological changes typical of the 
dilated phase of HCM. They found the extent of myocardial fibrosis in biopsy specimens 
to be predictive of cardiac death. In studies of patients with HCM and normal renal 
function, LGCE is more likely to be observed in patients in the dilated phase of
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cardiomyopathy compared to the undilated, earlier phase (233,275). Thus, although it is 
likely that ICM is responsible for the majority of LVSD associated with uraemic 
cardiomyopathy, the dilated phase of concentric hypertrophic cardiomyopathy associated 
with uraemia is responsible for a smaller proportion. In the study of Aoki et al. (258) the 
40 patients studied with dilated cardiomyopathy and normal coronaries made up 13% of 
the total cohort of 286 studied and CAD was found in 65%. We did not observe any 
patients with LVSD and either patchy LGCE or no LGCE. This may be partly explained 
by the fact that our cohort only included those patients felt to be suitable for renal 
transplantation whereas the study of Aoki et a l included patients from the general 
haemodialysis pool.
The number of patients in our study was small and only 7 patients were found to have 
LVSD at baseline scanning. However, we have since published results on a larger series 
of 134 patients with ESRF using LGCE and found similar results in a total of 11 patients 
with ESRF and LVSD undergoing assessment for renal transplantation (276). All 11 
patients had evidence of previous AMI. Again, the number of patients in this study with a 
patchy distribution of LGCE is small but in the larger subsequent cohort this pattern of 
LGCE was observed in a total of 19 patients with a similar association of elevated LV 
mass but preserved LV function.
The results of this study therefore support the findings of Chapter 4. Rather than 
concentric and eccentric cardiomyopathy comprising the two predominant forms of 
cardiomyopathy in patients with ESRF with both culminating in LVSD, concentric 
hypertrophic cardiomyopathy and ICM are the two predominant forms with a much 
smaller contribution from primary eccentric/dilated cardiomyopathy. The presence of LV
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dilation or LVSD should precipitate investigation for CAD but of course the goal should 
be early identification of those with underlying CAD before ischaemia and AMI result in 
LVSD and subsequent adverse remodelling.
It is well recognised that post AMI, the ventricle undergoes remodelling with associated 
increase in LV volume and mass (277). In this cohort there was a trend towards an 
increase in both LV volumes and mass with follow-up in patients with evidence of 
previous AMI, suggesting ongoing LV remodelling. The patients displaying a pattern of 
discrete LGCE also had significantly higher LV mass than those without LGCE at 
baseline scanning and it is likely that this is due to a combination of initial concentric 
hypertrophy associated with hypertension in progressive renal failure, and remodelling 
post AMI. Patients with LGCE were also more likely to be male and diabetic and both 
these factors are associated with higher LV mass compared to women and non-diabetics 
(64) and this should also be taken into consideration.
As in previous studies involving patients with ESRF (33,172-174), the usefulness of ETT 
and radionuclide imaging to identify patients with severe CAD was disappointing. A high 
number of false negative ETT studies meant that the overall accuracy of ETT to detect 
severe CAD was only 50% and a high number of false positive radionuclide studies 
severely affected the specificity of this test and led to an overall accuracy of just 64%. It 
may be that a combination of both tests in all patients may lead to an improved overall 
accuracy but due to the protocol followed in this study we were unable to test this 
hypothesis.
The identification of LGCE, a test not involving stress, in this study was a more accurate 
method of identifying patients with severe CAD. The overall accuracy of this test was
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87% and the NPV was also better than that of either ETT or radionuclide imaging. 
However, the NPV was still relatively low at 75% suggesting that the addition of a stress 
imaging modality complimenting this technique would be preferable to a resting 
technique alone and may improve the NPV. However, the numbers of patients 
undergoing QCA in each group were small and very few patients underwent all three 
techniques in addition to QCA and these results should be interpreted with caution.
To better define the true relationship between LV abnormalities and CAD and to support 
these initial findings, patients with renal failure, normal ventricles and no symptoms of 
IHD would require repeated follow-up with CMR and LGCE to observe the developing 
pattern of abnormalities and this technique was felt to be capable of answering many of 
the remaining questions in this population without resorting to coronary angiography 
and/or myocardial biopsy. However, in light of recent evidence of an association between 
the administration of gadolinium based contrast agents and a condition known as 
nephrogenic fibrosing dermopathy (NFD) in patients with moderate to severe renal 
failure, as of June 2006 gadolinium based contrast agents have been used with caution in 
this population.
NED was first described in 1997 (278), but it was not until 2006 that the association with 
gadolinium was made (279-280). NFD consists of a thickening of the skin, initially 
affecting the hands, feet and limbs but can progress to involve the trunks and buttocks. 
The thickened skin becomes indurated and can result in significant debilitation with 
contractures of the joints. The lesions themselves resemble those of scleroderma but there 
is no associated monoclonal gammopathy. Biopsy of the lesions shows dermal fibroplasia 
and electron microscopy of the samples has demonstrated gadolinium, detected in areas
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of calcium phosphate deposition in blood vessels (281). Systemic involvement of the 
lungs, striated muscles and diaphragm has also been reported leading to an alternative 
name of nephrogenic systemic fibrosis (NSF) (282).
Patients developing the condition had been administered a gadolinium based contrast 
agent up to 18 months prior to the development of symptoms (283), almost invariably 
have ESRF (279-281) and are more likely to be on PD. NFD has very rarely been 
observed in patients who are not dialysis dependant. World wide around 220 cases have 
now been reported (283) and there is a registry on the U.S Food and Drug administration 
(FDA) MedWatch system for the reporting of new or suspected cases. The majority of 
patients who have developed NSF have done so after high doses of gadolinium contrast 
agent were administered for magnetic resonance angiography (MRA). Whether or not 
this condition is related to the dose of gadolinium based agent administered or whether it 
is an iatrogenic effect, remains to be established and it is unknown why some patients 
with ESRF have developed this condition while the majority have not, although 
concomitant acidosis and/or hypercalcaemia at the time of administration have been 
postulated (281) and a relationship to concomitant high dose erythropoietin has been 
suggested (284). It has also been found that a high proportion of patients who develop 
NSF, do so around 2 weeks after vascular surgery or an episode of deep venous 
thrombosis. In view of this observed association between NSF and gadolinium based 
contrast agent administration, the FDA published a health advisory in June 2006, updated 
in May 2007, regarding the use of these agents in patients with a GFR of <30ml/min 
(283) and as of May 2007 it is advised that patients with a GFR of <30ml/min do not 
receive gadolinium based contrast agents unless the information gained is deemed
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potentially life saving. Similar guidelines have now been implemented by the UK based 
Medicine and Healthcare products Regulatory Agency (MHRA) but whereas all 
gadolinium based contrast agents are included in the warning from the FDA, only 
Omniscan and Magnevist are included in the statement from the MHRA and it is unclear 
whether other chelates with a cyclical structure, in which the gadolinium is more tightly 
bound, are associated with the same potential risks (285). It is therefore unlikely that 
further studies using gadolinium based contrast agents in patients with renal failure will 
be possible, although the ongoing development of intravascular CMR contrast agents, and 
improvement of other CMR sequences such as T2 weighted infarct imaging, the 
establishment of dobutamine stress CMR (DSCMR) imaging or BOLD perfusion 
imaging may provide alternative methods of tissue characterisation and stress imaging 
using CMR in this population. It should be mentioned that after 4 years of follow-up no 
patient in this cohort has developed signs or symptoms of NSF.
The results of this study suggest that CAD plays a more important role in the aetiology of 
uraemic cardiomyopathy than previously realised, especially the findings of LVDil and 
LVSD. It is clear that more accurate, non-invasive methods of detection of underlying 
CAD in patients with ESRF are required to identify those patients who may benefit from 
intensive risk factor modification and secondary prevention before the development of 
LVDil and LVSD. Rather than using a single method of stress imaging in this population, 
it may be that a combination of stress imaging tests such as radionuclide imaging in 
addition to DSE or DSCMR would provide complimentary information, improving 
overall accuracy and further research is required in this area. The recent improvements in
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multi detector computed tomographic coronary angiography may also provide a future 
useful non-invasive means of anatomical assessment of CAD in this population.
Although this initial study has provided useful and unique information on the relationship 
between CAD and LV abnormalities, further studies using gadolinium based contrast 
agents are not currently possible. However, DSCMR has now been established clinically 
as a more sensitive and specific test than DSE for the diagnosis of CAD (286) and this 
technique provides accurate information regarding prognosis in both patients with 
suspected underlying CAD (287) and asymptomatic patients undergoing non-cardiac 
surgery (288). DSCMR does not require the administration of gadolinium based contrast 
agents and may provide a future useful means of non-invasive testing for CAD in this 
population.
Older patients with ESRF and resting LVDil or LVSD should undergo further, preferably 
non-invasive, investigation for underlying CAD. There is also an urgent need for 
prospective studies to establish whether revascularisation is beneficial in this population 
versus medical treatment in the current era. Patients with renal failure were not excluded 
from the recently published COURAGE trial (177) and sub group analysis involving 
patients with renal failure may provide much needed new evidence regarding PCI in the 
management of CAD in this population.
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Table 8.1 Difference in baseline demographics between patients in LGCE cohort and
total cohort
BASELINE VARIABLE LGCE cohort 
n=60
Total cohort 
n=148
Age (years) 52+/-9.2 50 +/-10
Sex (%male) 75 68.2
Patients on haemodialysis (%) 64 60
Time on dialysis (months) 30+/-29 31.6 (0-144)
Length of renal failure (yrs) 12+/-10 8.2 (0.2-39)
Previous renal transplant (%) 15 18.6
History of IHD (%) 15.5 19.3
Family history of IHD (%) 22.4 26.4
History of chronic heart failure (%) 0* 7.6
Diabetic (%) 19 18.8
History of hypertension (%) 91.4 94.5
History of hyperlipidaemia (%) 34.5 36
Current smoker (%) 34.5 29.2
Systolic BP (mmHg) 138+/-23.2 136+/-24
Diastolic BP (mmHg) 81+/-10.1 80+/-12
Cholesterol level (mmol/L) 5.8+/-1.4 5.6+/-1.7
Haemoglobin (g/dL) 11.5+/-1.5 11.6+/-1.6
• *denotes significance p<0.005
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Table 8.2 Baseline LV parameters for patients with ESRF undergoing CMR and LGCE
with corresponding normal reference ranges.
MEN LGCE cohort Normal range
PARAMETER
LVEDV 79(+/-25)ml/m2 82+/-15(53-112)ml/m2
LVESV 2 6(+/- 15)ml/m2 29+/-7(15-43)ml/m2
LVSV 50(+/-16)ml/m2 52+/-10(32-72)ml/m2
LVEF 66(+/-10)% 64+/-5(54-74)%
LVMI 110(+/-29)g/m2 65+/-9(47-83)g/m2
WOMEN
LVEDV 69(+/-16)ml/m2 77+/-10(57-97)ml/m2
LVESV 19(+/-7)ml/m2 24+/ -5(14-34)ml/m2
LVSV 50(+/-l l)ml/m2 42+/-6(30-54)ml/m2
LVEF 72(+/-5)% 64+/-5(54-74)%
LVMI 89(+/-23)g/m2 52+/-8(36-68)g/m2
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Table 8.3 Differences in baseline characteristics between patients with and without 
evidence of LGCE (*denotes significance at p<0.05)
BASELINE VARIABLE LGCE positive 
n=16
LGCE negative 
n=44
p-value
Age (years) 55+/-8.8 52+/-9.3 p=0.214
Sex (%male) 94 67 p=0.033*
Patients on haemodialysis (%) 50 68 p=0.250
Time on dialysis (months) 33.5+/-33.8 29.2+/-28.5 p=0.667
Length of renal failure (yrs) 12.5+/-9.5 12.0+/-10.9 p=0.887
Previous renal transplant (%) 13.4 16.3 p=0.843
Hi story of IHD (%) 33 9.3 p=0.028*
Diabetic (%) 40 11.6 p=0.017*
History of hypertension (%) 93 91 p=0.756
Hyperlipidaemia (%) 47 30 p=0.253
Current smoker (%) 33 35 p=0.667
Systolic BP (mmHg) 144+/-27.0 136.5+/-21.8 p=0.298
Diastolic BP (mmHg) 82+/-8.0 80+/-10.8 p=0.650
Cholesterol level (mmol/L) 5.1+/-1.0 6.1+/-1.5 p=0.009*
Haemoglobin (g/dL) 11.6+/-2.0 11.5+/-1.3 p=0.732
CRP 27+/-31 7+/-6 p=0.089
lg BNP 4.8 2.8 p=0.283
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Table 8.4 Differences in baseline LV parameters between patients with and without
evidence o f LGCE
LV measurement LGCE positive 
n=16
LGCE negative 
n=44
p-value
LVEF (%) 59+/-11.5 71+/-5.8 p<0.001**
LVEDV (ml/m2) 87.6+/-26.5 72.2+/-20.8 p=0.043*
LVESV (ml/m2) 36.6+/-21.9 20.3+/-7.1 p=0.034*
LVMI (g/m2) 118.0+/-34.3 99.4+/-24.3 p=0.05*
LVSV (ml/m2) 50.4+/-13.7 50.1+/-16.2 p=0.942
LVH (%) 76 72 p=0.732
LVDil (%) 43 4.7 p=0.001**
LVSD (%) 43 0 p<0.001**
• *denotes significance at p<0.05
• **denotes significance at p<0.005
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Table 8.5 Differences in LV parameters between patients displaying patchy LGCE,
discrete LGCE and those with no evidence o f LGCE.
LV  m easu rem en t LGCE negative 
n=44
Discrete LGCE 
n = ll
Patchy LGCE 
n=5
LVEF (%) 71+/-5.8 56+/-12.4* 66+1-5.1#
LVEDV (ml/m2) 72.2+/-20.8 87.2+/-27.0* 88.3+/-28.3
LVESV (ml/m2) 20.3+/-7.1 42.3+/-27.6* 29.8+/-11.7*
LVMI (g/m2) 99.4+/-24.3 114.6+/-35.3 126.2+/-34.6*
LVSV (ml/m2) 50.1+/-16.2 46.7+/-9.5 58.5+/-18.9
LVH (%) 72 67 100
LVDil (%) 4.7 42* 40
LVSD (%) 0 42* 0
• * denotes significant difference compared to LGCE negative group (p<0.05)
• # denotes significant difference compared to discrete LGCE group (p<0.05)
Table 8.6 LV parameters at baseline and follow up in patients displaying discrete LGCE 
(n= ll)
Discrete LGCE 
(baseline)
Discrete LGCE 
(follow-up)
PARAMETER
LVEDV 79.3+/-21.5ml/m2 81.4+/-15.5ml/m2 p=0.719
LVESV 32.9+/- 17.0ml/m2 35.3+/-12.4ml/m2 p=0.577
LVEF 59+/-10.5% 57+/-14.0% p=0.620
LVMI 104+/-25.0g/m2 110+/-18.6g/m2 p=0.248
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Graph 8.1 D ifference in LV M I betw een patients displaying (a) no LG C E and LGCE; 
(b) no LG CE, discrete (focal) LG CE and patchy LG CE
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Table 8.7 Differences between LV parameters and BP for patients with and without
severe CAD at QCA (* denotes significance, p<0.05)
Variable Severe CAD
(stenosis>70%)
n=23
Non-severe CAD 
(no stenosis>70%) 
n=15
p-value
LVEF (%) 53+/-17 67+/-11 p=0.013*
L VMI (g/m2) 123+/-34 112+/-47 p=0.447
ED V (ml/m2) 
Corrected to BSA
99+1-31 77+/-40 p=0.116
ESV (ml/m2) 
Corrected to BSA
51+/-37 28+/-25 p=0.049*
Systolic BP 
(mmHg)
133+/-26 147+/-26 p=0.143
Diastolic BP 
(mmHg)
76+/-11 83+/-13 p=0.092
Table 8.8 Usefulness of ETT, nuclear stress perfusion (SPECT) and LGCE with CMR to 
detect severe CAD
ETT Nuclear
perfusion
LGCE
Sensitivity 42% 87% 91%
Specificity 80% 33% 75%
PPV 88% 64% 91%
NPV 27% 67% 75%
Accuracy 50% 64% 87%
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Graph 8.5 H istogram  displaying range o f exercise tim es for 119 men and w om en
with ESRF felt suitable for renal transplantation
Men: Num ber = 80, M ean =7.28 minutes, SD = 2.54 minutes
• Women: Num ber = 39, M ean = 5.77 minutes, SD = 2.59 minutes
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Chapter 9
Left Ventricular Abnormalities, Coronary Artery 
Disease and Outcome in patients awaiting Renal
Transplant
9.1 Introduction
The annual mortality rate of patient’s waitlisted for renal transplant is 2.6 times lower 
than patients with ESRF not felt suitable for transplant and 1.7 times higher than patients 
with a functioning renal allograft (1). In an observational study of 604 wait-listed patients 
in Canada, Gill et a l found the annual CV event rate was 12.7% per year for diabetics 
and 4.5% per year for non-diabetics whereas the corresponding mortality rate was 3.4% 
and 1.2% per year respectively (13). Thus, CV morbidity and mortality for waitlisted 
patients is still 10 times that of the general population and CVD is responsible for 50% of 
deaths in the first 5 years after renal transplant.
Several factors affect prognosis, both whilst waiting for renal transplant and post­
transplantation. Increased age and a history of diabetes identifies patients at higher risk of 
CV morbidity and mortality and these factors, along with a history of previous IHD or 
other vascular disease, help identify those patients who should have careful assessment 
for underlying CVD. In an effort to minimise the impact of CVD on survival after renal 
transplantation, guidelines exist for CV screening of transplant candidates to identify 
those patients at higher CV risk (34,243-244). Thus, theoretically, treatment can be 
instigated to minimise risk prior to transplant or the patient is excluded from the waiting 
list if estimated prognosis is very poor (e.g. severe, irreversible LVSD). However, whilst
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following the screening guidelines, which focus mainly on the identification of CAD, can 
identify patients with obstructive CAD, there are no clear guidelines regarding the need 
for assessment of resting LV abnormalities and there is no clear consensus regarding how 
often CV screening should be carried out whilst patients remain on the waiting list. This 
is despite evidence from longitudinal observational studies that LV abnormalities are 
strong predictors of outcome both in patients on RRT and in patients who have 
undergone renal transplantation and that LV abnormalities progress with time.
McGregor et a l (86) studied 67 patients prior to renal transplant between 1988 and 1990 
and found that LV mass and LV systolic function predicted post transplant outcome. In 
the more recent study by Sharma et a l (87), 203 patients underwent echocardiography 
prior to transplant between 1996 and 2001. Echocardiographic findings of LV posterior 
wall thickness (p=0.014, (3=1.06), LV ESD (p=0.002, (3=3.03), and the presence of mitral 
valve annular calcification (p=0.036, (3=2.71) all predicted poorer outcome and a greater 
risk of CV events after transplant.
In view of the association of LV abnormalities and CAD with outcome in this population 
a combined, preferably non-invasive, screening test that accurately assesses both LV 
structure and function and the degree of underlying ischaemia is required and ideally such 
a non-invasive test should also give information regarding prognosis. Recently the work 
of Sharma et a l (33) reported an improved sensitivity and specificity of DSE to detect
I
underlying significant CAD and resting LV abnormalities in a group of 125 renal
| transplant candidates. The results of DSE were compared to QCA and DSE was found to
l
have a sensitivity of 88% and a specificity of 94% for the detection of a coronary artery 
stenosis of >70%. However, as previously discussed in Chapter 8, other studies assessing
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the use of DSE in this population have not shown such a high accuracy based on the 
previously discussed arguments regarding both the visualisation of the LV and the 
calculation LV mass and function using echocardiography. We therefore aimed to 
determine whether CMR measurements of LV anatomy and function in this population 
were predictive of outcome and whether other positive findings such as the presence of 
LGCE or a high BNP level added additional prognostic information.
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9.2 Methods
9.2.1 Subjects and Procedure
The 148 patients who were screened for the initial study were followed up yearly and 
details of outcome (all cause mortality) recorded via the West of Scotland renal database 
for a total of 4 years from the date of the initial CMR scan. Details regarding date of 
death were recorded and if the patients underwent renal transplantation, date of 
transplant. Follow-up ended in April 2007.
9.2.2 Statistics
Statistical analysis was performed using SPSS Version 14 software (SPSS inc. Chicago 
IL, USA). Baseline data are expressed as mean +/- SD or median, if not normally 
distributed. Differences between the groups were assessed using a two-sample t test 
(normally distributed data) or Mann Whitney U test (nonparametric data). The 95% 
confidence intervals for differences between groups in mean percentage change from 
baseline are given. Univariate predictors of outcome were identified using the Pearson 
chi-squared test with continuity correction. A p-value of less than 0.05 was considered 
significant. Independent predictors of outcome were identified using a Cox proportional 
hazards model using a multivariate stepwise paradigm. In addition a 3 step modelling 
procedure was performed with variables included in the model in the same order as in 
clinical practice. Firstly, only baseline demographic data was entered, followed by cine 
CMR results and finally results of LGCE imaging were added. The Kaplan Meier method 
was used to construct survival curves for compared groups of patients and the curves 
displayed with corresponding log rank statistics.
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9.3 Results
9.3.1 Baseline follow-up
Patients were followed up for a mean of 50 months +/-18.8 months and 2 patients were 
lost to follow up (both patients moved to another city and transplant centre). During the 
follow up period a total of 39 patients died (26.4% of total cohort) before renal 
transplantation. A further 39 patients underwent transplantation, making up 35.1% of 
surviving patients and of the patients who received renal transplant, 5.1% have since died 
(2 patients). The remaining 68 patients were alive and on RRT at the end of follow-up. 
Mortality rate for the whole cohort was 5.3% per year and when this was split into 
diabetic and non-diabetic groups the annual mortality rate for diabetic patients was 10.4% 
per year and for non-diabetics was 4.2% per year.
9.3.2 Baseline characteristics of transplanted patients
The baseline demographics of patients who had received a renal transplant during follow- 
up were initially compared to those of surviving patients on RRT to examine any 
potential differences and are shown in Table 9.1. The only significant difference found 
between patients remaining on RRT at the end of the follow-up period and those with a 
functioning renal allograft was the number of previous transplants the patients had 
previously received. Of those patients who remained waitlisted on RRT, 29% had a 
history of previous failed renal transplantation whereas only 7.7% of patients with a 
transplant at the end of follow up had previously been transplanted (p=0.007).
Baseline demographics of the transplanted patients were then compared to those of 
patients who died during follow-up (Table 9.IT Transplanted patients were significantly
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younger (46+/-11.7 years vs. 55+/-8.9 years, p=0.021) than those who had died and had a 
lower prevalence of IHD (12.8% vs. 37.8%, p=0.043) and diabetes (17.9% vs. 35.1%, 
p=0.046). Patients who died also had a significantly lower haemoglobin level compared 
to patients who were eventually transplanted (10.9+/-1.5g/dL vs. 11.8+/-1.6g/dL, 
p=0.039).
9.3.3 Baseline characteristics ofpatients who died during follow-up
The baseline demographics of the 39 patients who died during follow-up are displayed in 
Table 9.1. Initial comparisons were made with both patients who remained on RRT 
during follow-up and those who received a renal transplant. Compared to those who 
remained on RRT, patients who died had a shorter period of diagnosed renal failure 
7.4+/-8 years vs. 9.5+/-8 years, p=0.035) and had been on RRT for a shorter period of 
time (24.9+/-26 months vs. 36.8+/-32 months, p=0.035). They were also less likely to 
have had a previous renal transplant (10.8% vs. 29.0%, p=0.042) and had a higher 
prevalence of IHD (37.8% vs. 13.0%, p=0.23) diabetes (35.1% vs. 10.1%, p=0.31) and 
other vascular disease (13.5% vs. 2.9%, p=0.48).
9.3.4 LV abnormalities and survival
LV measurements of mass, function and volumes for the group of patients who died 
during follow-up along with the corresponding results for those who remained on RRT 
and those who received a renal transplant are displayed in Table 9.2. A significantly 
higher proportion of patients who died were found to have LVSD (29.7%) compared to 
either those remaining on RRT (11.1%, p=0.035) or those who underwent transplantation
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(10.3%, p=0.030). Patients who died also had a significantly higher ESV than the other 
two groups. Although patients who died had a higher mean LVMI and EDV than the 
other groups and a higher overall prevalence of LVH and LVDil these differences did not 
reach statistical significance.
The survival curves for patients with and without LV abnormalities are displayed in 
Graphs 9.1-9.4. Again, the log-rank statistics indicated that patients with high ESV 
(p=0.005) and LVSD (p=0.002) had a significantly higher mortality rate than those who 
survived and remained on RRT. Patients who died had a higher prevalence of a dilated 
EDV but this just failed to reach statistical significance (p=0.052). There was no 
significant increase in mortality conferred by concentric LVH in this cohort (p=0.645) 
and no significant increase in mortality in those that fulfilled the criteria for concentric 
remodelling (p=0.189). Furthermore, there was no overall significant difference in 
survival between patients who had a normal LV and all those with an abnormal LV at 
baseline (p=0.543).
The survival curves for different types of uraemic cardiomyopathy are shown in Graph 
9.5. Patients with LVSD had worst overall survival followed by patients categorised as 
having eccentric LVH. Patients with normal ventricles had the best outcome.
9.3.5 Univariate predictors of outcome for total cohort
Patients who were alive at the end of follow-up and still on RRT were compared to those 
who had died during follow-up to identify univariate predictors of mortality in this 
population. Patients who underwent transplant during follow-up were censored from this 
analysis at the point of transplant. Univariate predictors of outcome are displayed in
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Table 9.3. From baseline demographics, age (p=0.001), a shorter length of time on RRT 
(p=0.046) and a previous transplant (p=0.023) were significant univariate predictors of 
death. A history of diabetes (p=0.001), IHD (p=0.002) and all other forms of vascular 
disease were univariate predictors, as was a history of hyperlipidaemia (p=0.004).
With regard to non-invasive investigations, a finding of LVSD (p=0.010) or a high ESV 
(p=0.008) on CMR scanning were univariate predictors of death, as was a finding of ST 
changes on either the ECG (p=0.022) or ETT (p=0.018) and length of exercise time on 
ETT (p=0.006) was also significant. Finally, with regard to haematological and 
biochemical results, a low haemoglobin (p=0.017), high BNP (p<0.001) and a high blood 
glucose level (p=0.004) were all significant univariate predictors of death.
9.3.6 Multivariate predictors of outcome for total cohort
Variables which showed significance on univariate testing were combined in Cox 
proportional hazards model using a multivariate stepwise paradigm and the independent 
predictors of outcome are shown in Table 9.3 along with corresponding hazard ratios and 
95% confidence intervals for the hazard ratios. After the baseline factors of age and a 
history of IHD or diabetes were corrected for, the majority of the other univariate 
predictors were not found to be significantly different between patients who died during 
follow-up and those who remained on RRT. Abnormal findings using CMR, ECG and 
ETT all lost significance, as did differences in drug therapy, haemoglobin value and 
glucose level. Apart from older age (p<0.001), a history of EHD (p=0.008) or diabetes 
(p=0.001), the only other independent predictor of death was serum BNP (p=0.015).
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9.3.7 Influence ofprogression of LV abnormalities on outcome
Over half the initial cohort (57%, 84 patients) had a follow-up CMR scan at least 6 
months after initial screening. The influence of progression and regression of LV 
abnormalities was examined to ascertain whether progression of LV abnormalities had 
any additional impact on outcome. Patients who showed more then 10% progression of 
LV mass, ESV, EDV or more than a 10% decrease in EF between scans were analysed 
compared to those who showed no change or regression of LV parameters during the 
study. There were no significant differences found for any LV parameter and on 
univariate testing, progression of uraemic cardiomyopathy or development of concentric 
LVH over a mean period of 8 months did not impact on outcome for the cohort.
9.3.8 Influence of coronary artery disease on outcome
The outcome of patients with severe CAD compared to those with mild or no CAD was 
significantly lower on Kaplan Meier analysis (p=0.032) (Graph 9.6T Although the group 
of patients who underwent coronary angiography was relatively small (38 patients), those 
who were found to have a significant stenosis of one or more epicardial coronary arteries 
they were significantly more likely to die during follow-up than those who did not have a 
significant coronary stenosis (p=0.032). When the results of coronary angiography were 
added in as a step in the multivariate model, QCA was not found to add independent 
weight to the model with regard to predicting outcome.
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9.3.9 Influence of late gadolinium contrast enhancement on outcome
A smaller proportion of patients in the cohort (40%, 60 patients) underwent CMR 
scanning before and after the administration of a gadolinium based contrast agent. 
Patients who displayed LGCE were compared to those who received gadolinium and did 
not display LGCE. Both the presence of any pattern of LGCE (p=0.019) and the specific 
subendocardial pattern suggestive of IHD (p=0.005) were significant univariate 
predictors of outcome. The diffuse pattern of LGCE by itself was not a significant 
univariate predictor of outcome (p=0.058).
Survival curves for patients with and without LGCE and type of LGCE are displayed in 
Graph 9.1. The corresponding log rank statistics were significant for the discrete pattern 
of LGCE consistent with ICM (p=0.005) but not for the pattern of diffuse LGCE 
consistent with hypertrophic cardiomyopathy (p=0.245).
However, when the presence of LGCE was included in the model along with age, a 
history of IHD and a history of diabetes neither the presence of any LGCE or the 
subendocardial pattern of LGCE were found to be independent predictors of outcome for 
the cohort.
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9.4 Discussion
Previous echocardiographic studies examining LV abnormalities in patients prior to renal 
transplantation have found that particular LV abnormalities identified pre-transplant, 
predict both CV and all cause mortality post-transplant. Whilst is has also been 
established that abnormal ventricular anatomy or function also has a significant impact on 
outcome in patients on RRT, relatively little is known about the impact of LV 
abnormalities in the subgroup of patients on RRT awaiting renal transplantation. As 
waiting time for renal transplantation continues to increase, management of patients on 
the waiting list becomes more important in an effort to minimise progression of CVD.
In contrast to the studies of McGregor et a l (86) and Sharma et a l (87) we did not find 
that LV abnormalities, identified using CMR, independently predicted poorer outcome 
although LVEF and LV ESV both showed significance on univariate testing and with 
Kaplan Meier survival analysis. In the study of McGregor et a l (86) ESV and LV 
function measured by Fractional Shortening were found to independently predict 
survival. However, although age was used in the Cox regression analysis model, a history 
of IHD and diabetes were not. Similarly, in the study of Sharma et a l (87) LV ESD and 
posterior LV wall thickness were found to be independent predictors of mortality post­
transplant. Age again was an independent predictor of mortality but whilst a history of 
IHD was significant on univariate testing (p=0.04) it was not found to be an independent 
predictor of mortality and a history of diabetes was not significant even on univariate 
testing. The reasons for this are not clear but it is notable that only 4% of the total cohort 
had a history of IHD whereas 42% of the cohort had a history of diabetes. This suggests 
the cohort of Sharma et a l was an extremely highly selected population or alternatively
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that the prevalence of identified IHD pre-screening was falsely low. Thus in the case of 
both studies the presence of LV abnormalities may have actually been a marker for 
underlying and previously undiagnosed CAD.
In previous chapters of this thesis we have found that LV abnormalities, especially a high 
ESV and low EF, are closely associated with a history of IHD. Once IHD and diabetes 
were factored into multivariate analysis along with age, the results of all non-invasive 
tests, namely CMR findings, ECG ST abnormalities and ETT time lost significance. 
Similarly, although the presence of a discrete pattern of LGCE, suggesting ICM, was a 
univariate predictor of outcome this too was not found to be an independent predictor of 
outcome, after diabetes and a history of IHD were included in the multivariate model. 
Patients who died whilst waiting for transplant had, on average, a shorter period of renal 
failure and time on RRT than patients surviving without transplant at the end of the study 
and it is likely that this reflects bias created by survival effect in those remaining on RRT. 
It is also unsurprising that patients undergoing renal transplantation were less likely to 
have had a previous transplant due to screening prior to transplant and the greater 
likelihood of cross-reactive antibodies in patients who have previously received a renal 
allograft. However, in contrast to previous studies (11) this was the only difference 
observed between patients who received a transplant during the study and those 
remaining on RRT at the end of the study. There was no difference in age, and diabetic 
patients, as well as those with a history of IHD, were equally as likely to receive a 
transplant as to remain on RRT, suggesting a well selected group of transplant candidates. 
Whereas 39 patients died whilst on RRT, only 2 patients died post transplant during 
follow-up. These deaths were both in the first year post transplant, one was the oldest
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patient in the cohort at 70 years of age and the other was a diabetic with a history of IHD. 
Again, although numbers are too small to carry out any meaningful analysis on patients 
post transplant, the three features of advancing age, diabetes and a history of IHD all 
feature in the patients who died after transplant. Although on the basis of risk 
stratification both these patients were high risk, it is very difficult to exclude patients 
from waiting lists unless prognosis is felt to be very poor as previous studies have shown 
that individual life expectancy is increased on average to 3 times that of remaining on 
RRT without transplant, even for higher risk patients (3).
It is also notable that a much larger proportion of patients died whilst waiting for renal 
transplant than died after transplant. Whilst some of this is undoubtedly due to the 
mortality benefit of transplantation and the potential negative impact on survival of 
remaining on the waiting list for a prolonged period of time, it is likely that a proportion 
of patients who were screened during the study did not gain access to the transplant 
waiting list for reasons other than CVD, which may have skewed the results and several 
patients died before decision regarding placement on the waiting list was made.
With a predictive model of age over 60 years, a history of diabetes and a history of IHD 
the sensitivity of predicting death was 80% and the specificity 51%. With the addition of 
a high BNP level to the model, the sensitivity remained at 80% but the specificity 
improved to 81%. This suggests that the addition of BNP to the model significantly 
decreased the number false negative results, in other words helped identify which patients 
outwith the initial model had a poorer prognosis. This is the first study to suggest that 
BNP level can independently predict outcome for patients felt suitable for renal 
transplantation and was a more powerful predictor than any of the other non-invasive
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tests in this cohort. It is well recognised that elevated levels of biomarkers such as the 
natriuretic peptides predict outcome in patients with normal renal function after AMI and 
in those with LVSD and is useful in monitoring treatment of heart failure. With regard to 
patients with renal dysfunction, previously Malamacci et a l (139) studied BNP levels in 
246 patients with ESRF (212 on haemodialysis and 34 on PD) and patients with a history 
of CHF or LVSD were excluded. The study found BNP to be predictive of both CV and 
all cause mortality after 26+/-10 months of follow up, independent of echocardiographic 
findings.
In a more recent study Madsen et al. (289) studied the use of NT-proBNP in 109 patients 
on haemodialysis. Similarly to BNP in our study and in other echocardiographic studies, 
NT-proBNP correlated more strongly with LV mass than LVEF in patients with ESRF 
and on multivariate analysis age and NT-proBNP level were found to be the only 
independent predictors of outcome. Patients with IHD and CHF were included in this 
study and 34% of the cohort was diabetic. Although we found the determinants of BNP in 
Chapter 5 to be LV mass and LV EF, the higher levels and range mean that BNP will not 
be as accurate in diagnosing LV abnormalities in patients with renal failure as it has been 
in patients with normal renal function. However, the ability of BNP to predict outcome in 
this population means it may become a useful adjunct in the renal transplant assessment 
clinic for decisions regarding the need for more aggressive investigation such as coronary 
angiography in this population.
Unlike previous studies in patients with ESRF, we did not find concentric LVH to be 
predictive of outcome. Although the survival curves had separated by the end of the study 
for those with LVH and those with normal ventricles, this did not reach statistical
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significance. Again, other factors in this fitter population of patients compared to those in 
the general dialysis pool may have affected the results or reflect the fact that patients with 
concentric LVH are earlier in the course of evolution of CVD than those with a dilated 
LV or with LVSD. Similarly, although we found with follow-up that progression of LV 
abnormalities was mainly via progression of LVH in the relatively short follow-up time 
of 8 months, we did not find that either an increase in LVMI over this period of time or 
the development of new LVH impacted adversely on outcome. Patients with a dilated LV 
or LVSD did not show further significant progression by the follow up CMR scan, 
although the tendency in patients with a low EF was continued adverse remodelling. 
Furthermore, although previous authors studying populations with essential hypertension 
had identified a further type of LV geometric pattern with adverse outcome we found no 
such association in this cohort
The findings of this study are supportive of those of Gill et al. (13) who observed in 604 
patients that a risk stratification system based on age, diabetes and a history of IHD was 
better at predicting CV outcome both whilst patients remained on the waiting list and in 
the first 12 months post transplant than any combination of ECG, ETT, echocardiography 
and MIBI and also found that repeat surveillance with non-invasive imaging did not 
predict outcome either.
However, the sensitivity and specificity of our model using risk stratification on the basis 
of age and co morbidity along with serum BNP only gave a specificity and sensitivity of 
81% and 80% respectively, which although is at the level generally accepted for a 
screening test does leave room for improvement and in combination with another form of
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functional stress imaging such as adenosine or dobutamine stress CMR may improve the 
overall accuracy with regard to predicting prognosis in this population.
Although several studies have advocated that only coronary angiography is predictive of 
post transplant AMI and CV death, when high risk patients such as diabetics are screened 
with invasive coronary angiography over half do not have significant CAD and only a 
small proportion, in the region of 10-12% have CAD that is treated with surgery or PCI 
(290). Thus, with this strategy, many unnecessary angiograms are performed that are not 
without undue risk.
In this population of 148 patients felt suitable for renal transplantation we have found that 
a careful clinical assessment for symptoms or history of IHD along with advancing age, a 
history of diabetes and an elevated level of BNP was a strong predictive model for 
adverse outcome. However, newer functional non-invasive imaging modalities may 
improve the accuracy of this model and decrease the number of patients subjected to 
diagnostic coronary angiography, simply for risk stratification. Further studies targeting 
the usefulness of BNP in deciding which patients need an invasive investigation strategy 
are required as well as investigation of other non-invasive techniques in efforts to 
improve the detection of underlying CAD, which in this study was found to be a stronger 
predictor of outcome than concentric hypertrophic cardiomyopathy, in patients 
undergoing assessment for renal transplantation.
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Table 9.1 Baseline demographics of surviving patients who remained on RRT, those who 
received a renal transplant and those who had died by end of follow-up period. (*-RRT 
vs. Transplant, p<0.05; **-RRT vs. dead, p<0.05; #-Transplant vs. dead, p<0.05)
Baseline Variable RRT
n=68
Transplant
n=39
Dead
n=39
Age (years) 50+/-9.2 46+/-11.7 55+/-8.9**#
Sex (%male) 71 69 62
Patients on haemodialysis (%) 62 65 51
Length of time on RRT (months) 36.8+/-32 28.6+/-25 24.9+/-26
Length of renal failure (yrs) 9.5+/-8 8.2+/-9 7.4+/-8**
Previous renal transplant (%) 29.0 7.7* 10.8**
History of IHD (%) 13.0 12.8 37.8**#
Previous AMI (%) 5.8 7.7 18.9**
History of CHF (%) 4.3 7.7 13.5
Diabetic (%) 10.1 17.9 35.1**#
History of hypertension (%) 97.0 87.2 97.3
History of hyperlipidaemia (%) 26.1 35.9 54.1
Current smoker (%) 30.9 25.6 29.7
Family history of IHD (%) 22.1 28.2 32.4**#
Peripheral vascular disease (%) 2.9 2.6 13.5**
Systolic BP (mmHg) 137+/-24 135+/-25 134+/-24
Diastolic BP (mmHg) 81+/-12 80+/-12 77+/-11
Cholesterol level (mmol/L) 5.7+/-1.8 5.8+/-1.8 5.2+/-1.2
Haemoglobin (g/dL) 11.8+/-1.5 11.8+/-1.6 10.9+/-1.5#
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Table 9.2 Differences in LV parameters between patients who remained on RRT, those 
who received a renal transplant and those who died during follow-up. (*-RRT vs. dead, 
p<0.05); #-Transplant vs. dead, p<0.05)
PARAMETER RRT
n-68
Transplant
n=39
Dead
n=39
LVEF (%) 67+/-11 66+/-10 60+/-17
LVSD (%) 11.1 10.3 29.7*#
LVMI 104(+/-33.2)g/m2 101(+/-36.3)g/m2 111(+/-36.7) g/m2
LVH (%) 72.2 59.0 78.4
LVEDV 74(+/-26.1)ml/m2 76(+/-31.4)ml/m2 84(+/-35.4)ml/m2
LVESV 25(+/-17.8) ml/m2 25(+/-17.9)ml/m2 3 6(+/-3 3,4)ml/m2#
DilLV (%) 12.5 17.9 24.3
Normal LV (%) 27.8 35.9 21.6
Concentric 
remodelling (%)
8.3 12.8 16.2
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G raph 9.1 K aplan-M eier survival curve displaying outcom e for patients with and w ithout
LVSD (Log-rank statistic, p =0.002)
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Graph 9.2 K aplan-M eier survival curve displaying outcom e for patients with and w ithout
elevated ESV (Log-rank statistic, p=0.005)
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Graph 9.3 Kaplan-M eier survival curve displaying outcome for patients with and without 
elevated ED V  (Log-rank statistic, p=0.052)
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G raph 9.4 K aplan-M eier survival curve displaying outcom e for patients with and w ithout
concentric LVH (Log-rank statistic, p=0.645)
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Graph 9.5 K aplan-M eier survival curve displaying outcom e for patients w ith different
types o f cardiom yopathy categorised by CM R (Log-rank statistic, p=0.012)
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Table 9.3 Univariate and multivariate predictors o f death in cohort
Univariate predictor p-value Multivariate
predictor
Hazard Ratio 
(95% Cl)
Age p=0.001 p<0.001 1.168
(1.088-1.254)
Length of time on RRT p=0.046 NS
History of previous transplant p=0.023 NS
History of IHD p=0.002 p=0.002 7.162
(2.016-25.444)
History of diabetes T3 II O O o p=0.001 10.264
(2.513-41.925)
History of CVA p=0.004 NS
History of PVD p=0.017 NS
History of hyperlipidaemia p=0.004 NS
LVSD p=0.010 NS
High ESV p=0.008 NS
ST changes on ECG p=0.022 NS
ETT time p=0.006 NS
ST changes on ETT II o o oo NS
Presence of LGCE p=0.005 NS
Haemoglobin p=0.017 NS
BNP p<0.001 p=0.001 3.414
(1.199-9.719)
Glucose level p=0.004 NS
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Table 9.6 K aplan-M eier survival curve displaying outcom e for patients w ith and w ithout
severe CA D  at QCA (Log-rank statistic, p=0.032)
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G raph 9.7 K aplan-M eier survival curve displaying outcom e for patients w ith patchy
LG CE, discrete LGCE and no LG CE on CM R scan (Log-rank statistic, p=0.005)
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Chapter 10
Discussion
10.1 Principle Findings of the Study
LVH is a potent marker of CV risk in the general population and those with essential 
hypertension, as documented in several longitudinal studies (291-294). Several factors 
explain this close link. The predictive power of LVH is due to the fact that it is both a 
marker of vascular abnormalities, such as hypertension and increased arterial stiffness 
and a causal risk factor by itself as it influences coronary haemodynamics and myocardial 
oxygen requirement. Furthermore, in the evolution of CVD from the exposure to causal 
risk factors to the clinical manifestations of overt disease, LVH occupies a central 
position as it is already a marker of the impending CVD when it is not yet clinically 
evident. Thus, as compared with causal risk factors, such as hypertension and diabetes, 
LVH identifies a condition of disease which is closer to the end of the natural evolution 
of CVD and LVH itself also directly accelerates this evolution.
It is therefore unsurprising that LVH has also been shown to be a strong predictor of CV 
outcome in patients with CRF and the prevalence of LVH described using 
echocardiography in patients with progressive renal failure not requiring RRT is similar 
to that observed patients with essential hypertension. Studies of patients with CRF have 
estimated that between 27-40% have LVH, depending on GFR (42) and in patients with 
essential hypertension the prevalence is between 28-50%, depending on age and sex 
(78,295). As the prevalence of hypertension in patients prior to RRT is around 80% (38-
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39), it may be more appropriate to compare patients with CRF to those with essential 
hypertension, rather than the general population when discussing LV abnormalities.
It is only once patients require RRT that the prevalence of LVH and LV dilation 
dramatically increases above that of patients with essential hypertension (69), in line with 
the point on the renal timeline that is most associated with haemodynamic overload and 
therefore, also most associated with a volume dependant increase in the diameter of the 
LV. One of the major findings of this study is that the proportion of patients with a 
dilated ventricle, measured using CMR, was dramatically lower than that previously 
documented using echocardiography. Whereas a total of 16.2% of the cohort were found 
to have a dilated LV, only 6.1% were observed to have eccentric LVH whereas the other 
10.1% had associated LVSD. Other echocardiographic studies in patients with ESRF 
selected for transplant have found a prevalence of between 20%-80% for LV dilation (86- 
87) and in the studies of Foley et a l (69), 28% of patients on RRT were found to have 
eccentric LVH. CMR is a direct method of measurement of LV structure and function, 
not dependant on geometric assumptions and therefore it is less dependant on loading 
conditions than echocardiography. The findings of this study support evidence from 
previous studies, of both patients with essential hypertension (296) and those with ESRF 
(202), in which the use of M-mode echocardiography was found to overestimate LV 
abnormalities, especially LVMI, compared to CMR. The calculation of LVMI is 
dependant on cubing the measurement of LVTDD and therefore, if a ventricle is volume 
loaded, the calculation of both LV volumes and mass will be falsely high (194-195). 
Overestimation of both LV mass and volume may partly explain the much higher
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prevalence of LV abnormalities in patients with ESRF compared to either those patients 
who are in the pre-dialysis stages of progressive renal failure or patients post transplant. 
Another major finding of this study was the observed close relationship between LV 
dilation, LVSD and IHD. The determinants of LVSD and ESV were identified as IHD 
and diabetes and the prevalence of IHD progressively increased from 11.3% in patients 
with concentric LVH, to 27.3% in those with a dilated LV and finally to 45.5% in those 
with LVSD. As expected, EDV was more dependant on loading conditions than ESV and 
displayed a relationship with both haemodialysis as type of dialysis therapy and diastolic 
BP but ESV showed no such relationship. A close relationship between LV dilation, 
LVSD and EHD was also observed in Chapter 8. All patients with LVSD who received a 
gadolinium based contrast agent displayed a pattern of LGCE typical of previous AMI 
and whereas 42% of patients displaying a pattern of LGCE typical of ICM had a dilated 
LV, only 4.7% of patients found to have no LGCE had elevated ventricular volumes. 
Previously, echocardiographic studies have found a strong relationship between LVSD 
and a history of IHD but a much weaker relationship between LV dilation and IHD (71). 
Such studies have observed stronger associations between LV dilation and factors 
exacerbating haemodynamic overload such as anaemia, hypoalbuminaemia and 
haemodialysis (17,71) and once again, using a loading independent method of 
measurement has revealed a stronger association with IHD and a much weaker 
association of LV dilation with markers of increased haemodynamic load.
As in previous echocardiographic studies (69,75-76), concentric LVH was found to be 
the dominant type of cardiomyopathy in this study and 50% of the total cohort were 
observed to have elevated LV mass in the context of normal LV volume. This pattern of
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LVH was associated with markers of pressure and volume overload, namely BP and type 
of dialysis therapy and unlike those with a dilated or poorly functioning LV, was not 
directly associated with IHD. However, patients with severe CAD at angiography had a 
higher mean LVMI compared to those with mild CAD or normal coronary arteries, 
suggesting that concentric LVH does have a relationship with CAD but that LVH may 
occur earlier in the evolution of CAD and CVD, whereas LV dilation and LVSD occur 
later.
Therefore, rather than the three types of uraemic cardiomyopathy proposed by Foley et 
al. (Figure 1.1) (69) in previous echocardiographic studies, we propose that the two major 
types of cardiomyopathy in patients with ESRF are concentric hypertrophic 
cardiomyopathy and ischaemic cardiomyopathy with a much smaller contribution from 
eccentric cardiomyopathy than previously thought and a much closer association of LV 
dilation with IHD, when a load independent method of measurement is used to identify 
and quantify LV mass, volumes and function.
This proposed pattern again shows similarities to studies in patients with essential 
hypertension. Although the natural pattern in essential hypertension is concentric LVH, 
this may not always be recognised as many patients also have underlying CAD which 
causes the myocardium to remodel to a more eccentric or dilated pattern. These patients 
therefore present with eccentric LVH and systolic dysfunction and this has been found in 
several studies of patients with essential hypertension including those using the 
Framingham cohort (297) and the LIFE study (257). The major evolutionary pattern of 
uraemic cardiomyopathy in patients with progressive renal failure is also concentric LVH 
and concentric LVH is found early in the course of CRF in association with hypertension
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and arterial stiffening (42). It is only in the later stages of progressive renal failure that 
volume overload plays a more important role, often when concentric LVH is already 
established and therefore patients are already likely to have pre-clinical CVD, for which 
concentric LVH is a marker.
Although 29% of patients were found to have a normal LV at baseline screening, a 
surprising finding was the relatively rapid development of concentric LVH when patients 
returned for follow up 8 months after initial screening. Although overall, no significant 
differences in LV parameters were observed, 45% of patients with initially normal 
ventricles had developed concentric LVH by the time of follow up. The reasons for this 
were not clear and the group of affected patients was relatively small (13 patients) but 
this finding suggests that CV risk assessment and surveillance should continue after 
patients are listed for renal transplant, rather than simply undergoing a single ‘gateway’ 
assessment, even in those who are initially categorised as Tower’ risk.
In addition to the haemodynamic overload associated with renal failure, anaemia also 
affects cardiac loading conditions through adaptive physiological mechanisms including 
increased venous return and increased heart rate. Using a ‘volume status independent’ 
method of measurement for the calculation of LV mass we found in this study that 
although anaemia was associated with a higher CO and a higher EDV, no relationship 
was observed between haemoglobin level and LV mass. As discussed previously, the 
calculation of LV mass using M-mode echocardiographic measurements is highly 
dependent on the internal diameter of the LV and it therefore could be concluded that this 
dependence has led to the overestimation of the relationship between anaemia and LV 
mass in this population. This observation is important and if replicated in future studies
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could lead to a move away from the continued and currently failing (107-108) attempts to 
prove regression of LVH is possible with treatment of anaemia, and instead a move 
toward concentrating on targeting regression of LVH via the control of BP. It is notable 
that erythropoietin was the most commonly prescribed drug in this cohort of patients 
whereas 33% of patients were not prescribed antihypertensive medication, despite the 
finding that 20% of these patients were hypertensive on the day of screening and in total, 
51% of patients in the cohort were found to have hypertensive BP readings. Furthermore, 
in high risk subgroups such as diabetic patients and those with a history of IHD, 55.6% 
and 42.9% respectively were found to be hypertensive at screening.
The prescription of cardioprotective medication was generally low in this population of 
patients, even in the higher risk groups. Following the UK Renal Association guidelines 
(244-245), 108 patients of 148 in the cohort are categorised as ‘high’ risk and only 
around 40% of these patients were established on any form of cardioprotective 
medication. It is well recognised that the evidence for primary prevention of CVD using 
aspirin, statins and ACEI’s is scant in patients with ESRF but in 1998 the National 
Kidney Foundation Task Force on CVD published a document detailing proposed 
guidelines for the future control of the ‘epidemic’ of CVD in patients with renal failure 
(247). This document stated that when managing CV risk in patients with CRF, although 
there was a lack of evidence for following the primary and secondary preventative 
strategies for CVD, established in the normal population, these guidelines should be 
applied to patients with CRF until more specific evidence was available. Furthermore, 
patients with CRF should be considered ‘high risk’ for the development of CVD and thus
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primary preventative measures, such as statin therapy, should be applied to this 
population.
In addition to improvements in the treatment of standard CV risk factors such as 
hypertension and hyperlipidaemia (50% of the total cohort and 60% of diabetics had high 
total cholesterol at screening), improvements in the identification of those patients with 
previously undiagnosed or asymptomatic CAD are also required. Using CMR, in this 
study 11 (18.3%) patients out of the 60 investigated using a gadolinium based contrast 
agent showed evidence of previously unrecognised AMI and 6 of these patients had no 
previous history of IHD. CMR imaging using LGCE therefore identified a group of 
patients at higher CV risk and whilst echocardiography may have identified those with 
associated LVSD, the aetiology of the cardiomyopathy as ICM would not have been 
apparent. The accuracy of this resting non-invasive imaging investigation was also higher 
than either of the currently used methods of non-invasive stress testing employed in the 
West of Scotland, with an accuracy of 87% for the detection of severe CAD compared to 
64% for stress perfusion imaging and only 50% for ETT. The sensitivity and specificity 
of SPECT imaging found in this study are similar to that from other studies investigating 
CAD in patients with ESRF (174) and it is likely that the high false positive rate and 
lower accuracy of this technique in patients with ESRF is due to additional perfusion 
abnormalities observed in patients with LVH (298).
With the use of CMR to quantify LV mass and function, we found that serum BNP 
correlated more strongly with LV mass and LVEF than previous echocardiographic 
studies (140). However, the accuracy of BNP to identify patients with LVSD was lower 
than that found when investigating the general population (122). Whilst the sensitivity of
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BNP to detect LVSD in patients with ESRF was similar to that found for the general 
population (77% vs. 79%), the specificity of the test was lower (87% vs. 79%) and this 
translates into a lower NPV (95% vs. 90%). This decrease in overall accuracy is likely to 
reflect the higher levels of circulating BNP in patients with renal failure and the higher 
range of variability. It is also likely that the high prevalence of LVH in this population 
also has a confounding effect. Both this and previous echocardiographic studies have 
found LVMI to correlate more strongly with BNP than LVEF and the predominance of 
LVH in this population, including those with LVSD may explain this finding. The high 
prevalence of LVH in this population means that the pre-test probability of LVH is much 
higher than that of the general population which infers that the NPV of BNP to detect LV 
abnormalities in patients with renal failure will be lower. Studies assessing the utility of 
BNP to detect LV abnormalities in patients with essential hypertension have also found a 
lower sensitivity and specificity than that observed in the normal population. Nishikimi et 
al. (299) investigated the relationship between LV geometry and BNP in 90 patients with 
essential hypertension using echocardiography. The study found a prevalence of LVH of 
63% in this population using M-mode echocardiographic criteria and found the sensitivity 
and specificity of BNP to detect LVH of 60% and 82% respectively, which is similar to 
the values we found for the detection of LVH in this study which were 63% and 79% 
respectively. Thus, although BNP is a more accurate method of detecting LV 
abnormalities than the resting ECG in this population, it is unlikely to be accurate enough 
to use as an alternative to echocardiography or CMR for the detection of LV 
abnormalities. However, a low BNP level does help exclude those patients who do not
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have LVSD and a high BNP level was found to be an independent prognostic indicator in 
patients undergoing assessment for renal transplantation.
This implies that whereas a low BNP level does not rule out LV abnormalities such as 
LVH or LVDil, it is unlikely that the patient has LVSD and the prognosis for the patient 
is better than that of a patient with an elevated BNP. Thus BNP may have potential for 
the identification of high risk patients for whom more intensive risk assessment should be 
performed before placement on the waiting list. For patients with essential hypertension, 
aggressive control of BP and resultant regression of LVH result in lowering of BNP 
levels and the findings of our study certainly warrant the further investigation of the 
usefulness of BNP for patients undergoing assessment for renal transplant both to identify 
those at higher risk of death and as a possible means of monitoring prognosis in 
interventional trials targeting LVH in this population.
The survival of patients also depended on the type of uraemic cardiomyopathy identified 
using CMR. If LV abnormalities suggesting an underlying ICM were identified, that is, 
LV dilation or LVSD, outcome was poorer than those with a normal ventricle using 
Kaplan-Meier analysis. However, patients who were found to have concentric LVH did 
not have a significantly different outcome compared to those with normal ventricles and 
this is in contrast to previous echocardiographic studies. The reasons for this are unclear 
but may represent a highly selected population of patients suitable for renal transplant. 
When the independent predictors of outcome in population were studied using a Cox 
regression model, LVDil and LVSD were not identified as independent predictors of 
outcome after age, a history of IHD and diabetes were included in the regression model. 
These findings once again are in contrast to previous studies of LV abnormalities in
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patients with ESRF. In this study a history of IHD was defined as previously documented 
CAD, previous AMI or a previously abnormal stress test in combination with the 
prescription of anti-anginal medication. This is in contrast to previous studies in which a 
history of IHD was defined on the basis of clinical symptoms suggestive of angina in 
addition to previously documented CAD. It is well recognised that symptoms of chest 
pain especially in patients with LVH do not necessarily imply underlying significant 
CAD and the more strict definition of IHD that we used in this study may help explain 
the lack of influence of LVSD and LVDil on outcome once baseline factors were 
controlled for. It also should be noted that this study was not specifically powered to 
determine outcome so the results should be interpreted with caution.
Using an outcome model including age, diabetes and a history of IHD, adverse outcome 
was predicted with a sensitivity of 80% and a specificity of 51%. This implies that 
whereas this model is relatively useful for the detection of those patients at high risk, the 
low specificity means there will be an unacceptable number of false negatives. However, 
once the finding of a high BNP was added into the model the specificity increased to 81% 
with no change to the sensitivity of the model.
In conclusion, this study has defined the prevalence and determinants of LV 
abnormalities in a group of patients considered suitable for renal transplantation in the 
West of Scotland using CMR. Using a loading independent method of measuring LV 
volumes and mass and the technique of LGCE, a close association between LVSD, 
LVDil and CAD has been identified and a history of CAD in association with older age, 
diabetes and high BNP level is a strong predictor of outcome. The findings of this study 
suggest that the evolution, natural history and determinants of LV abnormalities in
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patients with CRF may not be that different to the general population or other high risk 
patient groups, such as those with essential hypertension; rather CRF accelerates the same 
process.
CMR is a well tolerated and accurate method of assessing the uraemic heart. The high 
accuracy and reproducibility associated with this technique imply it is ideally equipped 
for use in future appropriately powered studies targeting both regression of LVH and the 
potential reverse remodelling of LVDil and LVSD in patients with progressive renal 
failure.
10.2 Strengths of the Study
The main strength of this study is the method of measurement used to identify and 
quantify LV abnormalities. The accuracy of CMR and resultant low range of variability 
means that studies of the LV using CMR of more than 60 patients are considered large. 
For example, in Chapter 5 we identified patients with initially normal ventricles who 
developed LVH with follow up and these patients on average gained lOg over the period 
between baseline and follow up scans. If an echocardiographic study was used to detect 
the same degree of change with a power of 90% and significance of p<0.05, then 4638 
patients would have needed to be recruited (213).
The strict definitions of both IHD and CHF are also relative strengths of this study and 
may have contributed to a much closer association of LV abnormalities with CAD than 
previously documented in other studies and use of the detailed West of Scotland renal 
database, in which every patient referred to the renal unit is included, meant that no data
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was missing regarding baseline demographics for the population and that mean 
measurements of haemoglobin level were used in the study rather than single values.
The long period of follow up is also a relative strength of this study. Although this study 
was not specifically powered to determine predictors of outcome, data on outcome and all 
cause mortality was collected yearly from the West of Scotland renal database and the 
use of the database also meant that all patients who underwent renal transplantation were 
easily identified and that very few patients were lost to follow-up.
10.3 Weaknesses of the Study
One weakness of this study is the lack of a direct comparison with echocardiography in 
the same patient group to prove there is a different pattern of uraemic cardiomyopathy 
when using CMR as the method of measurement as compared to echocardiography and a 
relationship between anaemia and echocardiographic measurements but not CMR 
measurements. However, previous work by our group has directly compared LV 
abnormalities in patients with ESRF using both echocardiography and CMR. Stewart et 
al. (202) studied 40 patients with ESRF on a post dialysis day using CMR and M-mode 
echocardiography. This study found that as the ventricular volume of the LV increased, 
echocardiography progressively overestimated LV mass compared to echocardiography 
and other studies have also found overestimation of LV mass when studying an abnormal 
LV using echocardiography. This study was designed as a preliminary study of the use of 
CMR in patients with ESRF to identify potential for future interventional trials targeting 
LV abnormalities and subsequent ongoing work within our group is now also directly 
comparing echocardiography and CMR. It should also be noted that one of the aims of
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this study was to compare the use of CMR to the current practice for assessment of CV 
risk in patients undergoing assessment for renal transplant. Whilst assessment for 
underlying CAD is relatively routine, the use of echocardiography is not and is at the 
discretion of the referring physician, usually only employed if the patient has a previous 
history of IHD or problems such as hypotension during dialysis.
Another weakness of this study was the relatively small number of patients who 
underwent coronary angiography. Due to both ethical and risk/benefit considerations, it 
was not possible to perform QCA on all patients entering the study. This meant that 
determination of the predictors of CAD in this population was not possible and 
conclusions regarding independent predictive power with regard to prognosis difficult. 
However, the main reason for including angiographic data was to validate the use of 
CMR imaging using the technique of LGCE in this population. It has already been 
established in other patients groups that the pattern of LGCE can differentiate NICM 
from ICM. In this study the typical pattern of LGCE found in ICM also was found to 
correspond with CAD at QCA. Again, our group has since reported on a larger 
population of patients undergoing CMR with LGCE and QCA.
Finally, the use of the West of Scotland renal database for follow-up meant that only data 
on all cause mortality could be collected. It was not possible to separate mortality into all­
cause and CV mortality or to accurately monitor CV morbidity. Therefore, analysis 
specifically regarding CV morbidity and mortality was not possible.
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10.4 Implications of the Study
The so called ‘epidemic’ of CVD in patients with progressive renal failure continues to 
account for the majority of morbidity and mortality observed in this population and after 
a shortage of donated renal allografts, is the biggest danger to life for patients awaiting 
renal transplantation. If the current demand for renal transplantation continues to rise, 
patients will wait longer for a renal transplant at a time in their lives when CV risk is 
more than 20 times that of the general population and therefore the early prevention, 
detection and treatment of CVD in patients awaiting renal transplantation is mandatory to 
improve survival for patients and to maximise the benefits of a subsequent renal 
transplant.
The aim of this study was to define the prevalence and pattern of LV abnormalities in a 
population of patients either already awaiting transplant or undergoing assessment for 
future transplantation, using the current standard of reference for the quantification of LV 
mass, volumes and function, CMR. In addition, the current practices for the primary and 
secondary prevention of CVD were examined as well as the current methods of 
identifying CAD in this population and the relationship of uraemic cardiomyopathy to 
CAD was explored using CMR imaging with LGCE. The implications of this study, 
possible action points and areas identified for future studies in this population are as 
follows;
• Both the primary and secondary prevention of CVD in this population could be 
better implemented. The prevalence of reversible risk factors such as 
hypertension and hyperlipidaemia were high and the prescription of 
cardioprotective medication low. The prescription rate of aspirin, statins, beta-
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blockers and ACEI’s was also low in ‘higher risk’ groups such as those with a 
history of IHD or diabetes. Strategies to improve the early identification and 
treatment of standard CV risk factors are required in this population in addition 
to a more aggressive approach to the implementation of secondary prevention.
• The predominant pattern of uraemic cardiomyopathy in this population is 
concentric LVH, which is determined by hypertension, volume overload and 
diabetes but not by anaemia. Future studies targeting regression of LVH in this 
population may be better served by treating hypertension with the prescription of 
medication or via strict control of volume status with differing dialysis regimes, 
rather than treating anaemia.
• The second main type of uraemic cardiomyopathy in this population is ICM 
rather than eccentric cardiomyopathy and IHD is closely associated with LVDil 
and LVSD. A finding of either of these LV abnormalities should precipitate 
careful investigation for underlying CAD but ideally CAD should be identified 
before the onset of adverse remodelling. CMR may be best equipped to study 
trials targeting reverse remodelling in this population. For example 30 patients 
would be required to detect a change of 3% in EF or 25mls in EDV in a trial 
studying active versus placebo medication, compared to 240 patients if using 
echocardiography.
• Patients with initially ‘normal’ left ventricles at baseline screening are at risk of 
developing abnormal ventricles via evolution of concentric LVH. This finding 
suggests these patients remain exposed to casual risk factors associated with 
LVH, such as hypertension, and as such, standard CV risk factors such as
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hypertension should be aggressively treated in all patients. Furthermore, regular 
reassessment of LV abnormalities and CV risk in patients already placed on the 
transplant waiting list may be beneficial.
• The currently used non-invasive methods of detecting obstructive CAD in this 
population are unsatisfactory and with both the increase in choice and the 
improvements in technology associated with non-invasive imaging in the current 
era further study is warranted. It may be that a combination of functional and 
anatomical non-invasive imaging modalities is better suited for the detection of 
CAD in patients with ESRF.
• A high level of BNP was found to be an independent predictor of outcome for 
patients undergoing assessment for renal transplantation. BNP is easily measured 
in the setting of a clinic visit and may prove to be a useful addition to risk 
assessment in this population. Further studies are required both to verify our 
findings and assess whether lowering BNP levels in parallel with attempts to 
modify cardiac risk are associated with an improvement in prognosis.
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Glossary
ACEI- angiotensinogen converting enzyme inhibitor
ACS- acute coronary syndrome
AMI- acute myocardial infarction
ANP- atrial natriuretic peptide
APD- ambulatory peritoneal dialysis
ARIC study- Atherosclerosis Risk in Communities study
ASE- American Society of Echocardiography
BNP- brain natriuretis peptide
BP- blood pressure
BSA- body surface area
CABG- coronary artery bypass grafting
CAD- coronary artery disease
CAPD- continuous ambulatory peritoneal dialysis
CBD- cerebrovascular disease
CHF- ‘congestive’ heart failure
CHOIR- Correction of Hemoglobin and Outcomes in Renal Insufficiency trial 
Cl- confidence interval
CMR- cardiovascular magnetic resonance imaging 
CNP- C-type natriuretic peptide 
CO- cardiac output
COURAGE- Clinical Outcomes Utilizing Revascularization and AGgressive drug 
Evaluation trial
CREATE- Cardiovascular Risk reduction by Early Anemia Treatment EPO trial
CRF- chronic renal failure
CRP- C reactive protein
CV- cardiovascular
CVD- cardiovascular disease
DSE- dobutamine stress echocardiography
ECG- electrocardiogram
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ED- end-diastole
EDV- end-diastolic volume
EF- ejection fraction
ES- end-systole
ESRF- end stage renal failure
ESV- end-systolic volume
ETT- exercise tolerance testing
FFR- fractional flow reserve
FLASH- fast low angle shot
FoV- field of view
FS- fractional shortening
Gd-DTPA- gadolinium
GFR- glomerular filtration rate
HLA- horizontal long axis
ICM- ischaemic cardiomyopathy
IHD- ischaemic heart disease
IVS- interventricular septum
IVSTD- interventricular septum thickness in diastole
LGCE- late gadolinium contrast enhancement
LV- left ventricular
LVDil- left ventricular dilation
LVESD- left ventricular end systolic diameter
LVH- left ventricular hypertrophy
LVIDD- left ventricular internal diastolic diameter
LVMI- left ventricular mass index
LVSD- left ventricular systolic dysfunction
MET- metabolic equivalent of work
MHRA- Medicine and Healthcare products Regulatory Agency 
NICM- non-ischaemic cardiomyopathy 
NPR-C- natriuretic peptide receptor C 
NPV- negative predictive value
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NT-pro ANP- N- terminal pro atrial natriuretic peptide
NT-pro BNP- N-terminal pro brain natriuretic peptide
PCI- percutaneous intervention
PD- peritoneal dialysis
PET- positron emission tomography
PVD- peripheral vascular disease
PWTD- posterior wall thickness in diastole
QCA- quantitative coronary angiography
RR- relative risk
RRT- renal replacement therapy
SA- short axis
SD- standard deviation
SEE- standard error of estimation
SPECT- single photon emission computed tomography
SSFP- steady state free precession
STICH- Surgical Treatment for IsChaemic Heart failure trial
SV- stroke volume
SVR- systemic vascular resistance
TE- echo time
TR- repetition time
TRUE FISP- true fast imaging with steady state free precession 
UK- United Kingdom
UK-HARP- United Kingdom Heart And Renal Protection study
US- United States of America
USRDS- United States Renal Data Service
VLA- vertical long axis
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of cardiovascular disease is 50 times that of the general population.
Non-invasive assessment in this patient population is difficult. Many patients, 
especially diabetics, do not have the classical symptoms of ischaemic heart 
disease due to poor exercise tolerance and for the same reason investigation such 
as exercise tolerance testing often provide unsatisfactory results. Resting ECG’s 
in this population are often abnormal and ETT results are difficult to interpret 
even if the patient can exercise adequately. Other non-invasive assessment is 
available using stress perfusion but this exposes the patient to small doses of 
radioactive material.
Cardiovascular magnetic resonance provides a non-invasive method of 
measuring previous myocardial infarction. A contrast agent (gadolinium) is 
injected into the patient’s vein and passes through the blood stream. Once it 
reaches the heart it diffuses through the myocardium. It diffuses through normal 
heart muscle very quickly. If, however there has been any previous damage from 
a myocardial infarction, however small, the contrast has delayed diffusion 
through this damaged tissue and has “delayed enhancement” of the contrast 
which is picked up by scanning the patient’s heart around 15 minutes after 
injection. This can then be measured to estimate the territory of the myocardial 
infarction and the size of the myocardial infarction. The contrast agent used is
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neither radioactive nor nephrotoxic and has proven to be at least as accurate as 
nuclear scanning in detecting myocardial infarction.
In this study we plan to carry out cardiovascular magnetic resonance utilising 
the method of late enhancement in high-risk patients with end-stage renal failure 
considered for renal transplant. These would be patients who are diabetic or who 
have evidence of left ventricular dysfunction or hypertrophy (the strongest 
predictive indicators of cardiac death in this patient group) on echocardiography 
and no previous history of myocardial infarction. We will also include 10 
controls from the same population of patients with end-stage renal failure who 
are assessed for renal transplantation who have normal echocardiograms of their 
hearts for comparison. From the information gained we will be able to detect 
non-invasively the proportion of patients in this high-risk group who have in the 
past had a myocardial infarction and determine the association with standard 
cardiovascular risk factors. This would enable us to better identify these patients 
non-invasively in the future and in those patients in which previous myocardial 
infarction is identified the appropriate secondary preventative treatment can be 
instituted such as aspirin and statins as well as appropriate cardiology referral
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4. Details of Procedure: (Explain how the study will be executed including 
details of recruitment, treatment allocation, procedures undertaken and 
study visits).
All new patients at the Transplant Assessment Clinic at the Western Infirmary 
Glasgow who attend for routine cardiovascular screening (this includes ECG, 
ETT, echocardiogram and history taking for standard cardiovascular risk factors 
and cardiovascular physical examination) and who are diabetic or have left 
ventricular dysfunction or hypertrophy, diagnosed by echocardiography, but no 
previous history of myocardial infarction will be invited to participate. All 
patients who agree to participate will undergo the following;
1. Clinical evaluation (case note review, interview, examination and 
questionnaire) to determine history of cardiac symptoms and assess for 
standard cardiovascular risk factors.
2. ECG to look for evidence of previous ischaemic heart disease and assess for 
LVH.
3. Cardiovascular Magnetic Resonance to assess left ventricular anatomy, mass 
and function and using late enhancement with gadolinium to assess the 
presence and extent of previous myocardial infarction.
4. Blood tests. Blood will be analysed and drawn for full blood count, lipids, 
glucose and BNP (a neurohormone)
Following this, those patients who have been shown to have a myocardial 
infarction will be referred to Professor Dargie’s cardiology clinic for appropriate
further investigation and management.
This process will involve a visit that should last one hour and thirty minutes. The 
clinical evaluation will take around thirty minutes and the cardiovascular magnetic 
resonance scan will take around 50 minutes. After analysis of the scans the patient may 
be recalled to discuss the results, if they are positive, and referred to the cardiology 
clinic.
If the patient has a positive scan, and fulfilled the required criteria on the treadmill and 
had a satisfactory echocardiogram they would still be added to the transplant 
register. Only if they had significant ECG changes at treadmill, a severely 
impaired ventricle on echo or a reversible defect on thallium scanning (if they 
cannot complete the treadmill time) would there be a delay to being added to the 
transplant register. This is the current workup for transplant candidates in this 
hospital.
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Facilities and Personnel to support the work : Indicate here how the facilities 
and personnel you have available will enable the project to be adequately 
executed).
Recruitment and consent of patients will be performed by Dr. Nicola Johnston 
who co-ordinates cardiovascular screening at the renal transplant clinic.
Screening will be performed in the Clinical Research Initiative (CRI) of the 
Western Infirmary by CRI staff using existing equipment. The cardiovascular 
magnetic resonance scans will be performed in the CRI scanner by existing staff 
(Miss T Steedman). Analysis of the scans will be performed by Dr. Nicola 
Johnston. Analysis of non-routine blood samples will be performed by Dr. Ian 
Morton in the Department of Medicine lab in the Western Infirmary. Decision to 
refer to cardiology clinic will be taken by Dr. Nicola Johnston and Professor 
Henry Dargie.
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6. Patient/Volunteers: (Please indicate how patients and/or volunteers are 
chosen giving the numbers chosen and justification for these numbers with 
power calculations where appropriate. Entry and exclusion criteria should be 
clearly stated.
Particular regard should be paid to the status of women of childbearing age.
All patients seen at the Transplant Assessment Clinic who are diabetic or have 
evidence of left ventricular dysfunction or hypertrophy, with no previous history 
of myocardial infarction will be invited to attend. Women of childbearing age will 
be invited to take part but will only undergo cardiovascular magnetic resonance 
scanning after a negative pregnancy test. Pregnancy or breast feeding at the time of 
recruitment are exclusion criteria as well as any of the usual contra-indications to 
cardiovascular magnetic resonance scanning e.g. permanent pacemaker, aneurysm 
clips etc.
Ten “normal” controls will be recruited from the transplant waiting list who have 
normal echocardiograms. This is to help clarify the relationship between left 
ventricular abnormalities and previous myocardial infarction in patients with end- 
stage renal disease. This number is calculated from that used in similar studies and 
using standard deviation of inter-observer variability for cardiovascular magnetic 
resonance imaging and it is estimated that 70 patients will require to be studied 
with this method of late enhancement.
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Drugs, dosages and non-standard products (Please include all drugs. If a 
new drug is to be used a copy of the Clinical Trials Certificate or Clinical 
Trials Exemption Certification from the Committee on Safety of Medicines 
must be attached).
Gadolinium-D TP A
Gadolinium is a metallic chemical element chelated to a substance called 
diethylene triaminepentaacetic acid (DTPA) for clinical use (Gd-DTPA). Gd- 
DPTA is a paramagnetic agent and increases the relaxation rate of surrounding 
protons thereby shortening the T1 relaxation times and increasing the signal 
density on cardiac MRI (CMR) images. Gadolinium is already in routine clinical 
use.
Dosages
An intravenous bolus via a peripheral line. It will be given as a bolus injection of 
7-10 mis by hand. Each injection will be 0.05 mmol/Kg body weight. The 
median lethal dose is 10 mmol/Kg, which is 50-100 times the diagnostic dose.
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8. Safety: (Please state briefly the known pharmacology of the drugs used 
indicating side effects and toxicity, together with hazards of any invasive 
procedure performed). The minimum information would be that contained 
in the British Formulary
Gadolinium
Pharmacokinetics
Half life 1.6 hours.
Contraindications
None
Cautions
Patients with a history of thrombotic syndromes. Patients with a history of sickle 
cell anaemia and other haemoglobiopathies such as haemolytic anaemia. Patients with 
severe renal or hepatic impairment. Patients with a known clinical hypersensitivity or a 
history of asthma or other allergic respiratory disorders
Side effects
The most common noted adverse event is headache with an incidence of 4.8%. 
The majority of headaches are transient and of mild to moderate severity. Nausea is the 
second most common adverse event at around 2.7%. Injection site coldness/localised 
coldness is the third most common adverse event at 2.3%. The incidence of anaphylactic 
adverse reactions is extremely rare (1 in 100,000 doses). There is no nephrotoxicity even 
at high doses, which is particularly relevant in this population.
Precautions -  general
As with other injectable products, cases of phlebitis and thrombophlebitis have 
been reported. Patency and integrity of the intravenous line will be determined before 
administration. As with other intravenous injections, appropriate surveillance of the 
dosing limb for the development of local injection site reactions following 
administration of the drug will be carried out.
Gadolinium is renally excreted, hence the caution for those patients with severe renal 
impairment. However, all o f these patients are on dialysis, whether it be peritoneal 
dialysis or haemodialysis and therefore the gadolinium will be effectively removed by 
dialysis causing minimal increased risk o f side-effects
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Radioactive Substances: (If radioisotopes are to used, details of premises 
clearance by Radiation Protection Officer should be given and certificate of 
registration with the DHSS must be attached. The approximate dose of 
radioactivity administration should be stated).
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10. Grant or Financial Support (ALL sources of support for the work should be 
stated including details of all payments to be made to investigators, patients 
and healthy volunteers.
The study will be funded by the Clinical Research Initiative of the Western 
Infirmary Glasgow. Dr. Nicola Johnston is supported by a British Heart 
Foundation Junior Research Fellowship
11. Supporting Declaration (ALL named investigators must sign).
“I certify that I have considered the declaration of Helsinki and this protocol 
adheres to the principles contained therein”.
12. Research on Healthy Volunteers (Must be signed by the principal
investigator/s).
“I certify that I have considered the report of the Royal College of Physicians and 
this protocol adheres to the principles contained in that report. I confirm that 
healthily volunteers will have their legal position fully explained to them,
particularly in respect of the ability to claim for damages should anything
untoward occur to them as a result of their participation in research trails” .
Signature....
Designation 
Date............
Approved by the Ethical Committee
Date............................................
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THIS SHEET HAS BEEN APPROVED BY THE W EST ETHICS COM M ITTEE
INFORMATION SHEET FOR PATIENTS/VOLUNTEERS IN CLINICAL RESEARCH 
PROJECT
Brief Title of Proi ect
The detection of asymptomatic myocardial infarction in patients with chronic renal 
failure
Patient’s Summary (Purpose of study, nature of procedure, discomfort and possible risks
in terms which the
patient or volunteer can understand).
You are invited to take part in a study looking at a very sensitive technique to detect any 
previous damage to the heart muscle. You have been selected because patients with 
kidney disease have a much higher risk of heart disease and problems with the circulation 
than the rest of the general population. Often it is difficult to fully assess heart problems 
in patients with kidney failure as some patients cannot exercise easily and therefore heart 
symptoms such as breathlessness and chest pain may remain undetected or silent. Also, 
the usual way in which we test the heart such as walking on a treadmill can often be 
difficult for patients with kidney disease as they often have other problems such as 
arthritis.
The study will involve a new test for heart disease. We will ask you questions about your 
health, examine you and perform an ECG, which is a simple recording of the heart done 
through leads attached to your chest by sticky labels and taking around 2 minutes to 
complete. We will then carry out a special scan called a cardiac MRI scan. Finally we will 
take a blood test. To do this we will insert a very fine plastic tube, a little wider than a pin, 
into a vein in your arm and from this we will withdraw approximately 20ml of blood, 
(roughly around 3 dessert spoonfuls)
Cardiac MRI
This is a way of getting very detailed pictures of the heart without using X-rays. MRI 
instead uses a magnet, radio waves and a powerful computer to produce the pictures. 
Before the scan you will need to change into a gown as zips and metal fasteners can 
interfere with the pictures. The radiographer will ask you a list of questions to check if 
you have any metal in your body (either from surgery or from accidents involving 
metal). When you are being scanned you have to lie very still in the scanner. The 
machine is shaped like a tunnel and can be claustrophobic. When the scan is on, the 
machine will make a loud knocking noise. Headphones will be given to you and music 
can be played. You will be in contact with the radiographer who will be monitoring the 
whole process from outwith the room. You will be given an emergency buzzer and very 
quickly can be taken out of the scanner should it be necessary. Each scan will typically 
require you to hold your breath for around 8 seconds. The whole exam may last between 
30 and 60 minutes. About half way through the scan we will inject a small amount of
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dye into a vein in your arm through a fine plastic tube. This “dye” is called gadolinium 
and provides greater contrast between normal and abnormal tissue. It looks like clear 
water and has been used for years in adults and children without any serious 
complications in thousands of patients. A few side effects such as headache, nausea and 
local burning can occur. Very rarely (less than one in a thousand) patients are allergic to 
gadolinium. These side effects may be more common in dialysis patients as the dye is 
removed from the body by the kidney and will therefore be removed during dialysis and 
may be in the body slightly longer than usual. Gadolinium does not affect the function of 
the kidney.
The results of these tests will be analysed. If the test shows up any abnormality we will 
discuss the results with you and may advise you to have further heart tests or to start new 
medication. If the tests do show up abnormalities this may result in a delay in joining 
the kidney transplant waiting list whilst these abnormalities are investigated.
Taking part in this study may not directly benefit you, although we may discover and be 
able to treat silent heart problems, which you could have. It is designed to help us assess 
and treat kidney patients better in the future. If you are willing to take part we will inform 
your GP and explain the nature of the study to him or her. Should you choose to drop out 
or not take part, you can do this at any time, without giving a reason and this will not 
affect your routine care in any way.
If you wish to discuss any aspects of the study please contact Dr. N Johnston at the 
Western Infirmary. Glasgow. (Telephone 0141 211 2637. or-email
niohnstoncri@vahoo.comI
N.B. Pregnancy would be a contraindication to taking part in this study and therefore if 
you are a woman of childbearing age we will perform a pregnancy test prior to any 
procedures and if you are pregnant or breastfeeding we would not ask you to take part in 
the study.
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W EST ETHICS COM M ITTEE
FORM OF CONSENT FOR PATIENTS/VOLUNTEERS IN CLINICAL RESEARCH 
PROJECT
Title of Project: The detection of silent myocardial infarction in patients with chronic renal 
failure.
By signing this form you give consent to your participation in the project whose title is 
at the top of this page. You should have been given a complete explanation of the 
project to your satisfaction and have been given the opportunity to ask questions. You 
should have been given a copy of the patient information sheet approved by the West 
Ethics Committee to read and to keep. Even though you have agreed to take part in the 
research procedures you may withdraw this consent at any time without the need to 
explain why and without any prejudice to your care.
Consent:
I,............................................................................................................................ (PRINT)
of............................................................................................................................
give my consent to the research procedures above, the nature, purpose and possible 
consequences
of which have been described to me
by.....................................................................................................................
Patient’s signature................................................................Date.
Doctor’s signature......................................................................... .
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